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The objective of the investigations in this thesis was to characterize the 
pharmacokinetics of antibiotics in the prevention of group B streptococcal (GBS) 
infections in pregnancy with emphasis on the possible changes which may occur in 
the perinatal period. A specific objective was to assess the implications of potentially 
altered maternal pharmacokinetics on the exposure of the infant.
 Group B streptococcus (GBS, Streptococcus agalactiae) has been known 
as a human pathogen since 19381. It is a gram-positive coccus, growing in chains or 
as diplococci. Because GBS causes complete destruction of red blood cells on sheep 
blood agar, colonies produce a characteristic appearance with narrow surrounding 
zone of β-hemolysis. Based on the expression of antigenic capsular carbohydrates, 
GBS is classified into nine serotypes: Ia, Ib and II-VIII. Recently a tenth serotype 
has been proposed2. Like carbohydrates, proteins are also expressed on the bacterial 
surface. Differences in the expression of carbohydrates and surface proteins account 
for differences in the pathogenesis of infection and possibly clinical presentation3,4. 
Factors playing a role in the development of invasive infection have been elucidated 
to some extent3. 
 In pregnancy GBS may cause a variety of serious infections in both mother 
and neonate. Most commonly known is neonatal GBS disease. GBS disease in 
the neonate is classified according to the age at which the first symptoms occur. 
Early-onset GBS disease (GBS-EOD) presents within the first week of life and 
late-onset disease (GBS-LOD) presents from 7 to 90 days of life. GBS is a major 
cause of neonatal morbidity and mortality. Diseases caused by GBS include sepsis, 
pneumonia and meningitis. GBS-EOD is usually acquired during delivery by 
neonates born from mothers colonized with GBS in the rectovaginal tract. Up to 
35% of pregnant women is colonized with GBS in the rectovaginal tract, most 
often without having symptoms5,6. Fortunately, only 1% of neonates of colonized 
mothers develop GBS-EOD. The occurrence of maternal GBS infections is often 
disregarded. 
 Intravenous administration of antibiotics is now the cornerstone of the 
prevention of GBS-EOD and of the treatment of intra-amniotic infection during 
pregnancy, shortly before and during labor. During pregnancy, antibiotics are 
administered intravenously to the mother, with the fetus as actual target of 
prophylaxis of neonatal GBS disease. Antibiotics are administered as short 
infusions and reach the fetus after transplacental transport. To protect both mother 
and neonate from GBS infections, the concentration-time profiles of the prescribed 
antibiotics have to be adequate in both maternal and fetal serum. A limitation of the 
current dosing regimens as recommended by the Centers of Disease Control and 
Prevention (CDC) is that they are not evidence-based in the sense that the actual 
exposure profiles have not been determined. 
 To study the efficacy of the recommended dosing regimens for GBS-
EOD prevention, knowledge of the disposition of drugs in the body is necessary. 
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Scope and Outline
Pharmacology (Greek ‘φαρμακος’ for medicine or drug and ‘λογος’ for study) is the 
science of the interactions of chemicals  with the human body7. These interactions 
are divided into two classes: pharmacokinetics (PK) and pharmacodynamics (PD). 
Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes 
and excretes drugs. The calculation of various rates at which these processes occur 
brings a quantitative component to assessing drug action8. PD is the study of the 
biochemical and physiological effects of drugs, the mechanisms of drug action and 
the relationships between drug concentration and effect. The effects of drugs are 
related to the time course of the drug concentration in plasma, albeit that these 
relationships may be complex9,10.  
 To describe the pharmacokinetics of a specific drug in a target patient group, 
it is important to take inter-individual variability into account. To this end advanced 
data-analysis techniques such as non-linear mixed effects modeling are increasingly 
applied. This is often referred to as the “population approach”. Using population 
pharmacokinetics the data of a group of individuals is simultaneously analyzed and 
the sources and correlates of variability in drug concentrations among individuals 
are studied. Specifically, in this manner patient demographical and therapeutical 
characteristics which might influence the pharmacokinetics are included in the 
analysis as covariate(s). A further advantage is that the population approach 
allows the analysis of data from unbalanced study groups11,12. This is particularly 
important for pharmacokinetic studies in pregnant women, because blood sampling 
might be limited due to practical and emotional problems. Typically, the number of 
blood samples collected from pregnant women during labor will be less compared 
to women before onset of labor. The number of umbilical cord blood samples is 
even more limited, because they can be collected only once for each patient. Thus, 
population pharmacokinetics describes the pharmacokinetics of a population of 
subjects. Furthermore, it tries to identify in a quantitative manner the factors that 
influence the pharmacokinetics. As such population pharmacokinetics constitutes a 
basis to adjust drug dosages in specific patient populations. 
 The description of the pharmacokinetics obtained in the population analysis, 
can be used to evaluate the efficacy of therapy and to optimize dosing regimens. 
Monte Carlo Simulation (MCS) is a technique used to evaluate the probability 
of achieving therapeutic concentrations using different dosing regimens. MCS is 
performed using pharmacokinetic parameters, data on the parameters describing the 
drug concentration-effect relationship and data on the inter-individual variability 
in these parameters13-18. To study the efficacy of antibiotics, the susceptibility of 
the micro-organisms is of importance. The susceptibility of bacteria is indicated 
by the Minimum Inhibitory Concentration (MIC). For the antibiotics used in the 
prevention of GBS-EOD, the efficacy is determined by the time the antibiotic 
concentration exceeds the MIC (time-dependent mechanism of action)19-21. 
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Chapter 1
 The aim of the research presented in this thesis was to describe the 
pharmacokinetics of the antibiotics used in the prevention of GBS-EOD. Preventing 
GBS-EOD requires an adequate concentration-time profile in both the mother and 
the fetus. To this end the effects of various dosing regimens and inaccuracies in 
the antibiotic administration on the efficacy of the amoxicillin were evaluated. 
Finally after birth, adequate dosing in (preterm) neonates with a suspected infection 
is essential. This requires knowledge of the pharmacokinetics in neonates. In this 
respect the pharmacokinetics of penicillin G in neonates was studies as well.
 Part I of this thesis reviews background information on the prevention of 
GBS-EOD and maternal GBS infections. In chapter 2 a detailed review of the use 
of antibiotics in the era of the prevention of GBS-EOD is presented. The available 
evidence on the pharmacokinetics of antibiotics used as intrapartum prophylaxis in 
relation to infection parameters and GBS-EOD incidence is described, to evaluate 
the efficacy and safety of currently advised prophylaxis. The efficacy of the 
prophylaxis is mainly attributed to a lowering of the incidence figures of GBS-EOD. 
However, incidence figures are influenced by many factors and may therefore not be 
considered conclusive proof. The available data on the changes in incidence figures, 
as well as data on the interruption of vertical transmission of GBS carriage, support 
the idea that antibiotics prevent GBS-EOD. But to advise antibiotic prophylaxis to 
approximately 35% of all pregnant women during labor, more data are needed on 
the pharmacokinetics of the antibiotics and on the unintended consequences for 
both mother and neonate. 
 Guidelines on the prevention of GBS disease focus on infections of the fetus. 
The fact that GBS also causes infections in pregnant women is less appreciated. 
Various maternal GBS infections, their characteristics, associated neonatal 
morbidity, and prevention and treatment strategies during pregnancy, delivery, and 
in the postpartum period are reviewed in chapter 3. GBS infections in the mother 
cause less morbidity than neonatal infection, but occur more commonly. Especially 
during the course of pregnancy and labor, GBS can endanger both mother and the 
fetus. Postpartum mastitis can also threat mother and the neonate, because it may 
be a cause of late-onset or recurrent neonatal GBS disease. With early recognition 
and proper treatment, maternal and neonatal severe morbidity and mortality due to 
GBS infections are rare.  
 The penicillins, such as amoxicillin, are antibiotics of first choice in 
the prevention of GBS-EOD during pregnancy and delivery. As an alternative, 
clindamycin is used. In part II the pharmacokinetics of amoxicillin is described. It 
is used as prototype to study all issues related to the prevention of GBS infection 
in pregnant women. In chapter 4 the pharmacokinetics of amoxicillin in pregnant 
women with preterm premature rupture of the membranes (PPROM) is described. 
Pharmacokinetic parameter estimates for patients with PPROM were all within the 
ranges reported in the literature for healthy non-pregnant individuals. Chapter 5 
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focuses on the influence of labor on the pharmacokinetics of amoxicillin. To this end 
the pharmacokinetics were determined in patients before the onset of labor, during 
labor and in the immediate postpartum period. An effect of labor was seen on the 
peripheral volume of distribution. A decrease in the peripheral volume of distribution 
was seen during labor and even more in the immediate postpartum period. In case 
of suspected intra-amniotic infection, co-amoxiclav, a combination of amoxicillin 
and clavulanic acid is used. When drugs are administered simultaneously, there 
is a possibility that these drugs influence their pharmacokinetic behavior. The 
influence of co-administration of clavulanic acid on the pharmacokinetics of 
amoxicillin is presented in chapter 6. In agreement with observations from 
earlier studies in healthy subjects it is shown that clavulanic acid has no effect 
on the pharmacokinetics of amoxicillin in pregnant women. Because the fetus is 
the actual target of the prophylaxis, the transfer of drugs over the placenta is an 
important factor. The investigations in chapter 7 aim therefore characterization 
of the concentrations of amoxicillin in umbilical cord serum and neonatal serum 
in relation to the concentrations in maternal serum. Approximately 1 hour after 
the start of the intravenous administration 2 gram amoxicillin over 30 min to the 
mother the neonatal concentration reached its highest level, and thereafter exceeded 
the concentrations in venous umbilical cord blood. Finally the population model 
of the amoxicillin pharmacokinetics in pregnant women with PPROM was used 
in chapter 8 to evaluate the probability of target attainment (as indicated by the 
MIC) after various dosing regimens and inaccuracies in the administration of the 
amoxicillin using Monte Carlo Simulations. Both regimens recommended by the 
CDC as well as the regimen described in the Cochrane Library result in adequate 
maternal concentration-time profiles22,23. 
 Most patients included in our study were relatively healthy. To describe 
the influence that co-morbidity might have on the pharmacokinetics we present a 
case-report of a pregnant women with PPROM and severe vomiting in chapter 9. 
We hypothized that the extreme vomiting had resulted in additional physiological 
changes and thereby changing the distribution of the amoxicillin.
 In part III pharmacokinetics of other antibiotics used in prevention or 
treatment of GBS infections are presented. Patients allergic to penicillins may not be 
treated with amoxicillin and in this condition clindamycin is used instead. Moreover 
in patients who need endocarditis prophylaxis, clindamycin is prescribed as well. 
Clindamycin should be studied in a similar manner as described for amoxicillin, but 
limited data were available. In chapter 10 the pharmacokinetics of clindamycin in 
pregnant women is described. A limited number of patients was available to study 
the pharmacokinetics in pregnant women and the transfer over the placental barrier. 
The results of our preliminary investigations show that for the average pregnant 
women the recommended dosing regimen is adequate, but it is doubtful whether the 
concentrations in the fetus are also adequate.
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Chapter 1
 Despite the prophylactic measures, neonates may still acquire GBS-EOD, 
partly because mothers of these neonates were not selected for antibiotic prophylaxis. 
In some neonates an overwhelming intra-amniotic infection had already developed 
at the time the antibiotics are prescribed. In both occasions, neonates have to be 
treated with antibiotics after birth. In this respect it is important that especially, 
preterm neonates are vulnerable for the development of GBS-EOD. For several 
drugs the pharmacokinetics in preterm neonates has been found to be different 
from older children and adults24-26. In chapter 11 therefore, the pharmacokinetics 
of penicillin G in very preterm neonates is described. The pharmacokinetics in 
neonates with a gestational age of less than 32 weeks differs from that in adults and 
older infants, which is indicated by a prolonged terminal half-life. 
 In the general discussion (part IV, chapter 12) all results of the various 
investigations are discussed and future perspectives are presented.
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Antibiotics in the prevention of 
neonatal group B streptococcal 
infections: the evidence. 
Anouk E. Muller, Rob A. Voskuyl, Paul M. Oostvogel, Lia (C.) Liefaard, 




To prevent group B streptococcal early-onset disease (GBS-EOD) in the neonate, 
many pregnant women are treated with antibiotics during labor and/ or delivery. 
During the last years several countries implemented the screening-based strategy 
to prevent GBS-EOD, resulting in an increase in the use of antibiotics during 
delivery. Overall, most incidence figures of culture-proven GBS-EOD decreased 
in the last decades. Because incidence figures are influenced by multiple factors, 
a decrease cannot be considered as exclusive evidence for efficacy of antibiotics. 
Despite limited knowledge on the efficacy of the antibiotics prescribed, they are 
used worldwide as preventive measure in up to 35% of pregnant women shortly 
before and during delivery. In this paper, we review the available evidence, from 
pharmacokinetics of antibiotics used as intrapartum prophylaxis to infection 




The evidence of GBS prophylaxis
Introduction
In the 1970s group B streptococcus (GBS) infection emerged as a major cause of 
neonatal morbidity and mortality in the industrialized world. This led the Centers for 
Disease Control and Prevention (CDC) and other organizations to issue guidelines 
in the 1990s for prevention of neonatal GBS disease by intrapartum prophylaxis 
with antibiotics (IPA)1. CDC guidelines discuss a wide variety of issues associated 
with GBS disease, such as transmission of infection and selection of patients 
eligible for prophylaxis, and highlight a steady decline in incidence of GBS disease 
since introduction of IPA. However, the guidelines recommend regimens for IPA, 
but give no arguments for dose, dosing interval and duration of treatment1,2.
 The decline in incidence of GBS early-onset disease (GBS-EOD), i.e. onset 
of symptoms within 7 days after birth, has generally been considered as evidence 
for effectiveness of IPA. However, because other factors may have influenced 
incidence figures as well, it is arguable whether this is conclusive proof. In a recent 
review it was discussed why time-trend analyses have their drawbacks in this 
respect3. The question remains how else efficacy should be judged and whether 
available evidence justifies widespread IPA.
 This paper reviews the available evidence for efficacy of IPA used in the 
prevention of neonatal GBS disease. We will first describe the clinical presentation of 
GBS-EOD, etiology and the working mechanisms of the recommended antibiotics. 
Pharmacokinetic-pharmacodynamic measures generally used to predict efficacy 
of antibiotic therapy, as well as the available data during pregnancy and delivery 
are described. Clinical studies were also reviewed to determine the likeliness for 
efficacy of IPA from this point of view. Finally, unintended consequences for mother 
and neonate are discussed.
Search strategy and selection criteria
Data for this review were identified by searches of PubMed, MEDLINE, Current 
Contents, the Cochrane Library, and references from relevant articles. Search terms 
included combinations of “Streptococcus agalactiae”, “group B streptococcus”, 
“pharmacokinetics”, “pharmacodynamics”, “elimination”, “half life”, “incidence”, 
“epidemiology”, “vertical transmission”, “neonatal”, “fetal”, “amniotic fluid”, 
“colonisation”, “anaphylaxis”, “adverse reactions”, “immune system”, and terms 
for the specific antibiotics (eg, “penicillin”). No date or language restrictions 
were set in these searches, but only English, Dutch, German, French and Spanish 




Etiology and clinical presentation of neonatal GBS disease
In figure 1 it is illustrated how GBS-EOD is usually acquired during labor 
or delivery. Of neonates born from GBS colonized mothers 1-2% develop 
GBS-EOD1. Mortality has decreased in the few last decades, but survivors 
may suffer from severe disability (e.g., hearing or visual loss, uncontrolled 
seizures, impaired psychomotor development and/ or mental retardation)1. 
Figure 1: Hypothesized pathogenesis of GBS-EOD.
1 Colonization in the rectovaginal compartment; 2 Rupture of the membranes; 3 GBS enters 
the amniotic fluid; 3a GBS colonization of skin and mucocutaneous areas; 4 Aspiration of 
infected amniotic fluid; 5 Infected amniotic fluid causes pneumonia (if the bacterial load 
is high enough); 6 Entry of GBS in the bloodstream (sepsis or bacteremia); 7 Entry in 
cerebrospinal fluid after hematogenous spread (meningitis). (See color inlay for a full color 
version of this figure.)
Designed by Vincent Khouw (VMK designs)
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GBS meningitis results in children with disabilities in 34.8% of cases4, and in an 
earlier study 33% of the surviving children showed abnormalities related to GBS 
septicemia or meningitis5. 
 GBS-EOD may present in different ways. GBS-EOD is diagnosed as 
culture-proven when streptococci are isolated from blood and/or cerebrospinal fluid 
and when physical signs and laboratory results are clear. The diagnosis probable 
GBS-EOD is used for cases of serious neonatal disease when GBS is detected at 
various sites, but not in blood and/or cerebrospinal fluid6. Finally, culture-proven 
GBS-EOD may also present as “asymptomatic” bacteremia7-9. Asymptomatic 
bacteremia was defined as positive blood cultures for GBS in neonates without 
clinical signs of infection. Such cases may be discovered by accident when blood 
cultures are taken shortly after birth in neonates when only maternal risk factors 
were present during delivery2. In this way, culture-proven GBS-EOD was found 
to be asymptomatic in 4-20%10-15. Weisman et al found that 15% of 149 term 
neonates with bacteremia were asymptomatic, whereas all 96 preterm neonates 
had clinical or laboratory signs of infection7. It is unclear for how long bacteremia 
persists. Prolonged bacteremia for >24 hours has been described8. The possibility 
of developing a life-threatening illness and poorly understood pathogenesis of 
late-onset GBS disease (GBS-LOD, i.e. 7-90 days of life), justifies treatment of 
asymptomatic GBS bacteremia in neonates.
 Both host related factors and bacterial properties may increase the risk on 
GBS-EOD. Host related factors include >18 hours of ruptured membranes, fever 
during delivery, GBS bacteriuria in current pregnancy, having a neonate with GBS 
disease in obstetrical history and preterm delivery. These factors are associated 
with an increased risk on GBS-EOD and were incorporated in guidelines to prevent 
GBS-EOD1. At least one of the risk factors preterm delivery, intrapartum fever and 
membrane rupture of at least 18 hours is found in 49% of GBS-EOD cases16. On 
the other hand, bacterial virulence properties might also influence this risk17. But, 
unfortunately little is known about specific virulent GBS subtypes. Furthermore, 
there are some other risk factors for GBS-EOD known, such as low levels of maternal 
anticapsular antibodies, increased number of vaginal exams and intrauterine fetal 
monitoring16,18,19. 
Intrapartum prophylaxis with antibiotics
The primary aim of IPA is to prevent fetal infection by lowering the bacterial load 
sufficiently. Optimal IPA requires an antibiotic that preferably selectively kills GBS. 
The ideal dosing regimen should be designed in a way to achieve prompt, effective 
concentrations at the site of infection for sufficient time to lower the bacterial load 




 Different strategies have been used to select candidates for IPA1,2. For 
instance, current CDC guidelines2 advise the administration of intrapartum 
antibiotics to all GBS carriers during delivery (2-35% of all pregnant women20-27). 
Dosing schedules are shown in table 1. Women with unknown GBS carriage during 
delivery, are treated with IPA when host related risk factors are present2.
Table 1: Dosing regimen as recommended by CDC2
* Dutch and Australian guidelines deviate without an explanation from these guidelines, 















4 h Not penicillin allergic
Ampicillin 2g 1g 4 h Not penicillin allergic
Cefazolin 2g 1g 8 h Allergic to penicillin; low risk 
of anaphylaxis
Clindamycin - 900 mg 8 h Allergic to penicillin; high risk 
of anaphylaxis; susceptibility to 
clindamycin proven
Erythromycin - 600 mg 6 h Allergic to penicillin; high risk 
of anaphylaxis; susceptibility to 
erythromycin proven
Vancomycin - 1g 12 h Allergic to penicillin; high risk 
of anaphylaxis;
resistant to clindamycin and 
erythromycin
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The choice of the antibiotics
Antibiotics as recommended by CDC are active against GBS. Beta-lactam 
antibiotics, such as the penicillins and cephalosporins, are active against GBS 
by disrupting the synthesis of the cell wall. Both erythromycin and clindamycin 
show a growth-inhibiting action by interfering with protein synthesis. Vancomycin 
resembles the penicillins with regard to the mechanism of action in that it interferes 
with cell wall synthesis and thereby increases cell wall permeability.
 According to the guidelines2, penicillin G is the antibiotic of first choice 
because of its narrow spectrum and lack of resistance of GBS to penicillin G, with 
ampicillin as alternative. Although not mentioned in the CDC guidelines, amoxicillin 
could be used as well. GBS may or may not be cross resistant to erythromycin and 
clindamycin, depending on the mechanism of resistance, and this is becoming an 
increasing problem28-31. Vancomycin is the last resort, and is not optimal because of 
its low intrinsic killing activity. 
Adequate concentrations 
Considering the infection pathway (figure 1), adequate levels in both fetal serum 
and amniotic fluid (AF) are required. Measures to evaluate efficacy should ideally 
concern fetal serum and amniotic fluid levels. Maternal levels are a prerequisite 
for adequate fetal serum levels and eliquibrium between fetal and maternal levels 
is reached within limited amount of time. Therefore, maternal concentration-time 
profiles might be used as well. Before reviewing and evaluating available data, 
we will discuss general criteria for effective concentrations and issues related to 
pregnancy which might influence pharmacokinetics and pharmacodynamics. 
General pharmacokinetic-pharmacodynamic measures for efficacy
In the simplest approach antibiotics are divided into agents that display time-dependent 
killing and agents with a concentration-dependent action. While this concept is still 
valid, it should be noted that several more refined measures have been developed in 
pre-clinical studies which are predictive for efficacy in humans as well32.
 Antibiotics mentioned in the CDC guidelines2, except clindamycin and 
vancomycin, display time-dependent killing32. For beta-lactam agents the time the 
free fraction of the drug, i.e. the fraction not bound to proteins (f), above the minimum 
inhibitory concentration (MIC) is the best predictor for efficacy (fT>MIC)33-36. In 
general, a fT>MIC for 30-50% of the dosing-interval is considered adequate for 
optimal treatment in non-neutropenic patients34,37,38. Clindamycin also has a time-
dependent action in vitro, but clinical efficacy is more closely related to the area 
under the concentration curve over MIC for 24 hours (AUC0-24h/MIC)
32. Similarly, 
although vancomycin displays time-dependent action in in vitro studies, animal and 
clinical studies suggest that the effect of vancomycin is better related to the fAUC0-
24h/MIC ratio
33. Furthermore, vancomycin seems to display some concentration-
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dependency. For this drug studies indicate that the fAUC0-24h/MIC ratio needs to be 
at least 25-30 to be effective34,37, but may be much higher for optimal effect.
 Development of invasive disease is also dependent on interaction of 
GBS with the neonatal immune system. Three basic mechanisms are required for 
effective elimination of invasive GBS: chemotaxis, phagocytosis and intracellular 
as well as extracellular bacterial killing. Deficiencies on all levels have been 
identified in neonates, particularly in those born prematurily39-41. Infants are 
protected in part by active transplacental acquisition of maternal antibodies that 
significantly occurs in the third trimester of pregnancy42. The neonatal adaptive 
immune system is still poorly developed due to low synthesis of IgG, especially 
of prematures42. Deficiencies in both innate and adaptive immune system make 
neonates vulnerable for GBS-EOD. Therefore (premature) neonates have to be 
regarded as immunocompromised patients and consequently the fT>MIC should 
be larger (40-60%) than in immunocompetent patients38.
Pharmacokinetics in the maternal-fetal unit
Since antibiotics reach the fetus after transplacental transfer, adequate maternal 
serum levels are the first requirement to reach fetal serum concentrations. Secondly, 
antibiotics should reach the AF. Transplacental passage of antibiotics occurs 
primarily by simple diffusion of the free fraction43. Therefore, the rate of transfer is 
related to the maternal-fetal concentration gradient and is inversely proportional to 
the thickness of the placental membrane44. The thickness decreases with gestational 
age and in various disease states, like diabetes and hypertensive disorders 
complicating pregnancy45. In the third trimester AF levels of antibiotics eliminated 
by the kidneys largely depend on fetal renal excretion46,47 and are influenced by 
maturation of the fetal kidneys48.
 The continuously changing physiological adaptations to advancing 
pregnancy are likely to modify the pharmacokinetics. Therefore, to determine 
whether the recommended dosing regimens are indeed adequate to achieve the 
desired concentration profiles it is essential to focus on pharmacokinetic information 
obtained shortly before and during labor. Unfortunately, most studies reviewed in 
Table 2 present data that are far from optimal to make a sound judgement. Essential 
data are often missing (e.g. fetal concentrations, protein binding) and presented 
pharmacokinetic data or observed concentrations do not allow proper estimation 
of fT>MIC or other indices. Also, the numbers of patients included per study 
were limited and exhibited a wide range in gestational ages. Furthermore, most 
studies included patients without uterine contractions, a factor which might further 
influence pharmacokinetics49,50. 
 CDC guidelines call for at least 4h of IPA prior to delivery to be adequate2. 
From a pharmacokinetic point of view there is no rationale for this interval of 4 hours. 
Antibiotics reach fetal serum within several minutes after the administration to the 
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mother48. Afterwards the concentration will decrease both in fetal and in neonatal 
serum. Antibiotics in neonatal serum will continue to eliminate bacteria with the 
same rate as before birth. Therefore, a short time interval between administration 
of antibiotics and delivery does not reduce adequacy of IPA. 
In conclusion, these data, especially data in relation to pharmacodynamic indices, are 
insufficient to judge efficacy of IPA. Most information is based on concentrations in 
maternal serum, but antibiotics reach fetal serum after transfer across the placental 
barrier, what might influence the T>MIC. Pharmacokinetic-pharmacodynamic 
measures found for other infections in non-pregnant individuals or animal models 
are not necessary valid in fetal serum and amniotic fluid. 
Clinical evidence in favor of the efficacy of IPA
In addition to pharmacokinetic data other studies may contribute to the evaluation 
of efficacy of GBS-IPA. The most direct indicator for efficacy is the bacterial load 
in neonatal blood cultures. Also the number of colonized mucocutaneous areas in 
the neonate has been shown to be a determinant of GBS-EOD51. Neonates with 
GBS-EOD had significantly more GBS positive surface areas than infants without 
GBS-EOD51. Obviously, effective prophylaxis should be reflected in decreased 
incidence figures. However other factors may influence these figures as well and 
blood cultures are taken from a selection of the neonates. Therefore, it is important 
to separate the contribution of IPA from the contribution of other factors whenever 
possible. 
Blood cultures
Prospective studies comparing antibiotic treatment with no treatment provide the 
strongest evidence for effectiveness. In a randomized prospective study Boyer and 
Gotoff52 observed a lower incidence of positive blood cultures in neonates of GBS 
carriers treated with ampicillin intrapartum compared to neonates of patients not 
treated with ampicillin52. In contrast to the present guidelines2, neonates in the study 
of Boyer received antibiotics after maternal IPA as well52. The reduced number of 
positive blood cultures suggests that IPA decreases the incidence of GBS-EOD52, 
but since clinical neonatal outcome was not reported, it cannot be concluded that 
current IPA is optimal. 
 Another issue is apparent IPA failure. Six studies report that 6-19% of 
neonates with invasive GBS disease were born from mothers with IPA12,14,53-57. 
Obviously, antibiotic treatment was not optimal in these cases. Maternal fever is 
associated with the presence of positive neonatal blood cultures after IPA (referred 
to as prophylaxis-failure)12,54,58. Most likely adequate fetal serum levels are achieved 
within the first hour, but apparently more time is needed to eradicate GBS, as is 
29





































































































































































































































































illustrated in figure 2. The amount of time needed to eradicate GBS depends on the 
bacterial load. The bacterial load is believed to be increased in cases with maternal 
fever and prolonged rupture of the membranes. Consequently, a short time span 
between administration of IPA and delivery will result in a higher number of positive 
blood cultures taken immediately after birth. This is consistent with the fact that 
within cases of prophylaxis-failures duration of IPA <1-2 hour prior to delivery is 
indicated as risk factor for failure53,56,59. This indicates that IPA is insufficient when 
an overwhelming infection might have been established in utero before initiation 
of antibiotics, because the antibiotic concentration was maintained for insufficient 
time to eradicate all bacteria at the time the blood culture was taken.
Reduction in neonatal colonisation
As explained above, observational studies suggested that vertical transmission of 
GBS might be interrupted by IPA. Most often neonatal colonization is determined by 
the use of cultures taken from three mucocutaneous areas (pharynx, umbilicus, and 
external auditory canal) to serve as a measure of effectiveness. In the absence of IPA 
in vaginal deliveries, neonates born from GBS colonized mothers were colonized 
in 43% to 53% at one or more surface areas60-64. Transmission from mother to child 
after caesarean section in patients with ruptured membranes or active labor was 
25.9%61. After administration of IPA with ampicillin a lower neonatal colonization 
rate has been seen after vaginal delivery, varying from 0% to 10%52,60,62,64-66. 
 The time interval between administration of IPA and delivery is an 
important determinant in interrupting mother-to-child transmission (figure 2)63, 65. 
Adequate AF antibiotic concentrations are likely to be involved in eradication of 
GBS from surface areas. Since there is some time needed to achieve adequate AF 
concentrations and eradicate GBS from these areas, the bacterial load will decrease 
after an increased time interval between IPA and delivery. De Cueto et al. found for 
ampicillin that when this interval is at least 2 hours, vertical transmission of GBS 
was minimized to 1.5%63. 
 Unfortunately, data on vertical transmission after IPA with clindamycin, 
erythromycin or vancomycin are scarce. One study in 7 patients receiving 
intramuscular erythromycin for an unknown period demonstrated that none of the 
neonates carried GBS when cultured within 24 hours after birth67. Since adequate 
AF antibiotic levels, rather that adequate fetal serum concentrations are likely to be 
involved in eradication of GBS from mucocutaneous areas of the fetus, the effect 
of IPA with erythromycin and clindamycin might be limited or delayed. 
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Changes in incidence figures and case fatality
Most trends in incidence rates of culture-proven GBS-EOD decreased within a 
geographical area after implementation of IPA, suggesting a causal relation. Before 
the implementation of prophylaxis in the US the incidence of GBS-EOD fell from 
2-3/1000 live births in the 1970s-1980s to 1.4-1.8/1000 live births in 1990 with a 
constant prevalence of maternal GBS colonisation of 20-25%68. While it is likely that 
IPA is in part responsible for the decrease in incidence and low mortality rate, other 
factors may contribute as well, among which are early recognition of infection and 
improved neonatal care3,56. Furthermore, natural fluctuations in incidence figures 
of GBS-EOD as large as 2.85 to 0.45 per 1000 live births from year to year69 may 
occur within regional populations and may therefore erroneously be interpreted as 
being caused by IPA. Such fluctuations may be due to changes in prevalence of 
maternal colonisation as well as variation in GBS subtype distribution.
 There are other issues to be considered as well. Many studies on incidence 
are difficult to compare because of methodological diversity56,70,71. Since there 
is an extremely low risk for full-term infants born by elective caesarean section 
without rupture of the membranes or onset of labor on GBS-EOD2,72, an increased 
application of this procedure will decrease the incidence. Incidence figures should 
therefore be corrected for this aspect. 
 The substantial decline in incidence figures is based on data of culture-
proven GBS-EOD. Since suboptimal IPA may lead to negative blood cultures in 
clinically ill neonates (see above), studies can be interpreted with confidence only 
when incidence figures of culture-proven as well as probable EOD are reported57, 73. 
With suboptimal IPA the incidence of culture-proven EOD will be decreased, while 
the incidence of probable EOD might be increased. Estimates of the incidence of 
probable GBS-EOD are higher than culture-proven incidence rates, indicating a 
greater disease burden than suggested by studies based on only culture-proven 
GBS-EOD57,74,75. Comparing incidence rates after correction for underreporting 
before and after the introduction of IPA showed that the incidence of probable GBS-
EOD was constant in the Netherlands (1.3-1.4/1000 live births). There was only a 
limited decrease in the culture-proven GBS-EOD from 0.54/1000 live births before 
introduction of IPA to 0.36/1000 live births afterwards75. Because asymptomatic 
bacteremic neonates are often included the culture-proven incidence rates, local 
protocols on neonatal blood cultures can also influence incidence figures.
 Finally, incidence figures do not always decline. Noteworthy is the 
unchanged incidence of GBS-EOD in a hospital where the intrapartum use of 
antibiotics increased from 13% to 44% of all deliveries between 1989 and 200276. 
As reviewed by Gilbert3 earlier, it appears from these findings that incidence rates 
provide only moderate evidence for efficacy of the GBS prophylaxis.  
 In the last 40 years the case fatality rate of culture-proven cases of GBS-EOD 
has decreased from 55% in the 1970s to <10% in 2000-20052,53,57,77. An important 
32
Chapter 2
factor in this decline is likely to be the improved neonatal care. IPA may have 
contributed to this decline by advancing the antibiotic effect on the child and 
decreasing the severity of the disease. However, recently Norway reported an yet 
unexplained, marked increase in case fatality from an average of 5.8% in 2000-
2005 to 33% in the first 6 months of 2006 and a slightly increased incidence of 
invasive GBS disease in neonates in the first 90 days of life using a risk factor 
based strategy78. Such changes in case fatality rates without alterations in antibiotic 
policy, might be explained by changes in the virulence characteristics of circulating 
GBS strains. 
From these clinical studies we can conclude that the intrapartum administration 
of antibiotics to prevent GBS-EOD is likely to have clinical effect. However, 
it is unclear to what extend the decrease in GBS-EOD can be attributed to the 
administration of antibiotics and whether the currently used dosing schedules are 
optimal. After reviewing the positive effects of IPA, it is also important to discuss 
the unintended consequences of IPA, as will be described in the following. 
Unintended consequences of IPA
To justify the administration of antibiotics as prophylaxis against GBS-EOD in up 
to 35% of women in labor, apart from being effective, prophylaxis should have 
minimal risks for both mother and child. The risk for the mother is limited to the risk 
on anaphylactic reactions on administered antibiotics. The (long-term) unintended 
consequences for neonates are still under debate. An increase use of (suboptimal) 
IPA may also affect the susceptibility of GBS. 
Maternal risks
An increased use of antibiotics will result in more adverse reactions. The most 
serious reaction is an anaphylactic shock with consequences for both mother and 
fetus. Many pregnant women have a history of penicillin “allergy”, often described 
as a rash. In spite of the fact that most antibiotic-associated rashes are not IgE-
mediated, the risk of anaphylaxis can not be ignored79. In general, the incidence 
of anaphylaxis among inpatients has been reported to be three to five per 10,00080. 
The incidence of anaphylaxis after administration of penicillin is estimated to be 
0.01% with a mortality rate of 9%81. Anaphylaxis occurs more often after parenteral 
administration than after oral administration. In pregnant patients with anaphylactic 
shock there will be fetal distress due to maternal hypoxia and hypotension. On 
the other hand parenteral antibiotics used for GBS prophylaxis have rarely been 
noted to cause severe reactions in pregnant women without a history of penicillin 
allergy82-85. Penicillin skin testing can be performed in advance in pregnant women 
and penicillin can be administered safely if the result is negative79.  
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Neonatal risks
Several possible unintended consequences of IPA have raised concern for the 
neonate. Firstly, some investigators have reported an increase in incidence of non-
GBS-EOD. These increases appear to be limited to preterm or low-birth-weight 
infants and ampicillin-resistant pathogens86-88. Among cases of sepsis, non-GBS 
sepsis in infants was caused more frequently by ampicillin-resistant pathogens in 
the era of IPA89,90. Especially rates of ampicillin-resistant Escherichia coli sepsis 
have increased among preterm neonates86,91,92. Is was suggested that the increase 
of ampicillin-resistant pathogens might be partially attributable to maternal 
antibiotic exposure before delivery. But, as reviewed by Moore et al., there are 
some confounders in the interpretation of these studies93. None of the studies was 
designed to estimate the efficacy of IPA against susceptible infections. Duration 
and indication of IPA as well as the presence of other known risk factors for EOD, 
like prematurity, and natural fluctuations in incidence numbers should be taken into 
account in the analysis93. Simultaneously, the proportion of community-acquired 
E. coli infections that are ampicillin-resistant has been increasing94 suggesting 
that trends in antimicrobial resistance should not be attributed to GBS prophylaxis 
alone2. To summarize, trend analyses do not allow a direct assessment of causality 
between IPA and risk of non-GBS sepsis93.
 Secondly, one study reported an association between the use of IPA 
and LOD95. GBS-LOD has usually been considered community-acquired. The 
incidence of GBS-LOD did not change after implementation of the prophylaxis2. 
Glasgow et al. compared the frequency of LOD in infants exposed to IPA and non-
exposed infants95. Exposure to IPA was strongly associated with the occurrence of 
LOD. Pathogens causing LOD were more likely to be ampicillin-resistant in infants 
exposed to IPA. Both findings seemed to be associated to the use of broad-spectrum 
antibiotics, rather than benzylpenicillin. 
 There is also some evidence from basic animal and human studies that 
peripartum antibiotics may have long-term consequences for the neonate. The 
use of antibiotics during delivery influences the maternal vaginal and fecal flora, 
which provide the first natural sources of colonizing organisms in the neonatal 
gut95,96. Acquired abnormalities in early-life bacterial colonization may affect the 
development of the immune system and a change in pattern of initial colonization 
of the gut in the first days of life may be linked to later development of allergic 
disease96,97. Unlike broad-spectrum antibiotics, benzylpenicillin does not perturb 
normal gastrointestinal flora98,99 and for intrapartum amoxicillin the influence was 
shown to be limited to a reduced initial colonization by Clostridium in infants 
exposed to antibiotics100. Apart from IPA it has also been found in infants with an 
age of one month that the intestinal flora was influenced by such factors as mode of 
delivery, breast-feeding, hospitalization after birth, prematurity and the presence of 
older siblings101.   
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Notwithstanding the fact that several confounders complicate the interpretation 
of the relation between IPA and non-GBS sepsis, and that many factors may be 
involved in the development of the neonatal immune system, the association with 
IPA may not be ignored. Based on current data, the estimated number of prevented 
infections from IPA still outweighs the possible neonatal unintended consequences. 
Concerning the choice of the antibiotic, available data suggest that the risk on 
neonatal unintended consequences is minimal with the use of benzylpenicillin, 
compared to broad-spectrum antibiotics, like ampicillin.
Risk on emergence of resistance
Besides aspects of efficacy, dosing schedules should also be designed to minimize 
the chance of bacterial resistance. Appropriate exposure to antibiotics achieved 
by adequate dosing is important to limit resistance development102. The potential 
for resistance development can be defined as the ability of a bacterial strain to 
survive killing and regrow. Thus, there is an inverse relationship between the 
efficacy of an antibiotic and the resistance induction potential of an antibiotic103. 
For several micro-organisms and antimicrobials the area under the curve of the 
unbound fraction over MIC (fAUC/MIC) has been investigated in the prediction of 
selecting resistant organisms104-107. However, since there are no data on prevention 
of resistance in GBS, dosing regimens used in the prevention of GBS-EOD can not 
be judged on their potential to select resistant organisms. Studies in pre-clinical 
infection models could be very useful for designing dosing regimens that avoid 
resistance development32.
Conclusions
Having reviewed data on efficacy of IPA, the question whether IPA is truly preventing 
GBS infection of the fetus, can not be answered with certainty. Limited available 
data suggest that IPA to some extent prevents GBS-EOD, but other factors are 
likely to contribute to lowering of the incidence. Apart from these studies, concerns 
on unintended consequences for mother and neonate are rising and are still under 
debate.
 It is surprising that discussions on effectiveness of IPA only have concerned 
proper identification of patients at risk, implementation of the prophylaxis and 
circumstantial aspects affecting incidence, but have not questioned practice itself. 
Dosing regimens are based on tradition108, rather than on pharmacokinetic data 
during pregnancy. Physiological changes due to complications of pregnancy, such 
as severe preeclampsia, might also have an additional effect on pharmacokinetics. 
CDC guidelines call for at least 4h of IPA prior to delivery to be adequate2. But 
neither studies on the decrease of transmission of GBS nor pharmacokinetic data 
provide a rationale for this 4 hour threshold109. Even if a short time interval is 
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expected between administration of antibiotic and delivery, this is no reason to 
omit IPA. Of the antibiotics advised for the prevention of GBS-EOD, the penicillins 
have been studied most extensively. But even their efficacy can not be guaranteed.
 The optimal timing in labor to initiate antibiotics is difficult to assess110. 
The presence of risk factors for development of GBS-EOD influences the initiation 
of prophylaxis. These factors might all be related to an increase in bacterial load in 
the AF (figure 3). The current practice in GBS prophylaxis is based on the idea that 
the risk on GBS-EOD primarily exists after rupture of the membranes. Indeed, the 
bacterial load increases with the duration of ruptured membranes and subsequently 
the attack rate increases with a marked rise after 18 hours111. However penetration 
of GBS through intact membranes can also occur, leading to severe cases of intra-
amniotic infection or abortion112. The ability of GBS to attach and invade the 
chorioamniotic membranes has been demonstrated in vitro113, but might be limited 
to a specific GBS subtype. In this scenario it might be appropriate to start antibiotic 
therapy earlier than is advised now.
 Nowadays, many pregnant women are candidates for IPA and this, in 
conjunction with the lack of high quality studies and concerns on the unintended 
consequences of IPA, should be the motivation to continue research. Although some 
data are available for the penicillins, additional studies including patients with uterine 
contractions as representatives for IPA-candidates are needed to clarify efficacy. 
For erythromycin, clindamycin and vancomycin maternal pharmacokinetics and 
transplacental transfer need to be further investigated in this special patient group. 
The increase in IPA due to change in strategy to the screening-based approach, adds 
to the general increase in antibiotic use. Widespread use of antibiotics generally 
contributes to the increase in resistance. As an alternative preventive strategy 
interference with the neonatal immune system has been mentioned. Especially the 
development of a universal maternal vaccine may benefit from the application of 
genomic/proteomic technologies114. However, implication of the current prevention 
strategy2 may interfere with clinical vaccine efficacy trials114. Furthermore, research 
on virulence factors within the different GBS types may lead to early detection of 
virulent GBS strains and thereby narrow the use of IPA to carriers of virulent GBS 
strains in the future.
 Reviewing the evidence for efficacy and unintended consequences, the 
use of IPA should be limited to patients at risk for GBS-EOD. The unintended 
consequences of IPA indicate that administration of IPA to all GBS carrying 
patients is not desirable. Until new information becomes available, the dosing 
regimen should be continued as recommended by the CDC2. Benzylpenicillin 
is still the antibiotic of first choice. Firstly, because most data are available for 
this antibiotic, suggesting efficacy. And secondly because the risk on neonatal 
unintended consequences is limited. Skin testing should be performed in patients 










































































































































































































































The evidence of GBS prophylaxis
alternative for penicillin allergic patients. In patients with a negative skin test the 
administration of benzylpenicillin is recommended. Since fever during delivery is 
the most important factor for development of GBS-EOD after IPA, neonates from 
mothers with intrapartum fever should always be admitted to the neonatal care 
unit.
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Group B streptococcus is known to be a leading cause of neonatal infection, but 
less appreciated is the fact that it causes maternal infection also. Maternal group 
B streptococcal infections during pregnancy and delivery threaten not only the 
mother, but the child as well. Postpartum infection, such as mastitis, bacteremia, 
sepsis, meningitis, endometritis and wound infections are hazards to the mother. We 
describe the various maternal group B streptococcal infections, their characteristics, 
associated neonatal morbidity, and prevention and treatment strategies during 




Group B streptococcus (GBS, Streptococcus agalactiae) has been known as a 
human pathogen since 19381. It emerged as leading infectious cause of neonatal 
morbidity and mortality in the 1970s2. Because of this, much attention has been 
given to the prevention of neonatal GBS disease. Guidelines to prevent neonatal 
GBS disease were developed in the 1990s. After the implementation of these 
preventive guidelines, the incidence of early onset disease decreased markedly 
from an estimated 1.8 cases per 1000 live births in 1990 to 0.32 cases per 1000 live 
births in 2003 in the Unites States3,4. Other countries showed a similar decrease. 
However, despite the decrease in the incidence, GBS remains the number one cause 
of infectious neonatal morbidity and mortality in the Western world. The majority of 
cases of early-onset GBS disease occur in infants whose mothers screened negative 
for GBS colonization5.
 GBS has also been recognized as an important maternal pathogen. A variety 
of maternal GBS infections may occur in the course of pregnancy and the postpartum 
period. Apart from cervicovaginal colonization, which is usually asymptomatic, 
GBS can cause urinary tract infections, vulvovaginitis, intra-amniotic infection, 
mastitis, bacteremia, sepsis, meningitis, endometritis and wound infections6. 
 Because of the serious complications that may affect both mother and 
fetus, these maternal infections require special attention and proper treatment. In 
this paper the various maternal infections, their characteristics and the specific 
prevention and/or treatment strategies are reviewed. The infections are described 
in the chronological order in which they may be encountered during and after 
pregnancy. 
The pathogen
GBS is a Gram-positive coccus, growing in chains or as diplococci. Because GBS 
causes complete destruction of red blood cells on sheep blood agar, colonies produce 
a characteristic appearance with narrow surrounding zones of β-hemolysis. Serologic 
identification of GBS suspected colonies is performed using latex agglutination.
 GBS is serologically classified into nine serotypes based on antigenic 
capsular carbohydrates as Ia, Ib and II-VIII. Surface proteins are expressed nearly 
independent of those serotypes. Differences in the expression of carbohydrates and 
surface proteins account for differences in the pathogenesis of infections7,8. Factors 
playing a role in the development of an asymptomatic or invasive infection have 
not yet fully been elucidated7. As colonization can often occur without symptoms, 
it is possible that only certain virulent GBS serotypes or surface proteins may cause 
symptomatic infections. This is currently an area of research7,8. However, the present 






Urinary tract infections (UTI) are the most common bacterial infections during 
pregnancy. GBS causes asymptomatic bacteriuria, cystitis, and pyelonephritis 
acquired by an ascending route from the vagina. UTI due to GBS are clinically 
indistinguishable from UTI due to other bacteria in pregnant and in non-pregnant 
women. GBS bacteriuria, often with low bacterial count, complicates up to 7% of 
pregnancies9-11, of which 70% are asymptomatic12. The frequency of symptomatic 
UTI in pregnancy could reflect asymptomatic bacteriuria acquired earlier in life. 
GBS causes about 10% of the cases of acute pyelonephritis, mainly in the second 
trimester13. Serotype III and non-typable strains are responsible for the majority of 
bacteriuria14,15. 
Sequelae  
UTI due to GBS have been associated with adverse pregnancy outcomes such as 
(preterm) premature rupture of the membranes ((P)PROM), preterm labor, and 
neonatal GBS infections, even with low bacterial counts (<102 bacteria per ml of 
urine)12. Nevertheless, the causal relation between GBS bacteriuria and preterm 
delivery and PROM is controversial, as several studies report contradictory 
results 12,16-20. 
 It has been suggested that GBS bacteriuria may be associated with neonatal 
GBS disease as well and is therefore one of the commonly used risk factors for 
neonatal GBS disease21. However, there is little evidence for a causal relation. The 
association with increased neonatal GBS disease is based on two studies, with 10 
and 14 patients respectively9,14. A third study reported several cases of neonatal 
GBS sepsis in patients with both GBS bacteriuria and premature delivery12. It has 
been assumed that asymptomatic GBS bacteriuria during pregnancy is associated 
with heavy genital colonization with GBS9,10,14, based on an enhanced prevalence 
of adverse neonatal outcomes. However, no quantitative cultures have been 
performed in these studies to confirm this. Two studies investigating the relation 
between bacteriuria and genital colonization reported a positive predictive value of 
GBS bacteriuria in first trimester of pregnancy for positive GBS genital culture at 
the time of labor of 30.2%11 and 61%22 respectively. McKenna et al. reported that 
in women with GBS bacteriuria, in only 63% the same serotype was found in the 
urine and genital cultures11.
 Acute pyelonephritis is a serious threat to maternal and fetal well-being23. 
It can lead to perinatal complications including premature delivery, low birth 
weight and fetal mortality15. Maternal acute pyelonephritis is associated with 
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anemia, thrombocytopenia, septicemia, transient renal dysfunction, preeclampsia, 
pregnancy-induced hypertension, and pulmonary insufficiency13,15.
Prevention
Strong evidence for a causal relation between GBS bacteriuria and adverse outcomes 
is absent, however screening for bacteriuria early in pregnancy may be considered. 
GBS bacteriuria should be treated, whether symptomatic or not24. Treatment in the 
first trimester has been shown to reduce the incidence of symptomatic cystitis and 
pyelonephritis25. Treatment of asymptomatic GBS bacteriuria at 28 weeks gestation 
has been shown to reduce the risk of preterm labor and PPROM in one randomized 
controlled trial20. 
 Though there is evidence for the benefit of treatment of GBS bacteriuria 
in third trimester as mentioned before, there is no evidence that treatment of GBS 
bacteriuria in first trimester prevents adverse neonatal outcome. First trimester 
bacteriuria does not automatically equate to heavy genital tract colonization at 35-37 
weeks gestation11. Nevertheless, current Centers for Disease Control and Prevention 
(CDC) guidelines call for intrapartum prophylaxis for early onset neonatal GBS 
disease if bacteriuria was diagnosed during the pregnancy21, and thus there is no 
need for rectovaginal culture at 35-37 weeks in women in whom GBS bacteriuria 
was diagnosed. 
Treatment
There are many antibiotics available for the treatment of urinary tract infections. 
However, there are insufficient data to recommend any specific regimen in 
general26, but during pregnancy the use of nitrofurantoin covers most common 
microorganisms, such as E. coli and other Gram-negative bacteria26,27. 
 First choice therapy of (a)symptomatic bacteriuria due to GBS is oral 
administration of penicillin for 4-7 days20,28. The effectiveness of shorter treatment 
has not yet been proven28. One week after completion of the antibiotic treatment the 
urine-culture should be repeated to confirm the effectiveness. Because of the high 
recurrence rate of bacteriuria during pregnancy29, urine cultures should be repeated 
monthly. GBS pyelonephritis is treated with penicillin G for a total duration of 14 
days, starting with intravenous administration. After clinical response to intravenous 
therapy, treatment should be continued orally. In some settings daily suppressive 





GBS is a commensal endogenous bacterium in the gastrointestinal tract, which is 
the likely source of subsequent vaginal colonization. Studies indicate that 10-30% 
of all pregnant women are colonized with GBS in the gastrointestinal or genital 
tract30,31. Colonization can be transient, chronic or intermittent. Most carriers are 
asymptomatic. 
 Bacterial vaginosis associated with various anaerobic bacteria, Gardnerella 
vaginalis and Mycoplasma hominis, is the most common cause of vaginitis. It is not 
clear whether there is an etiological role of GBS in pregnant women for excessive 
vaginal discharge and symptomatic vaginitis. In non-pregnant women there is some 
evidence that GBS could be capable of causing symptomatic vaginitis. GBS seems 
to be more prevalent in patients with purulent or excessive vaginal discharge32,33. 
Vaginitis seems to be related to colonization with GBS33. However, there is no 
consensus whether GBS is the actual causative microorganism in these cases or 
whether GBS is present only as a cofactor34,35. 
Sequelae
Whether vaginal GBS colonization is a risk factor for PROM, PPROM and preterm 
delivery is still controversial. Associations between the colonization with GBS and 
PROM or with preterm delivery have not been found consistently36-38. PROM and 
preterm delivery are risk factors of early-onset neonatal GBS infection.
 Vaginal GBS colonization increases the risk on several maternal infections, 
such as urinary tract infection, endometritis and wound infection. Other additional 
risks are secondary to PROM, PPROM, and the use of corticosteroids, antibiotics 
or tocolytic agents.  
 Studies on GBS transmission in colonized mothers during delivery report 
incidences between 16-53%39-42 and neonatal disease develops with a frequency of 
1%40 to 22%39 in colonized neonates. Only 1-2% of infants of colonized women 
develop early-onset GBS disease in the first week of life.
Prevention
During labor there are different strategies to prevent neonatal GBS disease. 
Guidelines from CDC and Canadian guidelines21,43 recommend universal screening 
for rectovaginal GBS colonization in pregnant women at 35-37 weeks of gestation 
and administration of prophylactic antibiotics during labor to all GBS positive 
women. Prior to these guidelines a risk-based strategy was common in the USA, 
indicating that only women with a risk factor should receive antibiotics during 
labor. Risk factors for neonatal GBS disease are prematurity, ruptured membranes 
for more than 18 hours, fever, GBS bacteriuria in current pregnancy, or a previous 
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neonate with GBS disease. A risk-based strategy is still being applied in the 
Netherlands. Another possibility is to combine the risk-based and the screening 
based strategy and treat only GBS positive women with a risk factor44. Schrag et 
al.45 demonstrated that routine screening for group B streptococcus prevents more 
cases of early-onset disease than the risk-based approach.
Treatment
There is no evidence that screening and treatment of asymptomatic bacterial 
vaginosis reduces adverse neonatal outcome46. Symptomatic bacterial vaginosis 
should be treated with a regimen based on the culture results46 or empiric with 
metronidazole47. It is advised not to treat GBS colonization before the onset of 






The term intra-amniotic infection (IAI) refers to the clinical syndrome of infection 
of the placenta and membranes accompanied by signs and symptoms in the mother 
and/or the fetus. Although the diagnosis is made using clinical symptoms, no 
universally accepted criteria have been described so far. Commonly used criteria 
include maternal temperature of >38˚ C, fetal tachycardia (>160 beats/minute), 
uterine tenderness and foul smelling amniotic fluid48. IAI due to GBS occurs after 
ascending spread from the vagina. The reported incidence varies with the duration 
of gestation and the criteria used to diagnose IAI. The incidence of IAI based on 
clinical diagnosis is approximately 1-2% of all term deliveries, but in preterm 
deliveries the incidence is increased49. Bacteria normally present in the vagina are the 
most common amniotic fluid isolates in women with IAI. GBS was found in 15.4% 
of the amniotic fluid of patients with IAI and one of the most frequently isolated 
species in infected newborns delivered of mothers with IAI50-52. Colonization with 
GBS increases the risk on IAI during labor53. The risk for IAI increases with the 
duration of rupture of the membranes. However GBS can sometimes be cultured in 
amniotic fluid samples from patients with intact membranes as well54,55.  
Sequelae
The risks for maternal and neonatal morbidity and mortality is increased in patients 
with IAI. Maternal consequences include infection (serious maternal pelvic 
infections as well as sepsis), prolonged duration of labor, the need for higher doses 
of oxytocin when uterine stimulation is required56 and an increased risk for delivery 
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by caesarean section57. Postpartum hemorrhage is more common in these patients, 
due to impaired myometrial contraction. Bacteremia occurs in 2-6% of patients with 
IAI. However, when GBS is the cause of IAI much higher incidences of bacteremia 
are reported (up to in 18%)58.
 Fetal aspiration of infected amniotic fluid can lead to stillbirth, neonatal 
pneumonia, or sepsis21. Neurodevelopmental delay and cerebral palsy are potential 
long-term disabilities resulting from IAI59,60.
Prevention 
Most neonatal infections are acquired in utero, often without clinical signs of 
infection. The current CDC guidelines21 recommend the administration of antibiotics 
to all GBS positive women during labor to prevent IAI due to GBS. The previously 
used risk-based strategy advised antibiotics only in situations with an enhanced risk 
for neonatal GBS disease61. 
 The presence of GBS influences the choice of management in patients with 
PPROM, since subclinical GBS intrauterine infection has been implicated as a major 
factor in the pathogenesis and consequential maternal and neonatal morbidity. For 
patients with PPROM and a positive or unknown GBS culture antibiotic therapy 
is recommended to prevent or treat ascending intrauterine infection21. Due to the 
administration of antibiotics pregnancy will be prolonged and both maternal and 
neonatal infectious morbidity is decreased62,63. Unfortunately, the majority of cases 
of IAI in the setting of PPROM do not produce the signs and symptoms traditionally 
used as diagnostic criteria for clinical chorioamnionitis. 
Treatment
When signs of infection are present antibiotic treatment is advised and delivery is 
expedited. Several studies have demonstrated the benefit of intrapartum therapy 
compared to maternal therapy starting postpartum for both the incidence of neonatal 
sepsis and maternal morbidity50,64. This was especially prominent with sepsis due to 
GBS. A Cochrane systematic review65 concluded that the outcome after intrapartum 
and postpartum treatment was not significantly different probably because the 
number of patients included was too low50. However, it should be noted that the 
interim analysis of Gibbs’ study50 was in strong favor of intrapartum treatment. 
Therefore, this study had to be stopped due to clearly worse neonatal outcome in 
the postpartum treatment group. 
 It is still under debate what is the optimal treatment regimen should be65. 
Most IAI are caused by either E. coli or GBS. However, culture results are not 
available at the time treatment starts. Therefore, treatment is usually initiated on 
an empirical basis with a combination of a penicillin for GBS and gentamicin for 








Mastitis is a parenchymatous infection of the mammary glands, most commonly 
caused by Staphylococcus aureus. Puerperal mastitis due to GBS can be either 
symptomatic or asymptomatic. The incidence of acute puerperal mastitis varies 
from 2.9% to 24%. Only one study has examined the breast GBS carriage rate in 
humans, finding an incidence of 3.5% in 1132 milk samples from healthy lactating 
mothers68.
Sequelae
Maternal milk (in cases of either clinical or sub-clinical mastitis) is a potential source 
of infection resulting in either late-onset (i.e. from one week of life to three months) 
or recurrent neonatal GBS disease69-75. However, the pathogenesis of mastitis is 
unclear. Most likely, infection of the maternal breast follows colonization of the 
neonate in the oropharynx acquired during delivery. Afterwards, neonatal infection 
is thought to occur as a result of aspiration of organisms in the mammary ducts 
when negative pressure is created by sucking70. But it is also possible that GBS has 
entered the mammary glands prior to labor and does not originate from the neonate 
itself.
Prevention
It is important to be aware of the possibility of GBS mastitis and GBS carriage 
in breast milk. Since the pathogenesis of GBS mastitis is unclear, prevention is 
difficult. In case of suspected or recurrent GBS neonatal disease, breast milk should 
be cultured and breast feeding stopped until the cultures are negative. 
Treatment
Treatment of mild cases of mastitis is conservative, with the use of compresses, 
rest, and antipyretics. Antibiotics are used only in febrile patients76. Empiric therapy 
consists of cloxacillin, or erythromycin77. All cases of GBS mastitis should be 
treated with ampicillin, because of the possibility of serious neonatal morbidity.
Bacteremia and sepsis
General
Bacteremia in pregnancy and the puerperium may result from common medical 
illnesses (e.g. pneumonia, appendicitis) or conditions unique to pregnancy (e.g. 
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endometritis, chorioamnionitis). Among cases of GBS puerperal infection, 
bacteremia occurred in 31% to 35%78. In general, bacteremia progresses to sepsis 
in 5-25%, while septic shock is rare79. Bacteremia within 15 minutes after manual 
removal of the placenta prior to the administration of prophylactic antibiotics was 
found in 14% (13 out of 93 patients) of patients in labor who were delivered by 
caesarean section. GBS are among of the most commonly isolated microorganisms 
(38%)80. 
Sequelae
The maternal sequelae due to GBS sepsis do not differ from those related to other 
bacteria. Sepsis remains an important cause of maternal mortality. In developing 
countries puerperal sepsis is one of the main factors leading to maternal mortality81. 
Nevertheless, in obstetric patients the incidence of death from sepsis is low, as it is 
estimated at 0-3%, compared to 10-81% in non-pregnant adults79. Another maternal 
complication of bacteremia is meningitis.
Prevention
Several factors predispose for bacteremia and sepsis. In vaginal delivery, prevention 
of predisposing factors might reduce the risk for bacteremia. Predisposing factors of 
bacteremia are early gestational age, low birth weight, internal fetal monitoring, and 
a positive chorioamnionic membrane culture80. Predisposing factors of puerperal 
sepsis include anemia in pregnancy, prolonged labor (at least 12 hours), frequent 
vaginal examination during labor (more than 5 times) and premature rupture of 
membranes82. To reduce the risk of bacteremia after caesarean delivery, antibiotics 
should be administered80. 
Treatment
To prevent the sequelae of bacteremia or sepsis rapid intervention with broad-
spectrum antibiotics (beta-lactam with aminoglycoside) is required on an empirical 
basis83. In case culture results show GBS bacteremia the narrow-spectrum antibiotic 
penicillin is sufficient. Microbiological evaluation should include specimens from 




The overall incidence of GBS meningitis is 0.3 cases/ 100.000 population84. 
Postpartum maternal GBS meningitis is rare85. In the literature only 10 cases have 
been described. All cases but one followed a vaginal delivery86,87. Only one patient 
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presented meningitis before delivery whereas one patient was diagnosed 6 months 
postpartum. The other 8 cases manifested between 14 hours and 6 days postpartum. 
One patient died. None of the mothers had received antibiotic prophylaxis during 
delivery. One additional case of GBS meningitis has been reported as a likely 
complication of obstetric epidural anesthesia88. 
 Bacterial meningitis usually develops after hematogenous spread. 
Bacteria then cross the blood-brain barrier into the subarachnoid space. In an 
experimental animal model, a high degree of bacteremia had been shown to be 
a primary determinant for meningeal invasion by GBS89. To cause meningitis via 
the bloodstream, bacteria have to escape the host defenses, multiply and reach the 
threshold level of bacteremia to invade the meninges. Another possible route of 
infection is after direct inoculation into the cerebrospinal fluid.
Sequelae
For young adults, outcome is related to the level of consciousness and the presence 
of seizures at the time treatment is initiated. Potential complications are dementia, 
seizures, hydrocephalus, cerebral infarction, cerebral venous thrombosis and 
brain abscesses. Ten percent of patients suffer from hearing deficits after bacterial 
meningitis. In general, about 30-50% of the survivors sustain neurological sequelae 
after bacterial meningitis90.
Prevention
Since the degree of bacteremia in the patient seems to be the primary determinant 
in the pathogenesis of GBS meningitis89, prevention of bacteremia should also 
prevent meningitis. The incidence of bacteremia after cesarean delivery is high, but 
GBS meningitis occurs predominantly after vaginal delivery. This can probably be 




To prevent complications from GBS meningitis treatment should start as soon as 
the diagnosis is suspected. Lumbar puncture and isolation of GBS is diagnostic. 
Treatment will start empirically with a 3rd generation cephalosporin91. GBS 






Endometritis is a more common complication of cesarean section than of vaginal 
deliveries (11.4 versus 0.4%)92. Endometritis following vaginal delivery develops 
more frequently in women who had pregnancies associated with adverse fetal 
outcomes including stillbirth, low birthweight, preterm delivery and serious neonatal 
morbidity93,94. Postpartum endometritis can occur up to 6 weeks following delivery.
 Risk factors for the development of endometritis include delivery by 
caesarean section, instrumental delivery, long duration of labor, internal fetal 
monitoring, frequent vaginal examinations, preterm labor, premature rupture of 
membranes, manual removal of the placenta, low socioeconomic status, infection 
with Neisseria gonorrhoeae and Chlamydia trachomatis, and colonization with 
GBS94,95. Patients with meconium have a higher risk for endometritis96, probably 
because the growth of GBS and E. coli is enhanced in meconium stained amniotic 
fluid97. 
 In early postpartum endometritis (i.e. within the first 48 hours), GBS is an 
important contributor as it is most frequently isolated98. High-spiking fever (at least 
39˚ C) developing within the first 24 hours after delivery may be associated with 
very virulent pelvic infection caused by either group A or group B streptococcus53. 
In studies of endometritis, GBS has been identified as the sole pathogen in 2 to 14 
percent of cases. It appeared the only pathogen more often after vaginal delivery as 
compared to caesarean section99,100. 
Sequelae
Maternal morbidity associated with endometritis depends on the type of sequelae. 
Infection can extend to the peritoneal cavity followed by peritonitis and pelvic 
abscesses and can even cause sepsis. Septic pelvic thrombophlebitis is a rare 
complication.
Prevention
Several strategies have been suggested for the prevention of endometritis in general. 
To reduce the incidence of endometritis antibiotic prophylaxis at the time of cesarean 
delivery has become a common practice101. Fernandez et al.102 demonstrated that a 
single dose of amoxicillin and clavulanic acid is beneficial after vaginal deliveries. 
However, low incidence of endometritis after vaginal delivery and preference 
for the restrictive use of antibiotics make such practice undesired. There is also 
some evidence that the intravaginal administration of metronidazole gel reduces 
the incidence of post cesarean endometritis103. The efficacy of chlorhexidine 




 Strategies specifically aiming at GBS may be helpful as well. The incidence 
of GBS endometritis declined after the introduction of the GBS prophylaxis109. In a 
longitudinal study Locksmith et al.110 compared the infection rates following three 
consecutive protocols for the prevention of GBS disease. In the selective screening 
protocol, GBS cultures were obtained from women with PPROM or preterm labor 
and intrapartum antibiotics were administered to all women with positive culture 
and a risk factor for neonatal GBS disease. In the risk-based protocol, intrapartum 
antibiotics were given to all women with unknown colonization status and a risk 
factor for neonatal GBS disease111. Under the universal screening protocol, a culture 
was performed between the 35-37 week of gestation and intrapartum antibiotic 
prophylaxis given to all women with a positive GBS culture. Under all three 
protocols the postpartum endometritis rates were reduced110. The best success rate 
was achieved with universal screening110.
 
Treatment
Commonly postpartum endometritis is treated with an empiric regimen against 
mixed aerobic and anaerobic organisms. The combination of clindamycin with once 
daily gentamicin is appropriate. Once uncomplicated endometritis has clinically 
improved with intravenous therapy, oral therapy is not needed112. In case GBS 




Infections in perineal and abdominal wounds after delivery can be caused by GBS. 
Infections with hemolytic streptococci progress rapidly. Cellulitis, lymphangitis, 
and bleb formations are typical. Watery exudate from the wound is common. 
Infection of perineal wounds is relatively uncommon, despite the high prevalence of 
bacteria present at the site of infection. Owen et al. described episiotomy infections 
to occur in only 0.05% of all cases113. Besides technical procedures, duration of 
cesarean section over one hour and induction of labor increase the risk of wound 
infection114.
 Early-onset wound infection is commonly caused by group A streptococcus, 
presenting with systemic illness. Group B streptococcus may present in a similar 
fashion115. It is not known to what extent GBS contributes to the incidence of wound 
infections. Abdominal wound infections after caesarean section may be caused by 
the same microorganisms that can be isolated from the amniotic fluid. At caesarean 
section after rupture of the membranes for at least 6 hours, GBS can be cultured 




Episiotomy dehiscence is most commonly associated with infection. Maternal 
risks include the extension of the infection, fistula formation and sepsis. Failure 
to treat these infections exposes patients to the risk of necrotizing fasciitis and 
bacteremia.
 Necrotizing fasciitis is a rare obstetric complication. It involves the superficial 
fascia, subcutaneous tissue, and, occasionally, deeper tissue layers. It can be fatal 
and is often rapidly progressive and associated with significant tissue necrosis. 
Initially it is often unrecognized and later it presents as a fulminating disease with 
marked high mortality. Prognosis depends on the delay of diagnosis, antimicrobial 
treatment and wide surgical excision of all necrotic tissue117. Necrotizing fasciitis 
arising from an infected episiotomy due to GBS has been described118. Necrotizing 
fasciitis of an episiotomy may extend to the thighs, buttocks and the abdominal wall. 
Usually symptoms appear from 3 to 5 days postpartum. Risk factors postpartum for 
necrotizing fasciitis are diabetes mellitus, obesity, hypertension and drug abuse119.
Prevention
Puerperal endometritis increases the risk of wound infections114. Prevention of 
endometritis is therefore important for the prevention of wound infection. There is 
some evidence that GBS prophylaxis is also beneficial in the prevention of wound 
infections92. It is unclear whether this is a direct effect of the antibiotics, or indirectly 
through a reduction in the incidence of endometritis.
 General strategies to prevent wound infection and its extension are 
straightforward and not specific for GBS. Most important is proper hygiene and 
proper surgical technique. 
Treatment
If the wound infection is mild, antibiotics are not required. If the infection is severe, 
but does not involve deep tissues, a combination of ampicillin and metronidazole 
should be prescribed. In case deep tissues are involved or first signs of necrotizing 
fasciitis appear, a combination of broad spectrum antibiotics (penicillin, gentamicin 
and metronidazole) and surgical treatment are indicated77. Necrotizing fasciitis 
requires wide surgical debridement. GBS may be involved in most types of wound 




GBS not only is an important cause of serious neonatal infection, but also causes a 
variety of maternal infections. These infections cause less morbidity than neonatal 
infections, but occur more commonly. Especially during the course of pregnancy 
and delivery GBS can endanger both the mother and fetus. Mastitis may be a 
cause of late-onset or recurrent neonatal GBS disease. With early recognition and 
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Objective: To study the pharmacokinetics of intravenously administered amoxicillin 
in pregnant women with preterm premature rupture of the membranes (PPROM).  
Study design: Healthy women with PPROM were recruited and treated with 
amoxicillin (2 gram initially and 1 gram subsequently). Blood samples were 
obtained from the opposite arm and concentrations determined using HPLC. 
Nonlinear mixed-effects modeling was performed in NONMEM. 
Results: The pharmacokinetics of seventeen patients was described by a 
3-compartment model. Clearance and volume of distribution at steady state were 
22.8 L/h and 21.4 L respectively, similar to values in non-pregnant individuals. 
There was little variability between patients. No relationship was observed between 
values of individual pharmacokinetic parameters and various covariates.
Conclusion: The pharmacokinetics of amoxicillin in pregnant patients with PPROM 
is similar to non-pregnant individuals. Given the small inter-individual variability 
in pharmacokinetics, no dose adjustments are required to account for differences 
between subjects under normal circumstances.
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Introduction
Preterm premature rupture of the membranes (PPROM) complicates approximately 
3% of pregnancies and is responsible for one third of all preterm births1. Subclinical 
intra-amniotic infection has been implicated as a major etiological factor in the 
pathogenesis of PPROM2. The consequential maternal and neonatal morbidity are 
attributed to ascending infections from the vagina after rupture of the membranes. 
Antibiotic therapy has been recommended in the management of patients with 
PPROM to prevent or treat ascending intra-amniotic infection3,4. 
 Amoxicillin, a penicillin derivative, is an antibiotic frequently used 
in the management of PPROM. It is active against common pathogens that can 
cause infection in neonates, in particular Streptococcus agalactiae. The currently 
recommended amoxicillin dosages in pregnancy are derived from studies using 
ampicillin5,6. These dosage regimens essentially do not differ from regimens 
employed in non-pregnant individuals and are based on the assumption that 
pharmacokinetics in pregnancy and in young men are similar5,6. In non-pregnant 
individuals a slow elimination phase has been suggested for penicillin G and 
amoxicillin7,8. Especially for bacteria with a low MIC, like Streptococcus agalactiae, 
a slow elimination phase would be of clinical importance. In women with PPROM 
the presence of such elimination phase would be beneficial for efficacy of the 
prophylaxis by increasing the time the amoxicillin concentration remains above the 
MIC. However, during pregnancy physiological changes occur that may modify 
the pharmacokinetics of drugs, such as increase in plasma volume, increase in fat 
content, presence of the fetus, changes in elimination rate or metabolism9. These 
changes can be expected to affect the pharmacokinetics of drugs in various ways. 
If changes in pharmacokinetics indeed occur, pregnant women and their fetus 
are inherently at risk for under- or overdosing when they are treated with dosage 
regimens developed for non-pregnant individuals. A clear example is the drastic 
decrease in concentration of the antiepileptic drug lamotrigine during pregnancy10.
 Despite the widespread use of amoxicillin in pregnant women, the 
pharmacokinetics in patients with PPROM has not been adequately studied. The 
objective of this study is to describe the pharmacokinetics in this vulnerable 
patient group and to develop a population pharmacokinetic model. Since the 
pharmacokinetics in individual patients may be affected by various factors, 
it is important that the method of data analysis allows identification of such 
factors. Therefore, pharmacokinetic data analysis using Non-Linear Mixed 
Effects (‘population’) modeling was applied. This method has distinct statistical 
advantages, especially for such patient groups. The data of the whole population 
are simultaneously analysed, while taking into account inter-individual and intra-
individual variability in respectively the model parameters and the observations 
by assuming a stochastic distribution11. The influence of specific characteristics on 
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the individual PK parameters can be assessed by including these characteristics 
as covariates in the PK-model12,13. A more detailed background of population 
modelling can be found elsewhere14,15.
Material and methods
Patients
In the period between February 7, 2005 and February 14, 2006, all women with 
PPROM who needed antibiotic treatment with amoxicillin were eligible for this 
study. Following the local guidelines, all women with PPROM (gestational age <37 
weeks) were admitted to the hospital and monitored for fetal condition and signs 
of infection. Women with proven or unknown Streptococcus agalactiae carriage 
were treated with antibiotics. Delivery was induced only when signs of infection 
were present. The study was approved by the Medical Ethics Committee. Written 
informed consent was obtained from all patients. Women were excluded from the 
study when i) they had been treated with oral or intramuscular antibiotics within 2 
days before starting therapy, ii) were unwilling to comply with the requirements of 
the study, iii) were known to be allergic to amoxicillin or other penicillins, or iv) 
were receiving co-medication that exhibits interaction with amoxicillin. All patients 
were at least 18 years of age and not in labor. 
Drug administration and blood sampling
Before the administration of amoxicillin an intravenous catheter was placed in each 
arm. Amoxicillin was administered following local guidelines. The treatment started 
with an intravenous infusion of 2 gram amoxicillin (50 mg/mL) administered over 
30 minutes, followed by a second infusion after 4 hours of 1 gram amoxicillin 
over 15 minutes. Bloodsamples of 2 mL were collected from the second catheter 
in the contralateral arm at timed intervals beginning at 1 min after the start of the 
infusion and, at 7 and 15 min (1 gram infusion) or 15 and 30 min (2 gram infusion) 
during the first two amoxicillin administrations. After the infusion sampling was 
scheduled at 3, 6, 10, 16 and 36 minutes, and afterwards every 30 minutes until the 
next antibiotic dosage. The exact sampling times were recorded.
 Blood samples were placed immediately on ice, allowed to clot and 
processed within one hour after collection. The samples were centrifuged at 1200 
g for approximately 10 minutes. The supernatants were transferred into plastic 
storage tubes and frozen at –70° C until analysis.
Patient information
All patients received a standard work-up which included a medical history, 
biochemical and hematological examination. Furthermore blood pressure, pulse, 
oral temperature, and body weight were recorded. The amount of edema was scored 
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semiquantitatively from 0 (no edema) to 3 (above the knee). Before the start of the 
antibiotics a rectovaginal culture was taken to determine GBS carriage. 
Amoxicillin HPLC assay
Amoxicillin concentrations were determined by an isocratic high-pressure liquid 
chromatography (HPLC) (Shimadzu, Den Bosch, The Netherlands (NL)) method, 
using an ODS Gemini column (Bester, Amstelveen,NL) with  0.066 M KH2PO4 
solution containing 10% methanol as a mobile phase. A perchloric acid solution 
of 0.1 ml was added to the sample in an equal volume and after vortexing, added 
to 0.56 ml 0.028 M citric acid containing cefadroxil (Sigma, Zwijndrecht,NL) as 
an internal standard. The assay was linear over the concentration range measured. 
Controls were included in every run. The lower limit of detection was 0.2 mg/L and 
the between run CV < 4%.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated by means of NonLinear Mixed 
Effect (population) Modeling (NONMEM). The model was implemented in the 
NONMEM ADVAN5 subroutine and the analysis was performed using the FOCE 
method. All fitting procedures were performed with the use of the Compaq Visual 
FORTRAN standard edition 6.6 (Compaq Computer Cooperation, Euston, Texas, 
USA) and NONMEM® software package (version V, release 1.1, GloboMax, 
Hanover, USA). 
 To determine the basic structural pharmacokinetic parameters various 1-, 
2- and 3-compartment models were tested. Model selection and identification of 
variability was based on the likelihood ratio test, pharmacokinetic parameter point 
estimates, and their respective confidence intervals, and goodness-of-fit plots. For 
the likelihood ratio test on differences between two models, the objective function 
value (OFV) with a pre-specified level of significance of P<0.001 was used. 
NONMEM minimizes an objective function in performing nonlinear regression 
analysis. To detect systematic deviations in the model fits the goodness-of-fit plots 
were visually inspected. The data of individual observations versus individual or 
population predictions should be randomly distributed around the line of identity. 
The weighted residuals versus time or population predictions should be randomly 
distributed around zero. Population values were estimated for the parameters 
clearance (CL), the volumes of distribution (V) and the intercompartmental 
clearances (Q).
 Individual estimates for pharmacokinetic parameters were assumed to 
follow a log normal distribution. Therefore an exponential distribution model 
was used to account for inter-individual variability. Possible correlation between 
inter-individual variability coefficients on parameters was estimated and if present 
accounted for in the stochastic model (NONMEM Omega block option). 
74
Chapter 4
 Selection of an appropriate residual error model was based on the likelihood 
ratio test and inspection of the goodness-of-fit plots. The residual variability between 
the observed concentrations and those predicted by the model was described using a 
proportional error model. The residual error term contains all the error terms which 
cannot be explained and refers to, for example, measurement and experimental 
error and structural model misspecification.
 To refine the model covariate analysis was also performed. The estimated 
pharmacokinetic parameters were plotted independently against the covariates 
bodyweight, body mass index, duration of amenorrhea, blood pressure, pulse, oral 
temperature, and the amount of edema to determine whether this influenced the 
pharmacokinetics. The effects of covariates were tested for statistical significance 
using the likelihood ratio test and the residual intra- and inter-individual variability 
were visually evaluated. The volume of distribution at steady state (Vss) and terminal 
half-life (T1/2) were calculated following standard procedures
16.
 The accuracy of the final population model was established using a bootstrap 
method in NONMEM, consisting of repeated random sampling with replacement 
from the original data. This resampling was repeated 100 times. The estimated 
parameters from the bootstrap analysis were compared to the estimates from the 
original data.
Results
In total 17 patients were included. The population consisted of 15 singleton and 2 
twin pregnancies. The gestational age at the time of PPROM ranged from 29.4 to 
36.9 weeks of pregnancy. The patients were born in 8 different countries, illustrating 
the heterogeneity of the hospital population as well as the study population. The 
characteristics of the study patients are presented in table I. 
 A total of 416 blood samples was collected, which was close to the 
predefined sampling schedule. The 2 g and 1 g infusions resulted in mean peak 
concentrations of 96.7 mg/L (range 73.5- 136.6 mg/L) and 70.9 mg/L (n=16, range 
49.1-107.1 mg/L), respectively. A three-compartment open model best described 
the data. The estimates of the pharmacokinetic parameters and their respective 
coefficients of variation (cv) are summarized in table II. The cv’s were relatively 
small with values between 4.5 and 30.8%. Inter-individual variability was explained 
by variation in the parameters CL and V2 (18% for CL and 33% for V2). This means 
that the variability between subjects was in fact very small. A correlation between 
the random parameters for inter-individuality was found and accounted for in the 
stochastic model. Values of T1/2 and Vss were 1.10 h and 21.4 L, respectively. 
 None of the covariates tested, gestational age, bodyweight, body mass 
index, blood pressure, pulse, oral temperature, and the amount of edema could 
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improve the model. Finally, no difference in pharmacokinetics between the 2 g and 
1g infusion was observed. 
 The observed and population-predicted profiles for the final model are 
shown in figure 1. The scatter plot of the observed concentrations versus model-
predicted concentrations is shown in figure 2. 
 The bootstrap validation of the final model was performed with 100 runs. The 
mean parameter estimates of the runs obtained from the bootstrap analysis did not 
differ significantly from the predicted values from the NONMEM pharmacokinetic 
analysis. The standard error obtained from the bootstrap analysis was also 
comparable to those estimated by the model, except for the intercompartimental 
clearance between the central and second compartment (Q1). This value differs 
significantly from the standard error estimated by the model due to the small size of 
the study population. The mean values and standard errors are represented in table 
II.  
Table 1: Baseline patients demographic data of the 17 pregnant patients with PPROM.




Maternal age year 17 29.4 4.64 19.6-35.1
Gestational age week 17 35.1 1.75 29.4-36.9
Body Mass Index kg/m2 17 29.1 3.86 21.5-35
Weight kg 17 80.6 12.03 56.2-98.9
Edema (no/around the ankle/up to the knee) - 16 10/5/1
Leucocytes x109/L 17 11.8 4.43 6-25.9
Creatinin μmol/L 17 44.4 10.11 37-74
Nulliparity - 11 - - -
Twin pregnancy - 2 - - -
Positive maternal GBS culture - 7 - - -
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Figure 1: Observed concentration-time profiles.
The superimposed bold line shows the predicted profile obtained with the final model. The 
blocks indicate the time at which the infusions of the amoxicillin was started and stopped. 
Because there was variation in the start-time of the second infusion due to the clinical 
situation, in this graph the data were adapted assuming that the second infusions started at 
t=5.05h for all patients. (See color inlay for a full color version of this figure.)
Comment
 In this study a PK-model was developed to describe the pharmacokinetics 
of amoxicillin in pregnant women with PPROM. The pharmacokinetics in our 
population appears to be only slightly different from non-pregnant individuals with 
a Vss of 21.4 L and a T1/2 of 1.10 h. The variability between the patients was small. 
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Table 2: Population model parameter values and bootstrap estimates.
SE: standard error of the estimate; * mean of 100 bootstrap analyses. The parameter values 
were compared with the bootstrap estimates using the unpaired t-test.
parameter units Final model estimates Bootstrap estimates*
mean SE mean SE
structural model parameters
CL L/h 22.8 1.03 22.8 1.04
V1 L 5.59 0.826 5.26 1.32
V2 L 7.43 1.06 7.75 1.16
V3 L 8.61 0.768 9.07 0.99
Q1 L/h 60 18.5 82.2 69.8
Q2 L/h 7.72 1.72 7.92 1.78
variance model parameters
interpatient variability in CL 0.0317 0.0112 0.0300 0.0106
interpatient variability in V2 0.108 0.00440 0.0982 0.0476
residual variability 0.0365 0.00492 0.0359 0.00508
derived pharmacokinetics parameters
T1/2 h 1.10 - - -
Vss L 21.4 - - -
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Figure 2: Scatter plot of the individual predicted versus observed concentrations of 
amoxicillin for 17 patients. The correlation coefficient was 0.97. The figure shows the 
individual data points for the entire population and the line of identity (x=y).
With regard to amoxicillin, values for volumes of distribution, clearance and 
terminal half-life were all within the ranges reported in the literature for healthy 
non-pregnant individuals (table III). Only slightly lower peak serum concentrations 
were observed compared to 7 healthy non-pregnant individuals17, i.e. 96.7 mg/L and 
139.3 mg/L respectively for the 2 gram infusion. The value for Vss in our study was 
slightly larger than values found by Dalhoff et al. in healthy volunteers8, who also 
used a 3-compartment model. Possibly this was due to the increased extracellular 
fluid in pregnant women and the pregnancy itself.
 To our knowledge this is the first study on the pharmacokinetics of 
amoxicillin in pregnant women. Therefore, direct comparison with other studies 
under the same conditions is not possible. However, a comparison can be made to 
studies on ampicillin, which is closely related to amoxicillin (p-hydroxyampicillin). 
The two compounds differ very little in pharmacokinetics in healthy volunteers, 
except with respect to absorption after oral administration18,19. Several studies have 
been performed on the pharmacokinetics of ampicillin in pregnancy. In contrast to 
our study most studies on ampicillin did show differences in the pharmacokinetics 
during pregnancy, e.g. shorter half-life and higher plasma clearance during 
pregnancy20-24. This dissimilarity is intriguing; possible explanations are the use of 
different methods of analysis or the inclusion of patients at different gestational age 
and circumstances.
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 Two studies have noted that the clearance of amoxicillin after an 
intravenous dose exhibited a statistically significant dose effect17,25. However, the 
2 studies are inconsistent with respect to the range where deviation of linearity 
occurs. Mastrandrea et al. described a difference in clearance in the range from 
500 mg to 1000 mg25, whereas Hill et al. found a slight deviation from linearity 
after a 5 g dose compared with doses of 250-1000 mg17. In a study by Sjövall 
et al. the pharmacokinetics after infusions in doses ranging from 1.9 g and 2.8 g 
were linear19. In our data, covering the range of 1-2 g, there was no evidence for a 
dose effect on the clearance. It is unlikely that therapeutic consequences are to be 
expected.
 In general, inter-individual variability in pharmacokinetic parameters 
observed in clinical study populations are due to biochemical and physiological 
differences between subjects. In association with pregnancy, additional physiological 
alterations occur, which may further increase the variation in parameters between 
individuals in pregnant populations26. Surprisingly, the inter-individual variation 
in our data was remarkably small. While this was an unexpected finding, from the 
clinical perspective this is convenient, because specific adjustments are unnecessary 
for this patient group.
 An important question is whether this dosing regimen is adequate to treat 
or prevent morbidity in both mother and fetus. The efficacy of the penicillins 
is determined by the time the concentration exceeds the minimum inhibitory 
concentration (T>MIC) and, in general, T>MIC for 40-50% of the dosing-interval 
is required for efficacy27-29. The breakpoint MIC value of an antibiotic used is the 
highest MIC value of different causative microorganisms that results in a high 
probability of cure, as follows from the target T>MIC. Since rectovaginal carriage 
of Streptococcus agalactiae has been described in up to 30% of pregnant women, 
this is an important microorganism after PPROM in the development of neonatal 
infection3,30. MIC values of amoxicillin for Streptococcus agalactiae are scarce, but 
vary from 0.03 to 0.12 mg/L31,32. The peak serum concentrations in our pregnant 
population were slightly lower than in non-pregnant individuals, but nevertheless 
well above the MIC. More importantly, maternal serum concentrations remained 
above the MIC for sufficient percentage of the dosing interval (>95%), even taking 
into account the protein binding of amoxicillin. The presence of a slow elimination 
phase, represented by the third compartment, significantly contributes to the 
high value for T>MIC. Because amoxicillin reaches the fetus after transplacental 
transport, it should be noted that adequate maternal levels are a prerequisite for 
the prevention of fetal infection, but no guarantee. In treatment of the mother, the 
added value of a 2 g loading dose above a 1 g dose is doubtful. However, it remains 



















































































































































































































































































































































































































































































































































































































































































Amoxicillin PK in women with PPROM
 It is surprising that the pharmacokinetics in pregnant women with PPROM 
did not differ significantly from non-pregnant individuals. However, it should be 
noted that this is only valid for pregnant women with PPROM who are otherwise 
healthy. It has been suggested previously that it is not the state of pregnancy that 
influences the pharmacokinetics, but being in labor6. Since our patients were not in 
labor, this might explain why our data were similar compared to previously reported 
data of non-pregnant individuals.
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Aim: Many physiological changes take place during pregnancy and labor. These 
might change the pharmacokinetics of amoxicillin, necessitating adjustment of the 
dose for prevention of neonatal infections. We investigated the influence of labor 
on the pharmacokinetics of amoxicillin. 
Methods: Pregnant women before and during labor were recruited and treated with 
amoxicillin intravenously. A postpartum dose was offered. Blood samples were 
obtained and amoxicillin concentrations were determined using high-pressure 
liquid chromatography. The pharmacokinetics was characterized by nonlinear 
mixed-effects modeling using NONMEM.
Results: The pharmacokinetics of amoxicillin in 34 patients was best described by 
a 3-compartment model. Moderate inter-individual variability was identified in CL, 
central and peripheral volumes of distribution. The volume of distribution increased 
with an increasing amount of edema. Labor influenced the parameter estimate of 
peripheral volume of distribution (V2). V2 was decreased during labor, and even 
more in the immediate postpartum period. For all patients the population estimates 
(mean +/- SE) for CL and the volumes of distribution (V) were 21.1+/-4.1 L/h (CL), 
8.7+/-6.6 L (V1), 11.8+/-7.7 L (V2) and 20.5+/-15.4 L (V3) respectively. 
Conclusion:The peripheral distribution volume of amoxicillin in pregnant women 
during labor and immediately postpartum is decreased. However, these changes are 
not clinically relevant and do not warrant deviations from the recommended dosing 
regimen for amoxicillin during labor in healthy pregnant patients. 
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Introduction
The use of antibiotics during labor for prevention of neonatal infections has 
increased substantially in the last decades. Current guidelines from the Centers of 
Disease Control and Prevention (CDC) to prevent neonatal group B streptococcal 
(GBS) disease recommend the use of antibiotics during labor in all pregnant women 
carrying GBS1. The prevalence of GBS carriage varies according to the geographical 
region from 10% to 35% of all pregnant women, resulting in antibiotic use for this 
purpose in up to one of every three women2-5. Amoxicillin, a penicillin derivative, is 
one of the antibiotics used in the prevention of GBS disease. Amoxicillin is widely 
used in Europe, while ampicillin is more commonly used in the US. Amoxicillin is 
a bactericidal antibiotic and is primarily excreted unchanged in the urine both by 
glomerular filtration and by tubular secretion in the kidneys.
 Adequate dosing of antibiotics to the mother is essential to prevent the 
neonate from GBS disease. Antibiotics reach the fetus after transplacental passage. 
An adequate concentration-time profile in maternal serum is therefore a prerequisite 
for an adequate concentration-time profile in the fetus. Current dosing regimens are 
similar for non-pregnant individuals, pregnant women before the onset of labor 
and for pregnant women during labor. Many physiological changes take place 
during pregnancy, which may modify the concentration-time profile of specific 
drugs, such as an increase in plasma volume, presence of the fetus and changes 
in elimination rate or metabolism6. In a previous study we found no differences 
in the pharmacokinetics (PK) of amoxicillin between pregnant women with 
preterm premature rupture of the membranes (PPROM) and values reported in 
the literature for non-pregnant individuals7. During labor additional physiological 
changes occur of which many are expected to change the PK behavior of drugs8. 
Uterine contractions, mechanical compression of blood vessels by the gravid uterus 
as well as hyperventilation, might all have their separate circulatory influences 
affecting blood flow through the body and especially to the eliminating organs. The 
consequential change in concentration-time profile of the antibiotic for both mother 
and neonate are unpredictable. 
 Despite the regular use of amoxicillin during labor, the influence of labor on 
the PK has not been adequately studied. PK studies during labor face considerable 
ethical and practical difficulties, limiting the collection of blood samples. The 
number of blood samples collected in women during labor will therefore be smaller 
compared to pregnant women before the onset of labor. Unbalanced study groups 
harbor statistical problems. Non-Linear Mixed Effects  Modeling (NONMEM)9 
allows weighted analysis of observations from unbalanced study designs and 
incorporation of patients with small or incomplete datasets10, 11. Studying the 
whole population as one group, the influence of specific circumstances, such as the 
presence of labor, on the individual PK parameters can be assessed using covariate 
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analysis12,13. A more detailed background of population modeling can be found 
elsewhere14,15. The objective of this study is to investigate the influences of labor on 
the PK of intravenously administered amoxicillin.
Methods
Patients
In the period between February 7, 2005 and February 28, 2007, all women with 
gestational age of minimally 26 weeks who needed antibiotic treatment with 
amoxicillin were eligible for the study. From a subset of patients a part of the data 
was used in a previous study7. These patients were all diagnosed with preterm 
premature rupture of the membranes and therefore before the onset of labor (in total 
416 samples). Following the local guidelines, all women with proven or unknown 
Streptococcus agalactiae carriage were treated with antibiotics when pregnancy 
was complicated by one of the following factors: preterm premature rupture of 
the membranes, rupture of the membranes for >18 hours, prematurity, fever 
(>37.8° C), bacteriuria in current pregnancy and a previous child with invasive 
GBS disease. The choice of  the antibiotic for this study was dictated by the local 
guidelines, which recommend amoxicillin as first choice. Women were admitted to 
the hospital and monitored for fetal condition, onset of labor and signs of infection. 
When intra-amniotic infection was suspected, delivery was induced. The study was 
approved by the Medical Ethics Committee of the Medical Center Haaglanden, the 
Hague, the Netherlands. Written informed consent was obtained from all patients. 
Women were excluded from the study when i) they had been treated with oral or 
intramuscular antibiotics within 2 days before starting therapy, ii) were unwilling 
to comply with the requirements of the study, iii) were known to be allergic to 
amoxicillin or other penicillins, or iv) were receiving co-medication that exhibits 
interaction with amoxicillin. All patients were at least 18 year of age. 
 Both pregnant patients before the onset of labor and patients in labor were 
included in the study. Patients included before the onset of labor or during labor, 
who agreed to receive an additional dose of amoxicillin after their delivery for 
study purposes only were kept in the study until maximally 28 hours after delivery. 
Being in labor was defined as the presence of uterine contractions resulting in 
progressive cervical dilatation. The vaginal examinations were performed by the 
physician responsible for the delivery. When labor started during the study period, 
the time of the onset of labor was recorded.
 All patients received a standard work-up that included a medical history, 
biochemical and hematological examination. Furthermore blood pressure, pulse, oral 
temperature, and body weight were recorded at the onset of the study. Furthermore 
blood pressure, pulse, oral temperature, and body weight were recorded at the onset 
of the study. Temperature and pulse were recorded to register the possibility of 
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intra-amniotic infection, whereas the blood pressure and the amount of edema were 
recorded to account for differences in distribution volumes. The amount of edema 
was scored semiquantitatively from 0 (no edema) to 3 (above the knee).
Drug administration and blood sampling
Before the administration of the amoxicillin, an intravenous catheter was placed 
in each arm. Amoxicillin was administered according to local guidelines in the 
hospital. Treatment started with an intravenous infusion of 2 gram amoxicillin (50 
mg/mL) administered over 30 min, followed by an infusion of 1 gram amoxicillin 
over 15 minutes every 4 hours until delivery. In the prevention of GBS, antibiotics 
were administered until delivery. For the purpose of this study only, a single 
additional dose of 1 gram amoxicillin was administered after delivery 4 hours after 
the last dose before child birth. Blood samples of 2 mL were collected from the 
second catheter in the contralateral arm at timed intervals beginning at 1 min after 
the start of the infusion and, at 7 and 15 min (1 gram infusion) or 15 and 30 min (2 
gram infusion). After the infusion, sampling was scheduled at 3, 6, 10, 16 and 36 
minutes, and afterwards every 30 minutes until the next antibiotic dosage. Blood 
samples were collected when possible, taking into consideration the physical and 
emotional inconvenience to the woman. The exact sampling times were recorded. 
 Blood samples were placed immediately on ice, allowed to clot and 
processed within one hour after collection. The samples were centrifuged at 1200 
g for approximately 10 min. The supernatants were transferred into plastic storage 
tubes and frozen at -70˚ C until analysis. 
Amoxicillin HPLC assay
Amoxicillin concentrations were determined by an isocratic high-pressure liquid 
chromatography (HPLC) (Shimadzu, Den Bosch, The Netherlands (NL)) method, 
using an ODS Gemini column (Bester, Amstelveen,NL) with 0.066 M KH2PO4 
solution containing 10% methanol as a mobile phase. A perchloric acid solution 
of 0.1 ml was added to the sample in an equal volume and after vortexing, added 
to 0.56 ml 0.028 M citric acid containing cefadroxil (Sigma, Zwijndrecht, NL) as 
an internal standard. The assay was linear over the concentration range measured. 
Controls were included in every run. The lower limit of detection was 0.2 mg/L and 
the between run CV < 4%.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated by means of Non-Linear Mixed Effect 
Modeling (NONMEM). The model was implemented in the NONMEM ADVAN5 
subroutine and the analysis was performed using the FOCE with INTERACTION 
method. All fitting procedures were performed with the use of the Compaq 
Visual FORTRAN standard edition 6.6 (Compaq Computer Cooperation, Euston, 
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Texas, USA) and NONMEM® software package (version VI, release 1.2, ICON 
Development Solutions, Ellicott City, Maryland, USA ). 
 To determine the basic structural pharmacokinetic parameters various 
2- and 3-compartment models were tested. Model selection and identification of 
variability was based on  evaluation of the mean objective function value (OFV), 
pharmacokinetic parameter point estimates, and their respective confidence 
intervals, and goodness-of-fit plots. For differences between two structural 
models, the OFV with a pre-specified level of significance of p<0.001 was used 
(corresponding to a difference in OFV of 10 points). NONMEM minimizes an 
objective function in performing nonlinear regression analysis. To detect systematic 
deviations in the model fits, the goodness-of-fit plots were visually inspected. 
The data of individual observations versus individual or population predictions 
should be randomly distributed around the line of identity. The weighted residuals 
versus time or population predictions should be randomly distributed around zero. 
Population values were estimated for the parameters clearance (CL), the volumes 
of distribution (V) and the intercompartmental clearances (Q). 
 Individual estimates for pharmacokinetic parameters were assumed to 
follow a log-normal distribution. Therefore an exponential distribution model 
was used to account for inter-individual variability. Possible correlation between 
inter-individual variability coefficients on parameters was estimated and if present 
accounted for in the stochastic model (NONMEM Omega block option). 
 Selection of an appropriate residual error model was based on the likelihood 
ratio test and inspection of the goodness-of-fit plots. A proportional error model, 
additive error model and a combined proportional-additive error model were tested 
to describe the residual variability between the observed concentrations and those 
predicted by the model. The residual error term contains all the error terms which 
cannot be explained and refers to, for example, measurement and experimental 
error and structural model misspecification.
 To refine the model covariate analysis was also performed. The estimated 
pharmacokinetic parameters, on which a random effect has been identified, were 
plotted against the covariates bodyweight, body mass index, gestational age, blood 
pressure, pulse, oral temperature, and the amount of edema, single or twin pregnancy, 
creatinin, the renal function calculated with the Cockcroft-Gault (CG) and the 
modified Modification of Diet in Renal Disease (MDRD) equation to determine 
whether this influenced the pharmacokinetics16,17. Covariate analysis was performed 
by forward addition of each candidate covariate into the model structure until no 
further improvement of goodness of fit was observed. A significance level of 0.05 
was selected (corresponding to difference in OFV 3.84 points). A further criterion 
for acceptance of covariate effects was that the estimated 95% confidence interval 
of the covariate effect did not overlap with zero. Contribution of each covariate to 
the final model was the confirmed by backward elimination of each covariate from 
91
Influence of labor on Amoxicillin PK
the model to account for possible interaction between covariates. The residual intra- 
and inter-individual variability were visually evaluated. The volume of distribution 
at steady state (Vss) and terminal half-life (T1/2) were calculated following standard 
procedures18.
 Finally, the effect of the presence of labor was investigated on structural 
PK parameters. The state of being pregnant but before the onset of labor, being 
in labor and being in the immediate postpartum period were implemented in the 
model as covariate in the entire group of patients. A significance level of 0.05 was 
selected (corresponding to difference in OFV of 3.84 points). A further criterion for 
acceptance of the influence of labor was that the estimated 95% confidence interval 
of its effect did not overlap with it’s null value. Contribution of an effect of labor to 
the final model was the confirmed by backward deletion of both the effect of labor 
and the continuous covariates from the model to account for possible interaction 
between covariates and the effect of labor.   
 The accuracy of the final population model for the entire population was 
established using a bootstrap method in NONMEM, consisting of repeated random 
sampling with replacement from the original data. This resampling was repeated 
100 times. The estimated parameters from the bootstrap analysis were compared to 
the estimates from the original data.
Results
In total, 34 patients were included. From 8 patients blood samples were taken both 
before the onset of labor and during labor. From 17 patients blood samples were 
taken only before the onset of labor and from 9 patients only during labor. Eight 
patients agreed with a postpartum dose of amoxicillin as well. The postpartum 
doses of amoxicillin were administered between 1.5-3.8 hours after child birth. The 
study population consisted of 31 singleton and 3 twin pregnancies. All 17 patients 
participating in the study during labor, delivered vaginally. The gestational age at 
the time of the study ranged from 30.0 to 40.6 weeks. The characteristics of the 
study patients are presented in Table 1. 
 Peak concentrations were comparable in patients during labor and in 
patients before the onset of labor. Peak concentrations after the 2 gram infusion 
were 97.4+/- 20.7 mg/L in patients before the onset of labor and 92.3+/- 16.6 mg/L 
in patients during labor (mean+/-SD). Peak concentrations after the 1 gram infusion 
were 71.8+/- 14.8 mg/L, 62.8+/- 7.9 mg/L, and 65.7+/- 15.5 mg/L, respectively, 
in patients before labor, during labor and postpartum. The terminal half-lives for 
the three stages of labor were not significantly different (1.1 +/- 0.3 h during labor, 
1.2+/- 0.2 h before labor and 1.2+/- 0.2 h postpartum). The volume of distribution 
in steady state was  40.4 L. 
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 A total of 898 blood samples were collected in this study. Of these samples 
550 were taken before the onset of labor, 187 during labor and 161 in the immediate 
postpartum period. For patients included before the onset of labor between 7 and 
34 samples were obtained per patient, during labor between 5 and 24 samples and 
in the postpartum period between 12 and 25 samples.  A three compartment open 
model best described the data. The residual error was found to be proportional 
to the blood concentrations. Inter-individual variability was mainly observed in 
clearance (CV 19.8%), V1 (CV 23.1%) and V2 (CV 31.6%). Correlations between 
the random parameters for inter-individual variability were found and implemented 
in the model. For the selected continuous covariates, there was a significant effect 
of edema on the total volume of distribution. The volume of distribution increased 
with an increasing amount of edema (Figure 2b). Furthermore, the effect of renal 
function on CL was found inconsequential. Using the serum creatinin concentration 
and the estimated creatinin clearance calculated with the CG-formula, no influence 
on the CL of amoxicillin was seen. However, renal clearance was found to have 
a small, but significant effect on CL when calculated using the modified MDRD 
formula. CL was inversely correlated with an increased MDRD (Figure 2C). In 
figure 1 the observed concentrations are plotted versus the model-based population 
predicted concentrations, illustrating the unbiased model-fit.
Table 1: Baseline patients’ demographic data of 34 pregnant women.
SD= Standard Deviation
Data units Mean SD Range Number of 
patients
Maternal age year 29.0 5.5 20-38 34
Gestational age week 35.9 2.3 30-41 34
Body Mass Index Kg/m2 28.8 5.0 18-38 33
Weight Kg 79.0 13.6 53-107 33
Leucocytes x109/L 12.5 5.2 6-28 34
Creatinin μmol/L 45.1 8.2 30-74 34
Nulliparity - - - - 15
Edema (no/around the 
ankle/up to the knee - - - - 21/10/2
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Figure 1
Scatter plot of the population predicted vs observed concentrations of amoxicillin for 34 
patients. The figure shows the individual data points for the entire population and the line 
of identity (x=y) with linear scale (Fig 1A) and logarithmic scale (Fig 1B).
Figure 2
Plots of values for V2 for the three stages of labor (figure 2a), values of V1 versus the amount 
of edema (figure 2b) and values of MDRD versus CL (figure 2c).
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 Labor status in patients was found to have a small but significant effect on 
peripheral distribution volume (V2). V2 was larger in women before the onset of 
labor compared to women during labor and in the postpartum period. Compared to 
women before the onset of labor, V2 was decreased with 13.7% during labor and 
29.5% in the immediate postpartum period. Figure 2a shows the different values 
for  V2 for the three stages of labor . Figure 3a shows the observed concentrations 
of patients before and after the onset of labor for the first 4 h after the 2 gram 
infusion, whereas figure 3b shows the observed concentration for all three stages of 
labor  after a 1 gram dose. The estimates of the pharmacokinetic parameters of the 
final model and the relative standard errors derived from the bootstrap analysis  are 
presented in Table 2.
 The bootstrap validation of the model of the entire population was 
performed with 100 runs. The mean parameter estimates of the runs obtained from 
the bootstrap analysis did not differ significantly from the predicted values from the 
NONMEM PK analysis (data not shown). The bootstrap validation was successful 
for 95 runs. The standard errors obtained from the bootstrap analysis were also 
comparable to those estimated by the model.  
Figure 3
Figure 3a shows the observed amoxicillin concentrations after a 2 gram dose and figure 3b 
after a 1 gram dose. Time of infusion is indicated by black bars. The open squares represent 
all data points of the patients before the onset of labor; the filled dots data points of patients 
during labor and data points of patients in the postpartum period are indicated by the open 
triangles. Because there was variation in the start-time of the second infusion, in figure 3b 
the data were adapted assuming that the 1 gram infusions started at t=0 for all patients. 
(See color inlay for a full color version of this figure.)
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Table 2: Population model parameter values with standard error of 34 women presented 
with SE% or CV% and 95% confidential interval as derived from the bootstrap analysis.
SE: standard error of the estimate, SE%: relative SE (%), 95%CI: 95% confidence interval, 
CL: clearance, V1: volume of distribution of the central compartment, V2: volume of 
distribution of the first peripheral compartment, V3: volume of distribution of the second 
peripheral compartment, Q1: intercompartmental clearance between V1 and V2, Q2: 
intercompartmental clearance between V1 and V3, IIV: Inter-individual variability, CV%: 
relative coefficient of variation (%)
Parameter Units Estimates of all patients 
Structural model parameters
Mean (model) SE% (bootstrap) 95%CI (bootstrap)
CL L/h 21.1 4.1 19.6 - 23.0
V1 L 8.7 6.6 7.5 - 9.8
V2 L 11.8 7.7 9.9 – 13.4 
V3 L 20.5 15.4 14.3 – 26.7
Q1 L/h 21.9 16.9 15.0 – 29.8






IIV in CL 4.2 19.8 1.6 – 6.1
IIV  in V1 5.1 23.1 -0.16 – 10.6
IIV in V2 9.7 31.6 1.1 – 17.9
Residual 




The PK of intravenously administered amoxicillin of our entire study population 
was best described by a three-compartment open model. Volume of distribution 
increased with an increasing amount of edema. An effect of labor was seen on 
the peripheral volume of distribution (V2). When compared to pregnant women 
before the onset of labor, V2 was decreased during labor and even more decreased 
in the immediate postpartum period. For our patients dose adjustments were not 
indicated, but it can not be excluded from this study that the current dosing schedule 
is adequate for patients with pregnancy-related disorders.  
 Estimation of glomerular filtration rate (GFR) in pregnant women is difficult. 
Serum creatinin levels are often used to estimate GFR, especially in conjunction 
with either the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease 
(MDRD) formulae16,17. Both the CG and MDRD formulae are based on cohort 
studies of patients with mild to moderate renal insufficiency, and none of the subjects 
was pregnant16,17. Unfortunately, estimation of GFR in the pregnant population 
using either the CG or the MDRD formula has not been validated. There have 
been several reports demonstrating that the MDRD formula tends to underestimate 
GFR in subjects with normal or near-normal renal function19,20. Whereas the CG 
formula is weight based, and weight gain in pregnancy will obviously exaggerate 
estimated GFR. Alper et al, investigated the GFR in preeclamptic patients. Neither 
the CG or the MDRD formula were very accurate in predicting GFR in this group 
of patients, although the MDRD formula performed modestly better21. In our 
analysis, both serum creatinin values and estimated GFR using the CG-formula did 
not have a significant effect on CL, but when GFR was estimated with the MDRD 
formula the CL decreased with an increasing GFR. This is unlikely, and therefore 
illustrates the importance of the use of validates formulas in special patient groups. 
Pharmacokinetic parameter estimates did not change after the implementation of 
GFR calculated with the MDRD formula. Based on the absence of an effect of 
serum creatinin values and the GFR estimated using the CG formula, we concluded 
that CL is not influenced by renal function.
 Other studies on the influence of labor on the PK of amoxicillin are not 
available. One study has investigated the PK of oral amoxicillin after a single dose 
both in the second and third trimester of pregnancy as well as postpartum22. It was 
found that during pregnancy the renal clearance was increased compared to the 
postpartum period22. However, in the study of Andrew et al22 patients were included 
3 months after delivery, while our patients were measured within the first 27 hours 
after delivery. This probably explains the difference between the two studies. The 
PK of ampicillin, an antibiotic closely related to amoxicillin, has been studied both 
during pregnancy and during labour23-28. Differences in PK of ampicillin between 
pregnant and non-pregnant individuals have been described, such as a shorter 
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half-life and higher plasma clearance during pregnancy25,26,28. Furthermore, an 
effect of labor on the terminal half-life of ampicillin has been described24. Labor 
increased the terminal half-life in patients in labor, compared to pregnant women 
before the onset of labor from 39.2 +/- 4.27 min to 58.3 +/- 4.98 min24. Unlike 
other studies25,26,28, these investigators also could not demonstrate differences 
in the PK of ampicillin between non-pregnant individuals and pregnant women 
before the onset of labor24. In contrast to this study, we did not find differences in 
terminal half-life of amoxicillin between women before and after the onset of labor. 
Differences in study design might explain the discrepancy between the results. In 
the ampicillin study four blood samples were collected from each patient, whereas 
in our study an average of 18 blood samples was obtained for each patient per 
stage of labor. More intensive sampling will result in more reliable estimates of 
the inter-individual variability. The pharmacokinetic description of studies with a 
high sampling density are expected to be more accurate and harbor the possibility 
of detecting also small differences in pharmacokinetic parameters between 
various patients. Whether differences in methodology or true differences between 
the study populations underlies the different conclusions of the studies remains 
to be determined. Alternatively, differences in chemical structure or features of 
the two drugs might also explain differences in the results. However, since the 
pharmacokinetics of ampicillin and amoxicillin after intravenous administration in 
non-pregnant individuals has been shown to be similar in previous studies29,30, this 
is unlikely.
 Clinically relevant pharmacokinetic changes during pregnancy have also 
been demonstrated for other drugs. For example, the plasma concentration of 
the antiepileptic drug lamotrigine has been shown to decrease during pregnancy. 
Subsequently, in the immediate postpartum period, the plasma concentration 
increases rapidly, resulting in a risk for toxicity31. This indicates that changes of 
specific drugs during pregnancy and labor cannot be readily extrapolated on the 
basis of results obtained with other drugs.
 The inter-individual variability in amoxicillin pharmacokinetics between 
the patients was remarkably moderate. In figure 1 the observed concentrations 
are plotted versus the population predicted concentrations. The majority of the 
data points are located near the line of identity. However, for some observed 
concentrations the predicted concentrations are overestimated. These blood samples 
were taken during the antibiotic infusion. The antibiotic concentration increases 
very fast during the infusion. We recorded the sampling times with a precision of 
0.5-1 minute. Therefore, the model will predict concentrations during the antibiotic 
infusion less accurately compared to concentrations in blood samples collected 
after the antibiotic infusion. 
 An important question for the clinical practice is whether the recommended 
amoxicillin dosing regimen is adequate in the prevention of GBS disease. The 
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efficacy of amoxicillin is determined by the time the concentration exceeds the 
minimum inhibitory concentration (T>MIC) and, in general, T>MIC for 40-50 % 
of the dosing interval is required for efficacy32-34. The MIC value of an antibiotic is 
the highest MIC value of different microbial strains that results in a high probability 
of cure. MIC value of amoxicillin for GBS as indicated by the EUCAST is 0.25 
mg/L35. All concentrations remained well above the MIC of GBS for a sufficient 
percentage of the dosing interval, even when taking into account the plasma protein 
binding of approximately 18-20 %36,37. 
 After delivery, the pregnancy-induced physiological adaptations will change 
back to normal. This process starts immediately postpartum, but will continue for 
several weeks38,39. In the first days after delivery, this includes an increase in blood 
volume and cardiac output. We found only minor differences in pharmacokinetic 
behavior of amoxicillin in the immediate postpartum period when compared to 
pregnant women. This supports our earlier study that demonstrated a similar PK of 
amoxicillin in pregnant women with PPROM compared to values reported for non-
pregnant individuals. 
 In our study, in none of the patients toxic or sub-therapeutic concentration-
profiles were reached. For this reason the differences in PK in the three stages 
of labor were considered not clinically relevant. This finding supports the current 
practice that the dosing regimen is not adjusted during the course of labor. However, 
it should be noted that we included only healthy patients and that only 8 patients 
were included both before and during labor. Our patient group may be considered to 
be small, but taking into account the situation in which the patients had to be studied 
this is a relatively large population. Antibiotics in the prevention of GBS are also 
used to protect the fetus. Therefore, adequate fetal concentrations are imperative. 
Since uterine contractions might influence the blood flow in the umbilical cord, 
studies investigating the transplacental transfer of amoxicillin during vaginal 
deliveries are needed to describe the PK in umbilical cord serum and ultimately in 
the fetus. 
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Clavulanic acid does not influence 
amoxicillin pharmacokinetics in 
pregnant women during labor. 
Anouk E. Muller, Rob A. Voskuyl, Johan W. Mouton, Paul M. Oostvogel, 




We studied the pharmacokinetics of amoxicillin when co-administered with 
clavulanic acid in pregnant women during labor. Co-administration of amoxicillin 
with clavulanic acid did not result in changes in amoxicillin pharmacokinetics. 
The mean values (+/- SD) of the estimates for the CL of amoxicillin in patients 
treated with amoxicillin and amoxicillin in combination with clavulanic acid  were, 
respectively, 22.8 +/- 2.4 L/h and 21.3 +/- 6.9 L/h. For V1 the mean values (+/- 
SD) of the estimates were 11.0 +/- 2.6 L and 13.4 +/- 7.0 L for patients treated 
with, amoxicillin with and without clavulanic acid respectively. Based on these 
pharmacokinetic findings dose adjustments for amoxicillin during labor are not 
necessary when the drug is co-administered with clavulanic acid. 
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Introduction
Augmentin® or co-amoxiclav, an antibiotic formulation of amoxicillin and 
clavulanic acid, is widely used in pregnant women as treatment of choice for intra-
amniotic infection (IAI). IAI during delivery is a serious complication and affects 
both mother and neonate. This can occur in up to 10.5 percent of all deliveries1-5. 
The frequency of IAI is highest in preterm deliveries6. 
 When amoxicillin and clavulanic acid are administered simultaneously, 
the activity spectrum of amoxicillin against both gram-positive and gram-
negative bacteria is enhanced. Clavulanic acid irreversibly inhibits a wide range 
of β-lactamases produced by micro-organisms, thereby protecting the β-lactam 
antibiotics from enzymatic inactivation7. The intrinsic antibacterial activity of 
clavulanic acid alone is negligible7.
 Previously, several other studies have reported that the pharmacokinetic 
behavior of amoxicillin in healthy volunteers and children is not modified by the 
co-administration of clavulanic acid8-11. On the other hand, one study administering 
varying doses of oral amoxicillin together with 125 mg clavulanic acid, showed 
that at the highest amoxicillin dose (875 mg) clavulanic acid absorption was 
reduced while amoxicillin absorption was unaffected12. Dose-dependency in the 
pharmacokinetics of amoxicillin has also been described in other studies13,14.
 Thus, it cannot be excluded that under certain circumstances co-
administration of clavulanic acid might influence the concentration-time profile 
of amoxicillin. Potential interactions between simultaneously administered drugs 
might be caused by inhibition of metabolic enzymes, competition for protein binding 
in plasma or changes in renal transporter-systems. Consideration of the elimination 
routes of the simultaneously administered drugs is therefore important to assess the 
probability of drug interactions. Both amoxicillin and clavulanic acid are eliminated 
by hepatic metabolization and renal excretion. Amoxicillin is in part metabolized to 
the inactive compound penicilloic acid and is eliminated by the kidneys. Clavulanic 
acid is also partly metabolized and in animal studies it has been shown that the 
metabolites are excreted by feces, urine and lung secretions15,16. Physiological 
changes taking place during pregnancy and labor, such as an increase in cardiac 
output and glomerular filtration rate17-19, may also influence the pharmacokinetics of 
(co-administered) drugs. These adaptations may include changes in protein binding 
and the function of and/or blood flow to the metabolizing and eliminating organs. 
The aim of this study was to investigate whether co-administration of clavulanic 






In the period between February 7, 2005 and February 28, 2007, all women who 
needed antibiotic treatment with amoxicillin or co-amoxiclav during labor and 
were admitted to the hospital, were eligible for inclusion in this study. Following 
local guidelines, women were treated with amoxicillin in the prevention of GBS, 
in case of a proven or unknown Streptococcus agalactiae (group B streptococcus, 
GBS) carriage, in the presence of generally recognized risk factors for neonatal 
GBS disease but without signs of infection20. In case of suspected intra-amniotic 
infection, women were treated with co-amoxiclav. The study was approved by 
the Medical Ethics Committee of the Medical Center Haaglanden, the Hague, the 
Netherlands. Written informed consent was obtained from all patients. Women 
were excluded from the study if they i) had been treated with oral or intramuscular 
antibiotics within 2 days before starting therapy, ii) were unwilling to comply 
with the requirements of the study, iii) were known to be allergic to amoxicillin or 
other penicillins, or iv) were receiving co-medication that exhibits interaction with 
amoxicillin. At the start of the study all patients were at least 18 years of age and 
in labor.
Drug administration and blood sampling
Before the administration of amoxicillin or co-amoxiclav an intravenous catheter 
was placed in each arm. The choice of the antibiotic and the dosing schedule was 
in accordance to the guidelines of the local hospital. Treatment with amoxicillin 
started with an intravenous infusion of 2 gram amoxicillin (50 mg/mL) administered 
over 30 minutes, followed by a second infusion after 4 hours of 1 gram amoxicillin 
(50 mg/mL) over 15 minutes. Treatment with co-amoxiclav (consisting of 1 gram 
amoxicillin (50 mg/mL) with 200 mg clavulanic acid) consisted of an infusion for 
15 minutes every 8 hours. Blood samples of 2 mL were collected from the second 
catheter in the contra-lateral arm at timed intervals beginning at 1 min after the 
start of the infusion and, at 7 and 15 min (1 gram infusion) or 15 and 30 min (2 
gram infusion) during the first two amoxicillin administrations. After the infusion 
sampling was scheduled at 3, 6, 10, 16 and 36 minutes, and afterwards every 30 
minutes until the next antibiotic dosage. Exact sampling times were recorded.
 All blood samples were placed immediately on ice, allowed to clot and 
processed within one hour after collection. The samples were centrifuged at 1200 
g for approximately 10 minutes. The supernatants were transferred into plastic 
storage tubes and frozen at –70° C until analysis.
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Patient information
All patients received a standard work-up at the onset of the study which included 
a medical history, biochemical and hematological examination. Furthermore blood 
pressure, pulse, oral temperature, and body weight were recorded. The amount of 
edema was scored semi-quantitatively from 0 (no edema), 1 (around the ankle), 2 
(up to the knee) to 3 (above the knee). 
High-performance liquid chromatography
Amoxicillin concentrations were determined by an isocratic high-pressure liquid 
chromatography (HPLC) (Shimadzu, Den Bosch, The Netherlands (NL)) method, 
using an ODS Gemini column (Bester, Amstelveen, NL) with  0.066 M KH2PO4 
solution containing 10 % methanol as a mobile phase. A perchloric acid solution 
of 0.1 ml was added to the sample in an equal volume and after vortexing, added 
to 0.56 ml 0.028 M citric acid containing cefadroxil (Sigma, Zwijndrecht,NL) as 
an internal standard. The assay was linear over the concentration range measured. 
Controls were included in every run. The lower limit of detection was 0.2 mg/L and 
the between run CV < 4%.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated by means of Non-Linear Mixed Effect 
(population) Modeling (NONMEM). The model was implemented in the NONMEM 
ADVAN5 subroutine and the analysis was performed using the FOCE method. All 
fitting procedures were performed with the use of the Compaq Visual FORTRAN 
standard edition 6.6 (Compaq Computer Cooperation, Euston, Texas, USA) and 
NONMEM® software package (version VI, release 1.2, ICON Development 
Solutions, Ellicott City, USA). 
 The data of all patients were analyzed simultaneously to determine the 
basic structural pharmacokinetic parameters. Various 2- and 3- compartment 
models were tested. The previously described pharmacokinetic population model 
in pregnant women with preterm premature rupture of the membranes (PPROM) 
consisting of 3 compartments, was used to start the analysis21. Model selection 
and identification of variability was based on the objective function value (OFV), 
pharmacokinetic parameter point estimates, and their respective confidence 
intervals, and goodness-of-fit plots. To estimate the structural parameters, a 
significance level of 0.001 was selected (corresponding to differences in OFV 
of at least 10 points). NONMEM minimizes an objective function in performing 
nonlinear regression analysis. To detect systematic deviations in the model fits the 
goodness-of-fit plots were visually inspected. The data of individual observations 
versus individual or population predictions should be randomly distributed around 
the line of identity. The weighted residuals versus time or population predictions 
should visually be randomly distributed around zero. Population values were 
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estimated for the parameters clearance (CL), the volumes of distribution (V) and 
the intercompartmental clearances (Q).
 Individual estimates for pharmacokinetic parameters were assumed to 
follow a log normal distribution. Therefore an exponential distribution model 
was used to account for inter-individual variability. Possible correlation between 
inter-individual variability coefficients on parameters was estimated and if present 
accounted for in the stochastic model (NONMEM Omega block option). 
 Selection of an appropriate residual error model was based on the OFV, 
their respective confidence intervals and inspection of the goodness-of-fit plots. 
A additive error model, proportional error model and a combined additive and 
proportional error model were evaluated. The residual error term contains all the 
error terms which cannot be explained and refers to, for example, measurement and 
experimental error and structural model misspecification.
 To refine the model covariate analysis was also performed. The estimated 
pharmacokinetic parameters were plotted independently against the covariates 
bodyweight, body mass index, gestational age, creatinin, leucocytes, oral 
temperature, and the amount of edema to determine whether this influenced the 
pharmacokinetics. The effects of covariates were tested for statistical significance 
using the OFV and the residual intra- and inter-individual variability were visually 
evaluated. A significance level of 0.05 was selected, corresponding to differences 
in OFV of 3.84 points. A further criterion for acceptance of the covariate effects is 
that the estimated 95% confidence interval of the covariate effect did not overlap 
with it’s null value.
 The effect of co-administration of clavulanic acid on structural amoxicillin 
PK parameters was investigated using the entire population as one group. The 
difference between treatment with amoxicillin alone of co-amoxiclav was 
implemented in the model as covariate on the structural parameters with significant 
inter-individual variability. The effect of co-administration of clavulanic acid was 
evaluated using the OFV with a significance level of 0.05, the 95% confidence 
interval and the goodness-of-fit plots. The residual intra- and inter-individual 
variability were visually evaluated.
 The accuracy of the final population model for the entire population was 
established using a bootstrap method in NONMEM, consisting of repeated random 
sampling with replacement from the original data. This resampling was repeated 
100 times. The estimated parameters from the bootstrap analysis were compared to 
the estimates from the original data. 
Results
Eighteen patients were included in the study. Nine patients were treated with co-
amoxiclav and 9 with amoxicillin alone. In total 218 serum samples were collected 
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in the study, 94 samples from patients treated with co-amoxiclav and 124 samples 
from patients treated with amoxicillin. All samples were used as a part of other 
study groups22, 23. The gestational age of patients treated with amoxicillin was lower 
(35.3 weeks) compared to patients treated with co-amoxiclav (39.8 weeks). Of the 
patients treated with co-amoxiclav 5 patients had a temperature above 37.8ºC, 
compared to 2 patients treated with amoxicillin. 9 patients were nulliparae. Of the 
patients receiving co-amoxiclav 2 delivered after a secondary caesarean section. 
All patients treated with amoxicillin delivered vaginally. The characteristics of the 
study patients are presented in table I.
A 3-compartment model best described the data. The inter-individual variability 
was mainly due to differences in CL and V1. A correlation between the random 
parameters for inter-individual variability was not found. An increase of V1 of 2.1% 
per kg body weight gain was found and incorporated into the model. Implementation 
of the other covariates did not improve the model-fit. The residual error was 
found to be proportional to the blood concentrations. The randomly distributed 
observed concentrations versus model-predicted concentrations as shown in figure 
1, illustrate the unbiased model fit. For some observed concentrations the predicted 
concentrations are overestimated. These blood samples were taken during the 
Table 1: characteristics of the study patients.
SD: standard deviation; The unpaired t-test was used to detect significant differences between patients 
treated with amoxicillin and patients treated with co-amoxiclav. * significant difference (p<0.001);  
significant difference (p<0.05) ** The amount of edema was score as: no (0) /around the ankle (1) /up 
to the knee (2) /above the knee (3).
Patients treated with amoxicillin Patients treated with co-amoxiclav
Data units mean SD Range Mean SD Range
Maternal age year 30.0 6.9 21.2-37.9 31.6 4.2 24.9-38.5
Gestational age week 35.3* 2.6 31.0-39.1 39.8* 1.9 36-42.4
Weight kg 73.4 10.8 53.0-87.3 81.3 16.2 56-108
Body Mass Index kg/m2 26.0∀ 4.3 18.3-32.0 31.7∀ 6.0 24.2-41.6
Leucocytes x109/L 16.4 6.4 9.4-28.2 14.3 4.8 8.4-23.1
Creatinin μmol/L 45.8 7.6 35-56 56.3 17.8 34-89
Temperature ºC 36.9 1.1 35.4-39.1 37.7 0.6 36.7-38.6
Edema** 1.22 0.4 1-2 1.78 0.7 1-3
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Figure 1: observed versus individual predicted concentrations.
Table 2: Parameter estimates of the final model.
CL Clearance; V1 Volume of distribution of the central compartment; V2 volume of distribution of 
the first peripheral compartment; V3 volume of distribution of the second peripheral compartment; 
Q1 intercompartmental clearance between V1 and V2; Q2 intercompartmental clearance between V1 
and V3.
Parameter Units Mean SE
Structural model parameters
CL L/h 21.3 1.58
V1 L 11.8 1.3
V2 L 5.72 1.01
V3 L 8.01 1.52
Q1 L/h 28.2 7.89
Q2 L/h 5.4 1.37
Variance model parameters
Interindividual variability in CL 0.080 0.051
Interindividual variability in V1 0.055 0.017
Residual variability 0.040 0.0092
111
Influence of clavulanic acid on Amoxicillin PK 
antibiotic infusion. The antibiotic concentration increases very fast during the 
infusion. We recorded sampling times with a precision of 0.5-1 minute. Therefore, 
the model will predict concentrations during the infusion less accurately compared 
to concentrations obtained after the infusion. Table 2 shows the estimated values 
for the pharmacokinetic parameters of the final model. The parameter estimates 
obtained with the bootstrap analysis did not differ significantly from the parameters 
estimated from the final model (99 of 100 runs successful, data not shown).  
 Co-administration of clavulanic acid to the amoxicillin did not influence the 
pharmacokinetics of amoxicillin during labor after intravenous drug administration. 
The OFV decreased with 1.01 and 0.15 points after implementation of the covariate 
for the difference between the drugs on CL and V1, respectively. This is supported 
by the individual estimates of CL and V1, as generated by NONMEM. The mean 
values (+/- SD) of the estimates for the CL of amoxicillin in patients treated with 
Figure 2:
Distribution of clearance (figure 2A) and central volume of distrubution (figure 2B) for 
patients receiving amoxicillin and co-amoxiclav.
amoxicillin and co-amoxiclav were, respectively, 22.8 +/- 2.4 L/h and 21.3 +/- 6.9 
L/h. For V1 the mean values (+/- SD) of the estimates were 11.0 +/- 2.6 L and 
13.4 +/- 7.0 L for patients treated with amoxicillin and co-amoxiclav, respectively. 
Figure 2A and 2B show the distribution of the structural parameters CL and V1 for 




Pharmacokinetics of amoxicillin in pregnancy has been described previously and it 
has been shown that adherence to the guidelines leads to adequate concentration-time 
profiles in the mother in the prevention of GBS21. However, as co-administration 
of other drugs might influence the concentration-time profile of an individual drug, 
we investigated in this study the frequently used alternative, the combination of 
amoxicillin and clavulanic acid. In this study, we show that the pharmacokinetics of 
intravenously administered amoxicillin during labor is not significantly influenced 
by co-administration of clavulanic acid. 
 A number of potential interactions had been anticipated. Both drugs bind 
to serum proteins and are eliminated via the same routes. Distribution might be 
influenced by competition of the drugs for the same serum proteins. This might in 
principle increase the unbound fraction of the drug, resulting in a different tissue 
penetration and a higher rate of biotransformation and excretion. However, since 
both amoxicillin and clavulanic acid have low plasma protein binding of respectively 
20% and 22%24, the probability that this would lead to a significant change after 
the administration of co-amoxiclav is small. Inhibition or induction of enzymes 
involved in metabolism might also have caused changes in pharmacokinetics of the 
drugs. Both amoxicillin and clavulanic acid are in part metabolized, but the absence 
of pharmacokinetic drug interaction in this study indicates that the individual drugs 
do not influence the enzyme activity involved in each others metabolism. Both 
changes in passive and active excretion of drugs could have caused drug interaction. 
Passive re-absorption may change due to a change in the pH of the urine and on the 
other hand, transporters involved in the active excretion of drug may be influenced. 
Our results indicate that administration of co-administration of clavulanic acid 
with amoxicillin did not significantly influence the distribution, metabolization and 
excretion of amoxicillin.
 Data on the pharmacokinetics of drugs in pregnant patients are difficult to 
obtain both for ethical and practical reasons. Therefore, comparison of different 
patient groups and discovering sources of variability is nearly impossible by using 
conventional statistical methods. Particularly in this type of studies the use of 
population modeling is an advantage, because covariate analysis applied to the 
whole group of patients maximizes the utilization of all information that is available 
for each patient. The finding that body weight has a slight influence on clearance 
illustrates this point. Furthermore, if data of more patients would became available, 
this can be simply added to the dataset, without the need to carry out a study with 
new groups of patients.
 In the analysis of the pharmacokinetics of amoxicillin in this patient group 
the volume of distribution of the central compartment increased with body weight. 
In an earlier study the volume of distribution of the central compartment increased 
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with an advancing gestational age23. Because gestational age is correlated with 
body weight (p<0.01), this is not a discrepancy between these analysis. The use 
of amoxicillin is indicated in patients during a preterm delivery. Consequently, the 
gestational age in patients treated with amoxicillin is lower than in patients treated 
with co-amoxiclav. The increasing body mass index increases with advancing 
gestational age, will also result in a significant difference in body mass index 
between the two groups. The effect of covariates on the PK is investigated in the 
entire patient group and these differences will therefore not influence the results. 
 A proper dosing regimen of amoxicillin is essential for the treatment of IAI 
in pregnant women. Co-administration of clavulanic acid to amoxicillin increases 
the antibacterial spectrum of the treatment. Different dose ratios of amoxicillin/ 
clavulanic acid had been used. But since the higher doses of clavulanic acid was 
associated with a higher rate of adverse effects, such as diarrhea, nausea and vomiting, 
the amount of clavulanic acid was decreased16. Data on the pharmacokinetics of 
clavulanic acid during labor are not available. Unfortunately, the concentrations 
of clavulanic acid could not be determined in this study due to stability issues. 
As there are no reports that the efficacy of the these dose ratio’s are different, the 
amount of clavulanic acid may not be that critical12.
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Chapter 7
Pharmacokinetics of amoxicillin 
in maternal, umbilical cord and 
neonatal serum. 
Anouk E. Muller, Paul M. Oostvogel, Joost DeJongh, Johan W. Mouton, 





The pharmacokinetics of amoxicillin was studied in umbilical cord and neonatal 
serum relative to maternal concentrations in prevention of neonatal Group B 
Streptococcus infection. Subjects were 44 pregnant women receiving amoxicillin 
as 1 or 2 gram intravenous infusion. To measure concentrations, blood samples 
were obtained from the mother, arterial and venous umbilical cord and neonate. 
The pharmacokinetics were characterized by a 5-compartment model using 
nonlinear mixed-effects (population) modeling. The population estimates for the 
clearance, central volume of distribution and the 2 peripheral maternal volumes of 
distribution 19.7 +/-0.99 L/h, 6.40+/-0.61 L, and 5.88+/-0.83 L, (mean +/- standard 
error), respectively. The volume of distribution of the venous umbilical cord and 
the neonatal volume of distribution were 3.40 L and 11.9 L. The pharmacokinetic 
parameter estimates were used to simulate concentration-time profiles in maternal, 
venous umbilical cord and neonatal serum. The peak-concentration in venous 
umbilical cord serum was 18% of the maternal peak-concentration. It was reached 
3.3  minutes after the maternal peak-concentration. The concentration-time profile 
in neonatal serum is determined by the profile in venous umbilical cord serum, 
which in turn depends on the profile in maternal serum. Furthermore, the simulated 
concentrations in maternal, venous umbilical cord and neonatal serum exceeded 
the minimal inhibitory concentration for group B streptococcus for more than 90% 
of the 4 hour dosing interval. In first approximation, the 2 gram infusion to the 
mother appears to be adequate in the prevention of group B streptococcal disease. 
However, to investigate the efficacy of the prophylaxis, further studies on the inter-
individual variability in pharmacokinetics are indicated.
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Introduction
Amoxicillin, a penicillin derivative, is an antibiotic used in the prevention of 
neonatal group B streptococcal (GBS) disease. Neonates from mothers colonized 
with GBS are at risk for vertical transmission, because they might be exposed to 
GBS in utero or in the vagina during delivery. While protection of the fetus is 
the actual objective of the prophylaxis, the procedure in GBS prophylaxis is to 
administer the antibiotics to the pregnant woman. Since antibiotics reach the fetus 
only after transport over the placenta via the umbilical cord, adequate concentrations 
in maternal serum are a prerequisite, but no guarantee, for adequate venous and 
arterial umbilical cord and fetal serum concentrations. While there are some data 
on ampicillin concentrations in umbilical cord blood1,2, data for amoxicillin are not 
available. The pharmacokinetics of amoxicillin in pregnant women before labor 
have been described previously and have been shown to exceed the MIC for an 
adequate percentage of the dosing interval for treatment of the infection in the 
mother3. To assess whether the administration of amoxicillin also protects the fetus 
from GBS infection, data on the pharmacokinetics in umbilical cord serum or fetal 
serum are necessary. 
 Studying the pharmacokinetics in fetal or umbilical cord serum faces 
ethical and practical difficulties. Because blood sampling of the fetus during 
delivery is not possible, blood samples of the umbilical cord taken after birth is 
in most instances the only direct information on fetal concentrations that can be 
obtained. Unfortunately, these samples can be obtained only at a single point in 
time for each individual. Alternatively, blood samples of the neonate taken by 
heel puncture shortly after birth can be considered as a good approximation of 
the fetal concentration. However, such samples are difficult to obtain because of 
the poor blood supply to the extremities directly after birth. When neonatal blood 
samples are taken hours later, these concentrations might not truly reflect the fetal 
concentrations, because of the differences in the rates and routes of elimination 
before and after birth.
 By necessity the time intervals between the last antibiotic dose and birth will 
be different for each individual. Therefore presenting either individual or average 
concentrations in the umbilical cord samples at birth will be of little value. To 
obtain useful information the pharmacokinetics (i.e. the concentration versus time 
profile) in the umbilical cord serum should be known. For this purpose population 
pharmacokinetic modeling is useful, because in this approach all data of the entire 
study population (i.e. all mothers and fetuses) are taken into account. An important 
feature of population pharmacokinetic modeling is that it enables the analysis of 
data from studies with unbalanced designs (e.g. unequal groups) and of incomplete 
datasets4,5. Specifically, Non-Linear Mixed Effects (‘population’) modeling can be 
used to connect the sparse data on umbilical cord and neonatal blood concentrations 
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to the more detailed information on the pharmacokinetics in the mother. A more 
detailed background of population modeling can be found elsewhere6,7. Recently 
a population pharmacokinetic model of amoxicillin in pregnant women has been 
proposed3. The objective of this study is to describe the concentration-time profile of 
amoxicillin in umbilical cord and neonatal serum, in relation with the concentration-
time profile in maternal serum. 
Methods
Patients
In the period between February 7, 2005 and February 28, 2007, all women who 
needed antibiotic treatment with amoxicillin or amoxicillin/clavulanic acid 
(Augmentin® or co-amoxiclav) shortly before or during labor were eligible for this 
study. To take full advantage of all data available to us for the development of a 
population pharmacokinetic model of amoxicillin in pregnant women, umbilical 
cord and neonate, the present study includes part of a dataset of a recently published 
study3. 416 blood samples from pregnant women with preterm premature rupture of 
the membranes were used in a previous study. None of the samples of the umbilical 
cord or the neonate were previously used. Following local guidelines, women 
were treated with amoxicillin in the prevention of GBS disease, when no signs 
of infection were present, but with proven or unknown Streptococcus agalactiae 
carriage, in the presence of generally recognized risk factors for neonatal GBS 
disease8. In case of suspected intra-amniotic infection, women were treated with 
co-amoxiclav. When signs of infection were present delivery was induced. The 
study was approved by the Medical Ethics Committee. Written informed consent 
was obtained from all patients. Women were excluded from the study when i) they 
had been treated with oral or intramuscular antibiotics within 2 days before starting 
therapy, ii) were unwilling to comply with the requirements of the study, iii) were 
known to be allergic to amoxicillin or other penicillins, or iv) were receiving co-
medication that exhibits interaction with amoxicillin. All patients were at least 18 
years of age.
 All patients received a standard work-up which included a medical history, 
biochemical and hematological examination. Furthermore blood pressure, pulse, 
oral temperature, and body weight were recorded. The amount of edema was scored 
semiquantitatively from 0 (no edema) to 3 (above the knee). The weight of the 
placenta with umbilical cord was measured. From the neonate birth weight and the 
Apgar-scores after 1, 5 and 10 minutes were recorded.
Drug administration and blood sampling
Before the administration of amoxicillin or co-amoxiclav an intravenous catheter 
was placed in each arm. Antibiotics were administered following local guidelines. 
119
Amoxicillin PK in maternal, cord and neonatal serum
Treatment with amoxicillin started with an intravenous infusion of 2 gram amoxicillin 
(50 mg/mL) administered over 30 minutes, followed by a second infusion after 
4 hours of 1 gram amoxicillin (50 mg/mL) over 15 minutes. Treatment with co-
amoxiclav (consisting of 1 gram amoxicillin (50 mg/mL) with 200mg clavulanic 
acid) consisted of an infusion for 15 minutes every 8 hours. Blood samples of 
2 mL were collected from the second catheter in the contralateral arm at timed 
intervals beginning at 1 min after the start of the infusion and, at 7 and 15 min (1 
gram infusion) or 15 and 30 min (2 gram infusion) during the first two amoxicillin 
administrations. After the infusion sampling was scheduled at 3, 6, 10, 16 and 36 
minutes, and afterwards every 30 minutes until the next antibiotic dosage. Exact 
sampling times were recorded.
 After cord clamping the umbilical cord was cleaned with normal saline and 
a sponge to prevent contamination of maternal blood in the umbilical cord samples. 
Both arterial and venous cord samples of 5-10 mL were taken. From the neonate a 
blood sample of approximately 0.5 mL was obtained by heel puncture after signed 
informed consent from both parents. These blood samples were taken at least 10 
minutes after birth depending on the physical condition of the neonate. 
 All blood samples were placed immediately on ice, allowed to clot and 
processed within one hour after collection. The samples were centrifuged at 1200 
g for approximately 10 minutes. The supernatants were transferred into plastic 
storage tubes and frozen at –70° C until analysis.
High-performance liquid chromatography
Amoxicillin concentrations were determined by an isocratic high-pressure liquid 
chromatography (HPLC) (Shimadzu, Den Bosch, The Netherlands (NL)) method, 
using an ODS Gemini column (Bester, Amstelveen,NL) with  0.066 M KH2PO4 
solution containing 10% methanol as a mobile phase. A perchloric acid solution 
of 0.1 ml was added to the sample in an equal volume and after vortexing, added 
to 0.56 ml 0.028 M citric acid containing cefadroxil (Sigma, Zwijndrecht,NL) as 
an internal standard. The assay was linear over the concentration range measured. 
Controls were included in every run. The lower limit of detection and the lower 
limit of quantification were  0.2 mg/L and the between run CV < 4%.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated by means of Non-Linear Mixed 
Effect (population) Modeling (NONMEM). The model was implemented in the 
NONMEM ADVAN5 subroutine and the analysis was performed using the FOCE 
method with INTERACTION. All fitting procedures were performed with the 
use of the Compaq Visual FORTRAN standard edition 6.6 (Compaq Computer 
Cooperation, Euston, Texas, USA) and NONMEM® software package (version VI, 
release 1.2, ICON Development Solutions, Ellicott City, Maryland, USA). 
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 To determine the basic structural pharmacokinetic parameters various 3-, 4- 
and 5- compartment models were tested. The previously described 3 compartment 
pharmacokinetic population model in pregnant women with PPROM, was used to 
describe the time course of amoxicillin in maternal blood3. Model selection and 
identification of variability was based on the likelihood ratio test, pharmacokinetic 
parameter point estimates, and their respective confidence intervals, and goodness-
of-fit plots. For the likelihood ratio test on differences between two models, 
the objective function value (OFV) with a pre-specified level of significance of 
P<0.001 was used. NONMEM minimizes an objective function in performing 
nonlinear regression analysis. To detect systematic deviations in the model fits the 
goodness-of-fit plots were visually inspected. The data of individual observations 
versus individual or population predictions should be randomly distributed around 
the line of identity. The weighted residuals versus time or population predictions 
should be randomly distributed around zero. Population values were estimated 
for the parameters clearance (CL), the volumes of distribution (V) and the 
intercompartmental clearances (Q).
 Individual estimates for pharmacokinetic parameters were assumed to 
follow a log normal distribution. Therefore an exponential distribution model was 
used to account for inter-individual variability. The correlations between the various 
random parameters for inter-individual variability were tested using the forward 
addition and backward deletion method in the NONMEM Omega block option. 
 Selection of an appropriate residual error model was based on the likelihood 
ratio test and inspection of the goodness-of-fit plots. The residual variability between 
the observed concentrations and those predicted by the model was described using a 
proportional error model. The residual error term contains all the error terms which 
cannot be explained and refers to, for example, measurement and experimental 
error and structural model misspecification.
 To refine the model covariate analysis was also performed. The estimated 
pharmacokinetic parameters were plotted independently against the covariates 
bodyweight, body mass index, duration of amenorrhea, blood pressure, pulse, oral 
temperature, and the amount of edema to determine whether this influenced the 
pharmacokinetics. Covariate analysis was performed by forward addition of each 
candidate covariate into the model structure until no further improvement of the 
goodness of fit was observed. A further criterion for acceptance of covariate effects 
was that the estimated confidence interval of the covariate effect did not overlap 
zero. Contribution of each covariate to the final model was confirmed by backward 
elimination of each covariate from the model to account for possible interaction 
between covariates. The residual intra- and inter-individual variability were visually 
evaluated. 
 The accuracy of the final population model for the entire population was 
established using the bootstrap option in NONMEM, consisting of repeated random 
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sampling with replacement from the original data. This resampling was repeated 
100 times. The estimated parameters from the bootstrap analysis were compared to 
the estimates from the original data.
Simulations
Simulations were performed to determine the relation in time between the maternal, 
umbilical cord and neonatal serum concentration-time profiles. The simulations 
were performed using Berkeley Madonna (version 8.3.5, Berkeley Madonna Inc, 
University of California, USA). The mean population parameter values of the 
pharmacokinetic model derived with NONMEM in the first part of the analysis 
were used in the simulations. 
Results
From 44 pregnant patients 53 umbilical cord blood samples were obtained, 
consisting of 25 arterial and 28 venous samples. Of 23 women both arterial and 
venous samples were obtained. Four umbilical cord samples of one twin pregnancy 
were collected. A total of 904 maternal serum samples were collected. Due to the 
unpredictable and variable duration of labor and to the varying emotional condition 
of the patient, the number of maternal samples obtained from each patient is variable 
(range 3-41 samples per patient). The time interval between the last antibiotic dose 
and birth varied from 24.4 min to 316.8 min. The patients gave birth at gestational 
ages from 30.0 to 42.4 weeks. Birth weight of the neonates ranged from 1340 gram 
to 4470 gram. Fourteen blood samples were taken from the neonates between 14.2 
min to 199.8 min after birth. The characteristics of the study patients and their 
neonates are presented in table I.
 The concentrations in cord serum range from 1.0-16.8 mg/L in arterial and 
1.1-18.0 mg/L in venous umbilical cord serum. The ratio of the arterial and venous 
umbilical cord serum concentrations is shown in figure 1. The ratio was <1 when 
the umbilical cord was clamped shortly after the administration of the last antibiotic 
dose and slightly higher with an increasing interval between the last antibiotic 
administration and umbilical cord clamping. The differences between the arterial 
and venous umbilical cord serum concentrations were too small to analyze these 
concentrations using two separate compartments. Since arterial cord blood originate 
directly from the fetal circulation, the arterial cord blood concentrations can be 
considered as fetal blood concentration. Venous cord blood concentrations reach 
the umbilical cord after passage of the placenta. Therefore these concentrations 
were analyzed separately. 
 In population modeling data of concentrations in maternal, arterial and 
venous umbilical cord, and neonatal serum were analyzed simultaneously. Of all 
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* Only patients from whom umbilical cord serum was obtained.
Table I: characteristics of the study patients, placental weight and their neonates
Maternal patient characteristics units mean SD Number of 
patients
Maternal age y 30.0 6.85 44
Maternal weight kg 79.4 13.9 43
Body Mass Index kg/m2 29.4 5.3 43
Edema (no/around the ankle/up to knee) - - - 29/12/3
Leucocytes x 109/L 12.8 5.14 44
Creatinin µmol/L 47.4 11.5 44
Amenorrea weeks 36 6/7 2.7 44
Nulliparity - - - 22
Twin pregnancy - - - 3
Mode of delivery (vaginal/vacuum extraction/ 
emergency caesarean section)
- - - 23/1/3*
Placental weight gram 546.5 165.0 40
Birth weight neonate gram 2887.4 627.9 46
Apgar score 1 min - 8.7 1.05 41
Apgar score 5 min - 9.6 0.84 41
Apgar score 10 min - 9.8 0.59 40
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Figure 1: ratio of arterial and venous umbilical cord serum concentrations as function of 
the time.
The ratio of the arterial and venous umbilical cord serum concentrations was plotted versus 
the time interval between the last antibiotic administration to the mother and child birth.
Figure 2: 5-compartment model
Structure of the final 5-comparment model consisting of a central volume of distribution of 
the mother (V1), peripheral volumes of distribution of the mother (V2 and V3), a volume of 
distribution of the umbilical cord (V4) and a volume of distribution of the neonate (V5). The 
k-values represent the intercompartmental exchange rate constants.
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models tested a multicompartment pharmacokinetic model with three compartments 
for the mother, 1 compartment for the venous umbilical cord, and 1 compartment 
for the neonate best described the data (figure 2). The peripheral compartments 2, 
3 and 4 were connected to the central compartment. Compartment 5 is attached to 
compartment 4 and antibiotics in compartment 5 are  transferred back to compartment 
4, and  eliminated from the system. During the analysis the values of the volumes 
of distribution V2 and V3 of compartment 2 and 3 were comparable (difference in 
the final model with separate estimates for V2 and V3 <0.5 L). The %CV of these 
estimates exceeded 51% and therefore for the final analysis V3 was assumed to 
be equal to V2. The inter-individual variability was mainly due to differences in 
clearance,  V1 and the residual error. A correlation between the random parameters 
for inter-individual variability was found and accounted for in the model. The 
residual error was found to be proportional to the blood concentrations. 
 The demographic and clinical characteristics of the patients were examined 
as potential covariates on the parameters CL, V1, K45 and the residual error. 
According to the specified OFV change criterion, gestational age (ΔOFV = - 10.5) 
and body mass index (ΔOFV = - 8.5) both influenced the volume of distribution. 
Although a correlation was noted between gestational age and body mass index, 
incorporation of these two covariates on the volume of distribution did not result 
in a significant decrease in OFV (ΔOFV = - 3.3). Because the decrease in OFV 
was larger after incorporation of gestational age then after incorporation of body 
Figure 3: Individual predicted vs observed concentrations of amoxicillin for the central 
compartment of the mother (V1), the umbilical cord (V4) and neonatal compartment (V5).
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Figure 3: Individual predicted vs observed concentrations of amoxicillin for the central 
compartment of the mother (V1), the umbilical cord (V4) and neonatal compartment (V5).
Scatter plots of the individual predicted vs observed concentrations of amoxicillin for 44 
patients (V1), 53 measures of the umbilical cord (V4) and 14 neonatal measures (V5). The 
figures show the individual data points and the line of identity (x=y).  
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Table 2: Population model parameter values.
CL: clearance, V1: volume of distribution of the central compartment, V2: volume of 
distribution of the first peripheral compartment, V3: volume of distribution of the second 
peripheral compartment, Q1: intercompartmental clearance between V1 and V2, Q2: 
intercompartmental clearance between V1 and V3, SE: Standard error
Parameter Units Mean SE 95% confidence 
interval
Structural model parameters
CL L/h 19.7 0.99 17.8 – 21.6
V1 L 6.4 0.61 5.2 – 7.6
V2 L 5.88 0.83 4.2 - 7.5
V3 L 5.88 0.83 4.2 – 7.5
Q1 L/h 56.6 9.5 38.0 – 75.2
Q2 L/h 10.7 2.2 6.3 – 15.1
K14  0.76  0.28 0.21 – 1.3
K41 1.4 0.31 0.83 – 2.1
K45 5.1 2.0 1.1 – 9.1
K54 1.4 0.31 0.83 – 2.1
K50 0.16 0.033 0.098 – 0.23
Variance model parameters
Interindividual variability in CL 0.076 0.026 0.026 – 0.13
Interindividual variability in V1 0.038 0.013 0.014 – 0.063
Residual variability 0.030 0.0040 0.022 – 0.037
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Figure 4: Simulated concentration-time profiles for the mother, umbilical cord and 
neonate.
Concentration-time profile of amoxicillin in maternal, umbilical cord and neonatal 
serum simulated after a single dose of 2 gram amoxicillin infused over 30 minutes. 
The simulations were performed with PK parameter estimates based on the final 
5-compartment model and carried out for 12 hours after a single antibiotic dose. 
(See color inlay for a full color version of this figure.)
mass index, only gestational age was incorporated in the final model. The effect of 
other potential covariates was also assessed. This resulted in maximum decreases 
of OFV of –0.5 for body weight, -0.3 for the blood pressure, and -0.2 for pulse. All 
model with the temperature incorporated resulted in running-errors. The following 
equation represents the covariate model in the final model including the gestational 
age as covariate for the volume of distribution. 
V1 = θ2 · (1 + θ12 · (GA – 36.8)) · exp(η2) 
In which V1 is the volume of distribution of the central compartment, θ2 is the 
estimate for V1, θ12 is the estimate for the effect of gestational age and GA is the 
gestational age centered by its median value in the study population (36.8 weeks). 
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η2 estimates the inter-individual variability on V1. An increase in V1 of 4.2% per 
week was found and incorporated into the model. The scatter plots of the observed 
concentrations versus model-predicted concentrations were randomly distributed, 
illustrating the unbiased model fit for maternal, umbilical cord and neonatal serum 
concentrations (figure 3). Table 2 shows the estimated values for the pharmacokinetic 
parameters of the final model. The volumes of distribution of the venous umbilical 
cord and the neonate were calculated (3.4 L for the umbilical cord and 11.9 L for 
the neonate).
  The bootstrap validation of the model of the entire population was 
performed with 100 runs. The bootstrap validation was successful for 91 runs. The 
mean parameter estimates of the runs obtained from the bootstrap analysis deviated 
1 to 36% from the predicted values from the NONMEM PK analysis, indicating 
that the accuracy of the final model is good.
 The parameter estimates obtained by the population modeling analysis 
were used to simulate concentration-time profiles of amoxicillin in maternal, 
venous umbilical cord and neonatal serum after a single dose of 2 gram amoxicillin. 
Figure 4 shows the obtained concentration-time profiles for the initial dose of 2 g 
amoxicillin infused to the mother over 30 minutes. Maternal peak concentration 
was reached at the end of the antibiotic infusion at 30 minutes (88.7 mg/L). Peak 
concentration in venous umbilical cord serum was lower and delayed compared 
to the maternal peak concentration. Peak concentration in venous umbilical cord 
serum was 16.0  mg/L (18% of the maternal peak concentration) and was reached 
3.3  minutes after the maternal peak concentration. 
 The sparse neonatal concentrations were analyzed simultaneously with the 
maternal and umbilical cord serum concentrations. The restricted blood supply to the 
extremities directly after birth and the need of an informed consent of both parents, 
were the main reasons for the limited number of samples from the neonates. Peak-
concentration after the 2 gram infusion to the mother in neonatal serum was 8.0  mg/L 
(compared to 16.0  mg/L in venous umbilical cord serum). Similar concentrations 
were reached 1.1 h after the start of the infusion and afterwards the neonatal serum 
concentrations exceeded venous umbilical cord serum concentrations.
 An intrapartum dose of 2 gram amoxicillin is commonly used to prevent 
neonatal GBS disease by achieving bactericidal concentrations in the fetus for a 
sufficient amount of time. According to the clinical breakpoints as determined by 
the EUCAST, for GBS, concentrations of at least 0.25 mg/L should be reached 9. 
The simulations show that the concentration of amoxicillin after a single 2 gram 
dose in the maternal, the venous umbilical cord and the neonatal serum, exceeds the 
minimally inhibitory concentration for more than 90% of the dosing interval. 
129
Amoxicillin PK in maternal, cord and neonatal serum
Discussion
This collection of data from the mother, umbilical cord and neonate, was a 
unique opportunity to develop a 5-compartment model to describe the overall 
concentration versus time profile in maternal plasma, umbilical cord and neonatal 
plasma. Peak- concentrations in umbilical cord and neonatal serum were lower 
and delayed compared to the maternal peak-concentration. Approximately 1 hour 
after the start of the antibiotic administration the neonatal concentration reached its 
highest level, and thereafter exceeded the concentrations in venous umbilical cord. 
In a first approximation, simulation of a 2 gram infusion on basis of the developed 
pharmacokinetic model demonstrated that amoxicillin concentrations in maternal, 
venous umbilical cord and neonatal serum exceeded the minimal inhibitory 
concentration for >90% of the dosing interval. 
 Studies on the pharmacokinetics in umbilical cord serum are scarce. For 
ampicillin, an antibiotic closely related to amoxicillin, two studies have been 
performed in women during elective caesarean section1,2. Due to differences in 
study design direct comparison to our study is not possible. Because physical 
changes during labor might influence the transplacental blood flow, the transfer 
of amoxicillin across the placental barrier might be different during vaginal 
delivery. Furthermore, data in both studies were not analyzed using a population 
pharmacokinetic approach. Nevertheless, results of both studies are in line with our 
results. The ampicillin concentrations in cord serum exceeded the MIC for GBS 
during the study periods of 7-71 minutes1 and 32- 343 minutes2 after the start of the 
antibiotic infusion. Colombo et al.2 focused on the ratio of the concentration in cord 
serum and maternal serum. They reported that initial cord serum concentrations 
were lower than maternal concentrations, but after approximately 80 minutes 
the concentrations in umbilical cord serum exceeded the maternal serum 
concentrations. In our study the venous cord concentrations did not exceed the 
maternal concentrations. 
 Both patients receiving amoxicillin and co-amoxiclav were included in 
the study. In the literature it has been described that the addition of clavulanic 
acid does not influence the pharmacokinetics of amoxicillin after intravenous 
administration10-12. Our data confirmed this finding (unpublished observations). 
Therefore, the pharmacokinetics of amoxicillin in these patients was assumed to be 
similar and all patients were analyzed simultaneously. 
 In the final analysis, the arterial umbilical cord and neonatal concentrations 
were considered similar. Several differences exist between these concentrations. 
Before clamping the umbilical cord antibiotics are eliminated from the fetus by 
transplacental transport to the mother and by fetal renal excretion. After cord 
clamping elimination of amoxicillin from the neonate takes place only by neonatal 
renal excretion. Because elimination from the neonate to the mother was included 
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in the model, the model predicted neonatal concentrations might be lower compared 
to the observed concentrations. Furthermore, many physiological changes occur 
immediately after birth in the neonate. These changes might influence the PK in the 
neonate. However, since all concentrations taken from the neonate and the arterial 
umbilical cord are distributed randomly around the line of identity, these differences 
do not seem to have a major influence on the PK within the first hours after birth
 Blood samples in venous umbilical cord serum are sometimes used as a 
representative for concentrations in fetal serum. In the simulated concentration-time 
profiles the neonatal serum concentration is slightly higher than the concentrations 
in venous umbilical cord. This might be explained by a change in elimination route 
after birth. Before umbilical cord clamping the amoxicillin was eliminated both by 
the mother and fetus. After birth the amoxicillin is eliminated only by the neonate. 
Together with the decreased glomerular filtration rate in neonates, this results in a 
slower elimination rate and higher serum concentrations. This indicates that venous 
umbilical cord amoxicillin concentrations will not overestimate the concentrations 
in fetal serum. 
 In our study the simulated concentration-time profiles in maternal, venous 
umbilical cord and neonatal serum are used to describe the PK in relation to each 
other. In a first approximation, an amoxicillin infusion of 2 gram seems to be 
adequate to prevent neonatal GBS disease in the average patient. But to evaluate 
the efficacy of the dosing regimen as recommended by the CDC8 for all pregnant 
women and to investigate possible improvement of the dosing regimen, further 
studies are needed. Such studies should take into account the inter-individual 
variability, correlation between the PK parameter estimates and knowledge of the 
concentration-effect relationship. 
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Objective: To determine whether the probability of target attainment differs 
significantly between commonly used amoxicillin dosing regimens and whether 
inaccuracies in antibiotic administration influence the probability of target 
attainment.
Study Design: Population pharmacokinetic parameter estimates and their inter-
individual variability in patients with premature rupture of the membranes were 
obtained from a previous investigation. Monte Carlo Simulations were then 
used to determine the influence of differences in the dosing of amoxicillin on the 
percentage of time that serum concentrations of the unbound drug remained above 
the Minimum Inhibitory Concentration (%fT>MIC).
Results: When administering 1 gram as a bolus injection, %fT>MIC was 
approximately 4% lower than after infusion over 15 minutes. Simulating the 
administration of 1 gram amoxicillin bolus injections every 6 hours, the %fT>MIC 
at steady state for the average population is 92%, for a value of 0.25 mg/L as MIC 
of group B streptococcus (GBS). When the lower 99% confidence interval (CI) was 
taken into account, this percentage decreased to 46%. After decreasing the dosing 
interval to 4 hours, the %fT>MIC for the average population and the lower 99% CI 
were 99% and 70%, respectively.
Conclusion: Minor differences in the probability of achieving effective 
concentrations were detected between the different dosing regimens of amoxicillin. 
A dosing schedule of 1 gram bolus injections every 6 hours is adequate to prevent 
GBS infections and minor inaccuracies in the administration are not influencing its 
predicted efficacy. An initial dose of 2 gram is has no added value.
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Introduction
During labor, especially after rupture of the membranes, pregnant women and their 
fetuses are at risk for ascending infections from the vagina. An important part of these 
infections is caused by group B streptococcus (GBS, Streptococcus agalactiae). Up 
to 35% of pregnant women are colonized with GBS in the rectovaginal tract1,2. 
To protect neonates of these mothers from infection, prevention strategies have 
been implemented3,4. Antibiotics are used in the management of pregnant patients 
to eliminate GBS from the site of infection. Proper dosing of antibiotics is essential 
to prevent both mother and fetus from infection. 
 Although several dosing regimen recommendations exist and are currently 
used, the rationale behind these regimens is not always clear. Specifically, limited 
information on the pharmacokinetics of antibiotics in pregnancy in general and in 
the peripartal period in particular, is available. In addition, at the time these regimens 
were designed less information was available with respect to the pharmacokinetic/
pharmacodynamic properties of the drugs used. This may lead, or may have lead, to 
therapeutic failure. Cases of neonatal GBS infection after maternal antibiotic therapy 
have been described5,6. In the literature different dosing regimens for the prevention 
of GBS infection are recommended. Guidelines to prevent neonatal GBS disease 
issued by the Centers for Disease Control and Prevention (CDC) recommend the 
use of an initial dose of 2 gram ampicillin and subsequent doses of 1 gram every 
4 hours4. The Cochrane Library on the other hand describes a dosing regimen of 
ampicillin 1 gram intravenously every 6 hours as the usual regimen7. Because the 
consequences of changes in antibiotic dosing are unknown, it is not possible to 
study different regimens in pregnant women. Computer-simulations using data 
of the prescribed regimens are an accepted alternative, particularly when detailed 
information on the pharmacokinetics and the inherent inter-individual variation is 
available.  
 Monte Carlo Simulation (MCS) is used to evaluate the probability of 
achieving therapeutic concentrations of different dosing schedules. MCS is 
performed using pharmacokinetic parameters, data on the concentration-effect 
relationship and on the inter-individual variability8-13. The relationship between 
pharmacokinetic properties, the susceptibility of the microorganism (as reflected 
in the Minimum Inhibitory Concentration, MIC) and clinical effects is increasingly 
well understood. Specifically, the efficacy of the penicillins such as ampicillin and 
amoxicillin, has been shown to be primarily correlated to the percentage of time that 
serum concentrations of the unbound drug remain above the MIC (%fT>MIC)14-16. 
In general, the therapeutic goal to cure infections caused by Gram-positives is a 
%fT>MIC of at least 40%, which corresponds to an in vivo static effect in animal 
studies. The pharmacokinetic behavior of drugs differs for each individual. The 
recommended dosing schedule should be adequate in preventing infections for the 
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entire population. Therefore, inter-individual variability is a determining factor 
in the prediction of the outcome of therapy in individual patients. To predict the 
probability of success of treatment, the %fT>MIC should be at least 40% for each 
individual within the population. 
 Outside the US, intravenous amoxicillin is often used in the prevention 
of neonatal GBS disease. Amoxicillin dosing regimens have been derived from 
studies using ampicillin, a beta-lactam antibiotic closely related to amoxicillin17, 18. 
Differences in dosing regimens, as well as inaccuracies in the administration of the 
antibiotic might influence the %fT>MIC and the associated efficacy in preventing 
GBS infections. The purpose of this study was therefore to perform MCS for 
amoxicillin concentrations in pregnant women to assess whether the probability 
of target attainment (PTA) differed significantly between the recommended dosing 
regimens and to examine the influence of inaccurate antibiotic administration on 
PTA. To this end, we used the population pharmacokinetic model for amoxicillin 
in pregnant women with preterm premature rupture of the membranes (PPROM) as 
previously described19. 
                                                                                                                                                      
                                                                       
Materials and Methods
Dosing schedules




1 gram 15 min 4 h
1 gram Bolus 4 h
1 gram Bolus 6 h
2 gram 30 min 4 h
Steady state
1 gram Bolus 4 h
1 gram Bolus 6 h
Inaccuracies
1 gram Bolus 8 h
1 gram Bolus 12 h
1 gram 30 min 4 h
1 gram Rate 66.7 mg/min -
Table 1: Simulated dosing regimens.
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Study population and pharmacokinetic modeling
The population pharmacokinetic model of the amoxicillin serum concentrations in 
pregnant women with PPROM has been described previously19. The amoxicillin 
was administered intravenously. The initial dose of 2 gram was infused over 30 
minutes and the subsequent 1 gram doses were infused over 15 minutes. Population 
pharmacokinetic parameter estimates were based on a population analysis of plasma 
concentrations in 17 patients using NONMEM. A total of 416 blood samples was 
obtained and used in the modeling procedure. A 3-compartment open model best 
described the concentration-time curves. Inter-individual variability was very 
small and largely explained by variations in the parameters clearance and volume 
of distribution of one of the peripheral compartments. The main demographic 
characteristics and pharmacokinetic estimates are summarized in table 2.
                                                  Demographic characteristics Structural model parameters
mean SD range mean SE
Maternal age (y) 29.42 4.64 19.6-35.1 CL (L/h) 22.8 1.03
Gestational age (wk) 35.1 1.63 29.4-36.9 V1 (L) 5.59 0.826
Body mass index (kg/m2) 29.1 3.87 21.5-35 V2 (L) 7.43 1.06
Weight (kg) 80.9 12.03 56.2-98.9 V3 (L) 8.61 0.768
Leucocytes x109L 11.8 4.43 6-25.9 Q (L/h) 60 18.5
Creatinin µmol/L 44.4 10.11 37-74 Q2 (L/h) 7.72 1.72
Table 2: Main demographic characteristics and pharmacokinetic estimates of the 17 
pregnant women with PPROM.
CL: Clearance, V1: volume of distribution of the central compartment, V2: volume of 
distribution of the first peripheral compartment, V3: volume of distribution of the second 
peripheral compartment, Q: intercompartmental clearance between V1 and V2, Q2: 
intercompartmental clearance between V1 and V3. More details can be found in Muller et 
al.19.
Monte Carlo Simulation
The estimates of the pharmacokinetic parameters and measures of dispersion were 
used to simulate various dosing regimens and obtain %fT>MIC as a function of 
MIC13. An amoxicillin protein binding of 22% was used in the simulations. MCS 
was performed using the MICLAB version 2.36 program (Medimatics, Maastricht, 
the Netherlands) simulating 10.000 subjects for each regimen. The program 
allows inclusion of the covariance matrix (or correlation matrix) of the parameter 
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estimates used in the simulations. The output consisted of a probability distribution, 
a cumulative probability distribution, and specific confidence intervals over user 
defined MIC and %fT>MIC ranges. MIC breakpoint of GBS for amoxicillin of 
0.25 mg/L was used according to the susceptibility breakpoints determined by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST)20. 
Results
The values for %fT>0.25 mg/L for the dosing regimens obtained from the MCS 
are shown in table 3. After an initial bolus injection of 1 gram the %fT>MIC was 
approximately 4% lower compared to the value after a 15 minutes infusion. The use 
of a loading dose of 2 gram administered over 30 minutes increased the %fT>MIC 
for the population including the 99% CI with 19%, but both values remained above 
the targeted value of 40%. 
 The most frequently used dosing intervals (4 and 6 hours) were also 
simulated in a steady state situation. Figure 1 shows the %fT>MIC for these 2 
dosing intervals. Simulating the administration of 1 gram amoxicillin every 6 hours 
as bolus injection the %fT>MIC in maternal serum for the average population was 
92%, given the MIC of GBS. When the lower 99% CI was taken into account, this 
percentage decreased to 46%. For the dosing interval of 4 hours as recommended 
Simulated dosing regimen %fT>0.25 mg/L
amount infusion interval average 95% CI 99% CI
Single dose
1 gram 15 min 4 h 99.3 88.1 73.2
1 gram Bolus 4 h 99.1 84.5 69.4
1 gram Bolus 6 h 91.4 56.8 47.9
2 gram 30 min 4 h 99.9 99.6 88.8
Steady state
1 gram Bolus 4 h 99.1 84.2 69.7
1 gram Bolus 6 h 91.5 55.7 46.3
Inaccuracies
1 gram Bolus 8 h 77.8 42.2 34.9
1 gram Bolus 12 h 53.3 28.2 23.3
1 gram 30 min 4 h 99.4 90.1 74.6
1 gram Rate 66.7 mg/min - - - -
Table 3: Simulated dosing regimens with the %fT>0.25 mg/L. The MIC of amoxicillin for 
GBS was determined by the EUCAST. 
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Figure 1: Percent of time the unbound fraction of amoxicillin remained above the MIC 
(%fT>MIC) as a function of the MIC for two dosing intervals, 4 hours (figure 1a) and 6 
hours (figure 1b), in pregnant women with PPROM in steady state situation.
Figure 2: Percent of time the unbound fraction of amoxicillin remained above the MIC 
(%fT>MIC) as a function of the MIC for two dosing intervals, 4 hours (figure 2a) and 6 
hours (figure 2b), in pregnant women with PPROM after the inital dose (black lines) and in 
steady state situation (red lines). (See color inlay for a full color version of this figure.)
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Figure 3: Percent of time the unbound fraction of amoxicillin remained above the MIC 
(%fT>MIC) as a function of the MIC for three different initial doses for a 4 hours dosing 
interval in pregnant women with PPROM. In figure 3A the %fT>MIC for a dose of 1 gram 
administered as bolus (black lines) and the 1 gram dose administered over 15 minutes 
(red lines) are shown. In figure 3B the %fT>MIC for the 1 gram dose administered over 
15 minutes (red lines) and the 2 gram dose administered over 30 minutes (blue lines) are 
shown. The solid lines are the values for the average pregnant women; the interrupted lines 
represent the 95% confidence intervals and the dotted lines the 99% confidence intervals. 
(See color inlay for a full color version of this figure.)
by the CDC the %fT>MIC for the average population and the lower 99% CI were 
99% and 70% at steady state, respectively. Therefore the probability of target 
attainment of amoxicillin administered every 6 hours would probably be lower 
than when administered every 4 hours, but the %fT>MIC for all patients exceeded 
the target percentage of 40%. As shown in figure 2, there are minor differences in 
the shape of the curves for initial dose and for doses administered at steady state 
at dosing intervals of 6 hours and 4 hours. In figure 3, the %fT>MIC for the three 
different initial doses is shown (1 gram bolus, 1 gram infusion over 15 minutes and 
2 gram infused in 30 minutes). This indicates that the use of a loading dose of 2 
gram amoxicillin is not beneficial to achieve adequate concentration-time profiles 
in maternal serum to prevent GBS disease.
 During daily patient care, the ideal infusion time is sometimes hampered 
by small accidents, overlooks or other misfortunes, resulting in possibly inadequate 
concentration profiles. We simulated some of these possible adverse regimens. In 
the first simulation the interval was extended to 8 hours and 12 hours respectively, 
predictably resulting in decreased %fT>MICs. Given the MIC of GBS, the %fT>MIC 
for the average population is 78% for an interval of 8 hours and 53% with an 
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interval of 12 hours. However, when the 99% CI was included in the analysis of a 
dosing interval of 8 hours and 12 hours the %fT>MIC decreased to values below 
the 40%. Another problem frequently occurring is obstruction during infusion. 
When an obstruction in the infusion system results in a slower administration the 
%fT>MIC is increased. When amoxicillin was administered with a rate of 66.7 mg/
min (1 gram over 15 minutes) with a dosing interval of 4 hours, the %fT>MIC was 
>50% for the population with the 95% CI included when the infusion is stopped 
after 2 minutes. 
Discussion
We determined the effect of the use of different dosing regimens on the probability 
of achieving therapeutic concentrations in the entire group of pregnant women with 
PPROM. Monte Carlo simulation using pharmacokinetic estimates and a three-
compartment model showed that both the dosing regimen as recommended by 
the CDC4 and the regimen mentioned in the Cochrane Library7 result in adequate 
concentration-time profiles in maternal serum. For both regimens accidentally 
missing a single dose results in a %fT>MIC above the threshold for efficacy for the 
majority of the population. Inaccuracies in the rate of the infusion of amoxicillin 
did not have clinically relevant changes on the PTA, primarily because the MIC of 
GBS is relatively low.  
 The CDC recommends an initial dose of 2 gram of ampicillin4. For the 
average population the %fT>MIC after such a loading dose for amoxicillin as 
well as after a bolus infection of 1gram is >99%. Taking into account the 99% CI 
this difference was 19%, but the values were above the target of 40%. Adequate 
concentrations were reached almost immediately after the start of the administration. 
Therefore the use of a 2 gram loading dose does not seem to be beneficial for 
reaching adequate maternal concentration-time profiles. 
 The rate of the administration of 1 gram amoxicillin does not have major 
influences on the %fT>MIC of the concentration-time profiles. The %fT>MIC 
after a bolus injection is only slightly lower compared to the standard infusion 
over 15 minutes. It is only when amoxicillin infusions are extended to hours, that 
major differences will result (results not shown). This is in line with the half life of 
amoxicillin.  
 An obstruction in the infusion system occurs regularly and in clinical 
practice finally the total amount of antibiotic is administered. Using MCS, it is not 
possible to simulate this particular situation. The best alternative is to simulate an 
infusion 1 gram with a constant rate of infusion and stop the infusion prematurily. 
In this way, a minimal infusion time was determined needed to reach the target 
%fT>MIC of 40%. This target was reached for the majority of the population after 
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2 minutes of infusion, but in clinical practice the infusion will only be temporarily 
blocked resulting in much higher values for %fT>MIC. 
 Studies showing a clear relationship between exposure to amoxicillin and 
its efficacy in preventing GBS infections in pregnant women are not available. To 
our opinion it is reasonable that in this patient group the exposure should correspond 
to exposures that correlate to a 1 to 2 log drop of colony forming units in various 
models, and thus be bactericidal rather than bacteriostatic. Thus, for amoxicillin the 
%fT>MIC should therefore be at least 40%. 
 Only the unbound fraction of the total drug concentration is active. 
Therefore, the percentage of protein binding is implemented in the MCS. Values 
for protein binding of amoxicillin vary between 18-20%21,22. Protein binding might 
even decrease in pregnant women23. It is likely that the protein binding of 22%, as 
used in our analysis, underestimates the active fraction of amoxicillin in pregnant 
women. The use of 22% is therefore a conservative estimate. This may lead to 
slightly underestimated %fT>MICs resulting from the simulations. 
 When prevention of GBS infection fails and the fetus gets infected, 
adequate fetal serum levels and probably amniotic fluid levels are required as 
well. Amoxicillin reaches the fetus after transplacental transfer from the mother. 
Consequently, adequate maternal serum levels are a prerequisite for adequate levels 
in fetal serum. Concentrations in fetal serum are lower compared to concentrations 
in maternal serum; therefore these simulations can not guarantee that these dosing 
regimens are adequate for the prevention of GBS infection in the fetus. 
 In conclusion, we present MCS using a three-compartment model. Both 
the dosing regimen as recommended by the CDC and as mentioned in the Cochrane 
Library will result in adequate concentrations in maternal serum. A two gram loading 
dose does not seem to be beneficial and the 1 gram doses can safely be administered 
by bolus injection increasing the comfort of the patient and facilitating prophylaxis. 
For the majority of the population considerable inaccuracies in the infusion of 
amoxicillin will not interfere with its predicted efficacy in preventing infections 
with GBS in the mother. A dosing regimen of bolus injections of 1 gram every 6 
hours was predicted to be adequate for the prevention GBS infection in pregnant 
patients.
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An aberrant amoxicillin PK profile
Pregnant women included in earlier studies were all relatively healthy1,2. Contrary 
to expectations these studies did not reveal large differences in pharmacokinetics 
between pregnant and non-pregnant individuals. In fact, the pharmacokinetics of 
amoxicillin in these patients were surprisingly similar compared to non-pregnant 
individuals. However, in rare instances the results may be dramatically different. 
Here we describe the case of a patient whose pregnancy was complicated by several 
factors starting from the 23th week. She was treated with amoxicillin because she 
had preterm premature rupture of the membranes (PPROM). After analysis of the 
amoxicillin concentrations it turned out that the pharmacokinetics were strikingly 
different in this patient compared to the pharmacokinetics in patients with PPROM 
as described earlier1. Her case is described here to demonstrate how unusual 
physiological and pathological conditions, and perhaps the medical interventions 
as well, can indeed affect the pharmacokinetics of a drug. 
Case
A 30-year-old primigravid woman presented to our hospital with a monochoreal 
diamniotic twin-pregnancy. 
Her medical history only reported a hernia inguinalis operated in 1982. Her twin-
sister had been diagnosed with multiple sclerosis.
From the 23th week of gestation she was complaining of pyrosis. At a gestational 
age of 25 weeks she was admitted to our hospital with unexplained nausea and 
vomiting. She was successfully treated with aluminiumoxide/magnesiumhydroxide 
(Antagel®), an antacid. Unfortunately, her stay in hospital was complicated by a 
deep venous thrombosis of her left leg. Therefore, she was treated with nadroparin 
(Fraxodi®). Nine days after she had been admitted, she left the hospital with minor 
discomfort of the stomach, but without vomiting.
 At a gestational age of 29 weeks, she presented with waxing and waning pain 
in her back, referring to her abdomen and she had some vaginal fluid loss observed. 
She was complaining of nausea since a couple of hours. It could not be determined 
whether the pain was caused by uterine contractions. Uterine contractions were not 
felt by external palpation and external electronic fetal monitoring did not register 
regular contractions. During speculum examination some clear fluid was seen and 
the cervix appeared to be opened for 1 cm. Although the fern-test was negative, the 
fluid seen in the vagina was suspected for amniotic fluid. Upon admission she had a 
pulse-rate of 82 beats per minute and a temperature of 36.8 °C. Her hematological 
parameters were as follows: hemoglobin 7.3 mmol/L, hematocrit 0.37 L/L, platelets 
353 x 109/L, leucocytes 10.6 x 109/L, C-reactive protein 7 mg/L. 
 Based on the history of uterine contractions, signs of cervical dilatation and 
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ruptured membranes, she was diagnosed with a threatening preterm delivery. It was 
decided to treat her with tocolytic drugs and antibiotics. Amoxicillin was prescribed 
for the ruptured membranes. She agreed to participate in our pharmacokinetic 
study.
 Initially, tocolytic therapy with nifedipine (Adalat®) was started. Nifedipine 
was administered orally and she started to vomit frequently. The capsules were 
thrown out. The intensity of the vomiting increased to a loss of 100-400 ml vomit 
once every 3 to 4 minutes. The vomit was dark brown and contained haemoglobin. 
Her heart-rate had increased. According to the study protocol two intravenous 
catheters were placed. One at the left hand for administration of the amoxicillin 
and a second catheter at her right arm for sampling. A 2 gram dose of amoxicillin in 
30 cc 0.9% NaCL was administered intravenously. The haematological parameters 
were similar to those upon admission. The liver functions were slightly enhanced 
(AF 273 U/L, ASAT 56 U/L, ALAT 77 U/L, γGT 39 U/L) and the renal function was 
normal (ureum 3.2 mmol/L, creatinin 59 μmol/L, uric acid 0.35 mmol/L). After the 
first antibiotic dose, it was very difficult to draw blood from the sampling catheter 
during the first 4 blood samples at respectively 2, 16, 27 and 33 minutes after the 
start of the infusion. It was offered to the patient to stop the study, but she insisted 
on continuation. Subsequent blood samples could be obtained without problems 
out of the sampling line. Because she was still complaining of pain in her back, it 
was decided to start tocolytic therapy with intravenously administered ritodrin, a 
beta-2 agonist. Ritodrin was started at a low dose (200 μg/min) approximately one 
hour after the start of the amoxicillin. Her heart-rate increased up to 120 beats per 
minute, which was attributed to a side effect of the ritodrin. She had no fever. 
 Although she was treated with aluminiumoxide/magnesiumhydroxide 
(Antagel®) and 40 mg pantoprazole (Pantozol®) intravenously in the first hours 
after the amoxicillin infusion, she continued vomiting. To prevent the fetuses 
from respiratory distress syndrome she received an intramuscular dose of 11.4 mg 
celestone chronodose. At 3.5 hours after the first amoxicillin dose she received a 
rectal dose of metoclopramide (Primperan®) and fluid suppletion was increased. 
Subsequently she stopped vomiting and fell asleep. She reported some decrease in 
the pain in her back.
 The second dose of 1 gram amoxicillin was administered with an interval 
of 4 hours after the first dose using the same intravenous catheter located on her 
left hand. At that time she was sleeping. Serial blood samples were easily obtained 
during the next four hours.  
 At a gestational age of 30 weeks and 4 days the patient delivered. Her 
two daughters were admitted to the paediatric department because of their 
prematuritas. They did not present signs of infection. The placenta was examined 
by the pathologist. In the diamniotic monochorionic twin placenta were no signs of 
infection. 
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 Blood samples were placed immediately on ice and processed within 1 
hour after collection. The samples were centrifuged at 1200 g for approximately 10 
minutes. The supernatants were transferred into plastic storage tubes and frozen at 
-70° C until analysis. To determine the amoxicillin concentrations a validated high-
pressure liquid chromatography was performed as described previously1.
 Concentration-time profiles of amoxicillin in this patient, and timing of 
medication, vomiting and uterine contractions are shown in figure 1. The profile after 
the first administration was different from the profile after the second administration. 
After the first dose, a low antibiotic concentration of 0.7 mg/L was measured in 
blood drawn from the opposite arm. Afterwards the concentration increased and 
the peak concentration was reached approximately 200 minutes after the end of 
the antibiotic infusion. Peak-concentration after the second dose was reached at 
the end of the infusion. The area under the curve (AUC) was calculated using the 
trapezoid rule for the first, 2 gram, amoxicillin administration in the case-patient, 
as well as for the concentration-time profiles simulated using Berkely Madonna for 
patients with PPROM after a 2 gram and 1 gram infusion1. For the 2 gram infusion 
Figure 1: Concentration-time profile of the case-patient. Important medical information is 
shown as well. Ritodrine 2 equals 200 μg/min.
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the AUC0-4.23 in this patient was 85.5 h∙mg/L and 78.9 h∙mg/L for the mean PPROM 
patient. AUC0-4.23 for the mean PPROM patient after a 1 gram infusion was 37.0 
h∙mg/L. 
Discussion
We described the concentration-time profile of amoxicillin in a patient with 
threatening preterm delivery. Her treatment was complicated by unexplained severe 
vomiting during the first amoxicillin infusion. At the time the second amoxicillin 
dose was infused the patient stopped vomiting and the frequency of the waxing 
and waning abdominal pain slightly decreased. The concentration-time profile was 
determined during the first and second antibiotic doses of respectively 2 and 1 
gram amoxicillin (figure 1). The profile measured during the second infusion was 
comparable to results from earlier studies1. Figure 2 shows the concentration-time 
profile of the case-patient and the concentration-time profile of a control-patient 
from our previous study. The control-patient was also a primigravid woman with a 
twin-pregnancy and PPROM. 
Figure 2: Concentration-time profiles of the case patient and control patient.  The black and 
white bars indicate the amoxicillin infusion. The detection limit represent the amoxicillin 
detection as well as the quantification limit. 
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 From the shape of the profile after the first dose it appeared that the 
amoxicillin distributed differently through the body when compared to the second 
dose. This raised a number of questions. In the first place, was the aberrant profile 
after the first amoxicillin administration an artefact caused by technical difficulties 
during administration and did it represent the true amoxicillin concentrations at 
the site of sampling? Second, if it was not an artefact, how could the deviating 
pharmacokinetics be explained? Third, if it represented the true plasma 
concentrations of amoxicillin, did this have consequences for the purpose for which 
amoxicillin was given, i.e. prevention of infection in the foetus?
 Firstly, possible explanations due to deviations in the practical execution of 
the study were considered. Both antibiotic doses were administered using the same 
catheter. Therefore, the difference between the concentration-time profiles obtained 
after the first and second antibiotic dose, can most likely not be explained by an 
accidentally subcutaneous administration of the first dose. Moreover, the antibiotics 
were administered using an infusion pump, which produces a warning sound when 
there is an obstruction in the system. The investigator was continuously present 
during the infusion and did not observe difficulties in the infusion. Furthermore, the 
AUC of the aberrant curve is not smaller compared to the AUC in healthy patients 
with PPROM. This indicates that the entire dose is absorbed. Normally, blood 
pressure is measured once every 15 minutes when a patient is treated with ritodrine. 
Due to the emotional and physical state of the patient her blood pressure was not 
measured. Therefore there is no possibility that the blood pressure cuff obstructed 
the blood flow in the arm. 
 An aberrant concentration-time profile might also be explained by 
an accidental exchange or faulty labelling of blood samples or by errors in the 
determination of the amoxicillin concentrations. The profile after the first dose 
was based on 12 blood samples. The concentration data of all samples produced 
a smooth curve, therefore our aberrant observation can not be explained by 
outliers. The amoxicillin concentrations in all samples were determined using the 
same HPLC-method and controls were included in every run. Consequently, it is 
unlikely that this profile is aberrant due to errors in the HPLC-method. Therefore, 
it is concluded that the concentrations as shown in figure 1 appear to represent the 
true concentrations at the sampling site. 
 To explain the aberrant concentration-time profile, physiological changes 
that may influence the pharmacokinetics of amoxicillin were considered. For various 
drugs it is known that the pharmacokinetics is influenced by the state of pregnancy 
and /or being in labour. As an example, the pharmacokinetics of ampicillin, an 
antibiotic structurally closely related to amoxicillin, has an decreased half-life 
in pregnant women according to several studies3-6. Other studies described an 
increased half-life of ampicillin, but exclusively in women during labor compared 
to non-pregnant individuals, not in pregnant women before the onset of labor7,8. In 
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our patient the aberrant pharmacokinetic profile was demonstrated only after the 
first (2 gram) dose. After the second (1 gram) dose the profile was comparable to 
the profiles described for pregnant women with PPROM1. The state of pregnancy 
and labor did not change between the two doses and it has been shown previously 
that shape of the concentration-time curve was not changed by pregnancy or labor2. 
Therefore, this aberrant profile cannot be explained by pregnancy or labor. 
 Additional factors might also influence the pharmacokinetics. This patient 
had a lot of psychological stress, was vomiting seriously and various drugs were 
administered in the period when the amoxicillin was infused. Psychological stress 
activates the sympathic nervous system, thereby inducing a cascade of physiological 
reactions, finally resulting in strengthening of the contractility of the heart and 
peripheral (arterial) vasoconstriction. Vasoconstriction limits the blood flow to the 
limbs as well as increases the critical closing pressure. An increased critical closing 
pressure facilitates the occlusion of the blood flow in restricted areas. 
 The possible physiological changes as a result of the serious vomiting are 
more complex. An enormous effort for the body is required to vomit frequently. 
The blood flow to the muscles involved in vomiting, mainly the respiratory and 
abdominal muscles, might change the distribution of blood through the body and 
restrict blood flow to less vital areas such as the arms. The fluid loss resulting from 
the vomiting might cause a (minor) hypovolemia. Clinically, an increased heart-rate 
will be seen. In our patient the heart-rate was increased but this was attributed to 
a possible intrauterine infection, stress and a side effect of one of the administered 
drugs (ritodrine). Initially, no fluid replacement was given. After large amounts of 
fluid loss, the hematocrit values are likely to increase. In patients with an increased 
hematocrit, the blood viscosity is increased because of cell deformation, which will 
result in a reduced blood flow. However, The hematocrit value in our patient was 
similar 120 min and 20 min before the start of the amoxicillin. Both due to the short 
time interval between the two measurements and to a limited blood flow in the arm, 
it is reasonable to that the hematocrit remained similar. Thus, it is inferred that the 
main effect of vomiting was to redistribute blood flow over the body and to restrict 
flow in the arms
 In the study period, several drugs were administered besides the amoxicillin. 
It is unlikely that the Antagel® or Pantozol® influenced the pharmacokinetics. 
However, ritodrine has a dilatating effect on the blood vessels. Because 
vasoconstriction in patients with hypovolemia occurs as compensation mechanism, 
ritodrine is contraindicated in those patients. Vasodilatation is these patients might 
result in venous stasis, thereby limiting the blood flow. In our patient ritodrine was 
administered 60 min after the start of the amoxicillin and in a low dose (200 μg/
min). The dose was increased minimally (see figure 1), because of the increase in 
heart-rate. This increased might be a side effect of the ritodrine, but might also in 
part be explained by a reaction on vasodilatation caused by hypovolemia.  
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 From the clinical point of view, it is important whether the deviation of 
this concentration-time profile from the average profile affects the efficacy of the 
amoxicillin in the prevention of both maternal and neonatal GBS infection. The 
efficacy of amoxicillin is determined by the time the concentration exceeds the 
minimum inhibitory concentration (T>MIC). In general a T>MIC for 40-50% of 
the dosing-interval is required for efficacy9-11. The MIC-value of amoxicillin for 
GBS as reported by the EUCAST is 0.25 mg/L12. The concentration in maternal 
serum of our patient exceeds the MIC-value for GBS within 2 minutes after the 
start of the infusion and stays above the MIC for the remaining time of the dosing-
interval. This aberrant concentration-time profile in maternal serum is therefore 
unlikely to reduce the efficacy of the amoxicillin in preventing maternal GBS 
infection. However, the main goal of this antibiotic administration is preventing 
the fetus from infection. Since the transfer of amoxicillin over the placental barrier 
might be influenced by the peak-concentration in maternal serum, the efficacy in 
preventing the fetus from infection might be reduced. Unfortunately, concentrations 
in umbilical cord blood and fetal blood could not be obtained in this case and it is 
therefore unknown whether the amoxicillin in this patient was adequate during the 
first dosing-interval to prevent the fetus from GBS infection. 
 In 1972, Rowland et al also reported an aberrant pharmacokinetic profile13. 
In this case, a male volunteer became faint 10 minutes after he received an oral 
dose of 650 mg aspirin. He recovered soon afterwards and during this event the 
study was continued. From the moment he became faint, the absorption stopped 
and aspirin levels decreased for the next 20 minutes, where after the levels began 
to rise again. Fainting is the result of a decline in the blood flow to the brain. 
To compensate for this, vasoconstriction outside the heart and brain is likely to 
occur, resulting in a redistribution of the blood flow, favouring the flow to the brain. 
A decreased motility of, and a decreased circulation to, the gastrointestinal tract 
probably explain this aberrant curve. In our case, the blood flow is also likely to be 
redistributed, favouring, besides the brain and heart, the body components used in 
vomiting like the respiratory muscles, abdominal muscles and the gastrointestinal 
tract. Therefore the blood flow to the extremities will be minimized. In both cases 
redistribution of the blood flow is a possible underlying mechanism causing the 
aberrant PK profiles. 
 In conclusion, the concentration-time profile of amoxicillin after the 
first infusion in our patient deviated from the normal profile. It is not possible to 
explain the course of the profile with certainty, however we hypothised that several 
physiological changes had occurred that all influences the peripheral blood flow 
and thereby changing the distribution of the amoxicillin. The arm in which the 
amoxicillin was infused might act as depot for the amoxicillin. After the blood flow 
slowly normalises the amoxicillin is steadily released from the depot. The registration 
of this profile is unique because blood samples were taken frequently in an acute, 
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emotional and very stressful situation. It is not possible to perform pharmacokinetic 
studies of a group of patients in this condition. Therefore, individual cases are 
valuable and indicate that although the pharmacokinetics is quite well described 
in healthy volunteers and several groups of patients, unexpected differences in the 
pharmacokinetic profile can occur in (critically) ill patients.
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Objective: This study was undertaken to describe the pharmacokinetics of 
intravenously administered clindamycin in pregnant women. 
Study Design: Pregnant women were recruited who needed treatment with 
clindamycin in the prevention of neonatal group B streptococcal disease or of 
endocarditis (900 mg every 8 hours and 600 mg every 6 hours respectively). 
Following delivery, both arterial and venous umbilical cord blood samples were 
obtained. Clindamycin concentrations were determined with the use of high-
pressure liquid chromatography. Nonlinear mixed-effects modeling was performed 
in NONMEM. 
Results: The pharmacokinetics of 7 patients was best described by a three-
compartment model. Clearance and volume of distribution at steady state were 10.0 
L/h and 6.32 x 103 L, respectively. Using a 900 mg dosing regimen in the average 
pregnant women, the ratios of the area under the concentration time curves in 
maternal serum over the Minimum Inhibitory Concentration (MIC) were 64, 32, and 
8 for assumed protein binding of 60%, 80% and 95% respectively. Concentrations 
in umbilical cord were lower compared to the maternal concentrations. 
Conclusion: Concentration-time profiles in maternal serum are likely to be adequate 
for the average pregnant woman. In contrast the observed concentrations in arterial 
umbilical cord blood indicate that the current dosing regimen may not be adequate 
to prevent the neonate from group B streptococcal disease. 
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Introduction
In pregnant women, clindamycin is used for various clinical conditions related 
to the mother or the neonate, especially when penicillin-allergy is encountered. 
Clindamycin is active against gram-positive cocci and anaerobic bacteria. In 
pregnant women at risk for endocarditis, it may be used to protect against infective 
endocarditis during labor1. Clindamycin is also one of the alternative drugs to protect 
neonates at risk for invasive group B streptococcal (GBS) disease2. Especially 
concerning the prevention of GBS disease, the use of antibiotics during labor has 
increased after the implementation of the culture-based prevention strategy in many 
countries2. 
 During pregnancy and labor important physiological changes occur that 
may modify the pharmacokinetics of drugs. In non-pregnant individuals it has 
been shown that clindamycin distributes widely over the body, but that it does not 
adequately cross the blood-brain-barrier, even in case of bacterial meningitis3. It is 
metabolized and subsequently excreted into the urine and bile. The protein binding 
in non-pregnant humans ranges between 62% to 94%4-8. Because clindamycin 
is recommended in the prevention of both maternal and neonatal infection, the 
pharmacokinetics during labor in the mother and the transfer of the drug over the 
placental barrier are important.
 Pharmacokinetic studies during labor face considerable ethical and 
logistical difficulties, limiting the opportunity for the collection of blood samples. 
These limitations may be overcome by the application of innovative approaches 
to the analysis of sparse data. Specifically, Non-Linear Mixed Effects Modeling 
(NONMEM) allows weighted analysis of data from both patients with large datasets 
and patients with small or incomplete datasets9,10. Moreover, by studying the 
population as a whole, the influence of specific circumstances on the individual PK 
parameters can be assessed using covariate analysis11,12. A more detailed background 
of population modeling can be found elsewhere13,14. The objective of this study 
is to describe the pharmacokinetics of intravenously administered clindamycin in 




In the period between February 7, 2005 and February 28, 2007, all women with 
a gestational age of more than 26 weeks who needed antibiotic treatment with 
clindamycin were eligible for this study. Following the local guidelines, all women 
with proven or unknown Streptococcus agalactiae carriage were treated with 
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antibiotics when pregnancy was complicated by one of the following factors: preterm 
premature rupture of the membranes, rupture of the membranes for >18 hours, 
prematurity, fever (>37.8° C), bacteriuria in current pregnancy and a previous child 
with invasive GBS disease. The choice of the antibiotic for this study was dictated 
by the local guidelines, which recommend clindamycin in case of penicillin allergy 
in the prevention of GBS disease. Patients with an increased risk on endocarditis 
received clindamycin approximately 1 hour before delivery. Clindamycin is the 
antibiotic of first choice in the prevention of endocarditis, following local hospital 
guidelines. 
 The study was approved by the Medical Ethics Committee of the Medical 
Center Haaglanden, The Hague. Written informed consent was obtained from all 
patients. Women were excluded from the study when (1) they had been treated 
with oral or intramuscular antibiotics within 2 days before starting the therapy, 
(2) were unwilling to comply with the requirements of the study, (3) were known 
to be allergic to clindamycin, or (4) received co-medication that exhibits known 
interaction with clindamycin. All patients were at least 18 years of age.
 All patients received a standard work-up that included a medical history and, 
biochemical and hematological examination at the onset of the study. Furthermore 
blood pressure, pulse, oral temperature, and body weight were recorded before the 
antibiotic administration. 
Drug administration and blood sampling
Before the administration of clindamycin two intravenous catheters were placed, 
one in each arm. Clindamycin was administered according to local guidelines 
in the hospital using the first catheter. The dose of 600 mg, as prescribed in the 
prevention of endocarditis, was administered over 20 minutes (12 ml/mL NaCl 
0.9%) every 6 hours. The dose of 900 mg, as used in the prevention of GBS disease, 
was administered over 30 minutes (9 mg/mL NaCl 0.9%) every 8 hours. The exact 
duration of infusion was recorded.
 Blood samples of 2 mL were collected from the second catheter in the 
contralateral arm at timed intervals beginning at 1 min after the start of the infusion 
and, at 10 and 20 min (600 mg infusion) or 15 and 30 min (900 mg infusion). After 
completion of the infusion, sampling was scheduled at 3, 6, 10, 16 and 36 minutes, 
and afterwards every 30-45 minutes until the next antibiotic dosage. Blood samples 
were collected when possible, taking into consideration the physical and emotional 
inconvenience to the woman. The exact sampling times were recorded. Immediately 
after birth, both arterial and venous umbilical cord blood was obtained. 
 Blood samples were placed immediately on ice, allowed to clot and 
processed within one hour after collection. The samples were centrifuged at 1200 
g for approximately 10 min. The supernatants were transferred into plastic storage 
tubes and frozen at -70˚ C until analysis. 
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Clindamycin HPLC
Samples were extracted by adding 0.05 ml NaOH (1.2 M) containing 40 mg/L 
propanolol as the internal standard. After vortexing, 2.6 ml dichloromethane (Sigma, 
The Netherlands) was added, and after vortexing, centrifuged during 5 min at 1500 
g.  The supernatant was removed and 2 ml pipetted in a new vial. The contents were 
dried at 40° C, airflow 5 L/min and solved in 0.2 mL potassiumdihydrophosphate, 
pH 4.6. 
 Clindamycin concentrations in 0.05 mL were determined by HPLC 
(Shimadzu, Den Bosch, NL). A reverse phase method (0.066 M pH 4.6 
potassiumdihydrophosphate with 20% acetonitril), a C18 column (Bester, 
Amstelveen, NL) with a UV-VIS detector, wavelength 200 nm, temperature 40° 
C was used. The runtime was 10 min, injection volume 0.05 ml, flow 1 ml/min. A 
standard curve of clindamycin (Sigma-Aldrich, NL) was determined during each 
run. The lower limit of detection and quantification was 0.1 mg/L and was linear up 
to 50 mg/L. Higher concentrations were determined by diluting the samples. The 
between sample between day coefficient of variation (CV) was < 5%.
Pharmacokinetic analysis
Pharmacokinetic parameters were estimated by means of Non-Linear Mixed 
Effect Modeling (NONMEM). The model was implemented in the NONMEM 
ADVAN5 subroutine and the analysis was performed using the FOCE method 
with INTERACTION. All fitting procedures were performed with the use of the 
Compaq Visual FORTRAN standard edition 6.6 (Compaq Computer Cooperation, 
Euston, Texas, USA) and NONMEM® software package (version VI, release 1.2, 
ICON Development Solutions, Ellicott City, Maryland, USA).
 To determine the basic structural pharmacokinetic parameters various 
2- and 3-compartment models were tested. Model selection and identification 
of variability were based on the evaluation of the mean objective function value 
(OFV), pharmacokinetic parameter point estimates, and their respective confidence 
intervals, and goodness-of-fit plots. For differences between two structural 
models, the OFV with a pre-specified level of significance of p<0.001 was used 
(corresponding to a difference in OFV of at least 10 points). NONMEM minimizes an 
objective function in performing nonlinear regression analysis. To detect systematic 
deviations in the model fits, the goodness-of-fit plots were visually inspected. Data 
of individual observations versus individual or population predictions should be 
randomly distributed around the line of identity. The weighted residuals versus time 
or population predictions should be randomly distributed around zero. Population 
values were estimated for the parameters clearance (CL), the volumes of distribution 
(V) and intercompartmental clearances (Q). 
 Individual estimates for pharmacokinetic parameters were assumed to 
follow a log-normal distribution. Therefore an exponential distribution model 
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was used to account for inter-individual variability. Possible correlation between 
inter-individual variability coefficients on parameters was estimated and if present 
accounted for in the stochastic model (NONMEM Omega block option). 
 Selection of an appropriate residual error model was based on the evaluation 
of OFV and inspection of the goodness-of-fit plots. A proportional error model, 
additive error model and a combined proportional-additive error model were tested 
to describe the residual variability between the observed concentrations and those 
predicted by the model. The residual error term contains all the error terms, which 
cannot be explained and refers to, for example, measurement and experimental 
error and structural model misspecification.
 To refine the model covariate analysis was also performed. The estimated 
pharmacokinetic parameters, on which a random effect has been identified, were 
plotted independently against the covariates bodyweight, body mass index, 
gestational age, oral temperature, the amount of edema and singleton or twin 
pregnancy to determine whether this influenced the pharmacokinetics. Covariate 
analysis was performed by forward addition of each candidate covariate into the 
model structure until no further improvement of goodness of fit was observed. A 
significance level of 0.05 was selected (corresponding to difference in OFV of 
3.84 points). A further criterion for acceptance of covariate effects was that the 
estimated 95% confidence interval of the covariate effect did not overlap with 
zero. Contribution of each covariate to the final model was confirmed by backward 
deletion of each covariate from the model to account for possible interaction 
between covariates. Residual intra- and inter-individual variabilities were visually 
evaluated. The volume of distribution at steady state (Vss) was calculated following 
standard procedures15.
 The accuracy of the final population model for the entire population was 
established using the bootstrap option in NONMEM, consisting of repeated random 
sampling with replacement from the original data. This resampling was repeated 
100 times. The estimated parameters from the bootstrap analysis were compared to 
the estimates from the original data.
 The mean pharmacokinetic estimates of the final model derived from the 
PK analysis in NONMEM were used in Berkeley Madonna (version 8.3.5, Berkeley 
Madonna Inc, University of California, USA) to simulate the mean concentration-
time profiles after a 600 mg and 900 mg clindamycin dose in pregnant women during 
labor. These maternal concentrations were used to calculate ratios of the umbilical 
cord concentrations and simultaneous maternal concentrations. Furthermore, ratios 
of the area under concentration curve for the free-drug in maternal serum for 24 
hours over the MIC (fAUC0-24h/MIC) were calculated, taking into account various 
percentages of clindamycin protein binding. For clindamycin the ratio for the total 
drug concentration should be at least 147, whereas for free-drug concentrations this 
ratio should be at least 27 16. 
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Results
In total, seven patients were included. Of these patients four received clindamycin 
in the prevention of neonatal GBS disease and two to prevent the mother from 
endocarditis. One patient needed antibiotics to prevent both neonatal GBS disease 
and endocarditis. The physician decided to treat her with clindamycin using the 
dosing regimen for GBS prevention. Six patients with singleton pregnancies 
were in labor. One patient was treated because of preterm premature rupture of 
the membranes (PPROM) and had a twin pregnancy. The characteristics of the 
study population are presented in table 1. All patients receiving clindamycin as 
Data Units Mean SD Range
Maternal age Y 36.1 4.24 31.3-41.8
Gestational age wk 38.3 3.01 34-42.3
Body mass index kg/m2 32.1 5.36 22.1-39.1
Weight kg 86.1 14.2 59.5-104.8
Creatinin umol/L 55.9 20.3 38-100
Ureum mmol/L 3.39 1.17 1.8-5.6
Uric acid mmol/L 0.31 0.086 0.18-0.43
AF U/L 495 601 168-1794
ASAT U/L 22.6 6.78 15-34
ALAT U/L 10.9 5.27 5-18
γGT U/L 10.7 6.85 5-25
LDH U/L 351 74.6 247-445
Systolic blood pressure mmHg 118 17.8 100-150
Diastolic blood pressure mmHg 65 7.64 50-70
Pulse / min 84.6 11.1 74-108
Temperature ° C 36.9 0.23 36.7-37.4
Table 1 Population characteristics (n=7). 
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prevention of GBS were healthy. Of the three patients receiving clindamycin for 
endocarditis prophylaxis one had a minor stenosis of the mitral valve, the second 
had a prosthetic aortic valve, a prosthetic mitral valve and had been operated in 
the past on the tricuspidal valve. The third patient had a dysfunction of the aortic 
valve and autoimmune thrombocytopenic purpura (AITP), what had resulted in a 
splenectomy.
 A total of 177 samples were included in the study. Two samples were 
excluded because the concentrations were <0.1 mg/L. In one patient it was not 
possible to place the two catheters each on a separate arm. Both catheters were 
placed on the right arm. The catheter used for the clindamycin infusion was flushed 
after the clindamycin administration and occluded. The samples collected during 
the clindamycin infusion in this patient were excluded from the analysis. In one 
patient with endocarditis prophylaxis, only four samples could be obtained due to 
obstruction of the sampling catheter. In three out of the seven patients results of an 
infusion in the postpartum period only for study purposes were also included. One 
patient receiving clindamycin as GBS prophylaxis received a postpartum dose of 
600 mg, because she only agreed with a postpartum dose when the time interval 
between delivery and the last dose was short. 
 From all six patients in labor both arterial and venous umbilical cord blood 
samples were taken. The individual arterial and venous concentrations, the time-
interval between the collection of the samples and the start of the antibiotic infusion 
Table 2 Clindamycin concentrations in arterial and venous umbilical cord blood and in 
maternal blood.
* Maternal concentrations were determined by simulation using Berkeley Madonna with 





















1 900 1.85 1.38 2.5 1.1 5.08
2 900 4.27 3.67 0.9 1.0 1.88
3 900 1.45 0.85 4.0 3.3 6.01
4 600 4.53 4.15 1.1 1.1 0.69
5 900 10.5 10 0.1 0.1 0.19
6 600 0.95 0.65 1.7 2.7 3.03
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and the time of the antibiotic peak-concentration are shown in table 2. Ratios 
of the venous umbilical cord blood concentrations and simultaneous maternal 
blood concentrations ranged from 0.22 to 0.89, with one outlier of 1.59. Ratios 
of arterial umbilical cord blood concentrations and simultaneous maternal blood 
concentrations ranged from 0.48 to 0.67 with one outlier of 1.59.
 Various pharmacokinetic models were tested. Implementation of a 
3-compartment model instead of a 2-compartment model improved the model-
fit. The OFV decreased with 190 points, indicating that the 3-compartment model 
described the data better than the 2-compartment model. Using the 2-compartment 
model the concentration-time profiles in the two patients included for a prolonged 
period after the postpartum clindamycin infusion were not described adequately 
(figure 2A). Implementation of the 3-compartment model improved the model-fit, 
as is seen in figure 2B. Improvement of the model-fit using a 3-compartment model 
was also seen in the goodness-of-fit plots. 
 Considering the change in OFV, the visual inspection of the individual 
plots and the goodness-of-fit plots as well as the estimates of the pharmacokinetic 
parameters with their respective CVs, a three-compartment open model best 
0 10 20 30
























ID: 1 ID: 2
ID: 3 ID: 4
ID: 5 ID: 6
ID: 7
Figure 1: individual plots with the final 3-compartment model. The black dots correspond 
with the individual datum points. The line represents the individual estimate and the dotted 
line the population estimate.
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described the data. The residual error was best described by a proportional error 
model. Inter-individual variability was explained by variation in the parameters 
CL, V3 and the residual error (54% on CL, 4.0% on V3 and 55% CV on the residual 
error). None of the covariates could improve the model-fit. The Vss was calculated 
to be 6.32 x 103 L and the gamma-phase t1/2 was 2.6 h. The final estimates of the 
pharmacokinetic parameters and their respective CVs and 95% confidence intervals 
are presented in table 3. Due to the limited number of patients the parameter 
estimates for the inter-individual variability were not statistically significant. The 
individual plots and the plots of the observed concentrations versus the predicted 
concentrations are shown in figure 1 and 3 respectively. 
Figure 2: ID 3 modeled with a 2- compartment model (figure 2A) and a 3-compartment 
model (figure 2B). The blocks indicate the time at which the infusion of the clindamycin was 
started and stopped.
 The bootstrap validation of the model of the entire population was 
performed with 100 runs. The bootstrap validation was successful for 92 runs. 
From the mean parameter estimates of the runs obtained from the bootstrap analysis 
only the estimate for V3 deviated significantly from the predicted values from the 
NONMEM PK analysis. The estimates for V3 could not be determined with good 
accuracy, because in the study population only two patients were included with a 
prolonged concentration-time profile. Therefore, this indicates that the accuracy of 
the final model is good.
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Table 3: final estimates of the pharmacokinetic parameters and their respective CVs of the 
3-compartment model.CL: Clearance, V1: volume of distribution of the central compartment, 
V2: volume of distribution of the first peripheral compartment, V3: volume of distribution of 
the second peripheral compartment, Q: intercompartmental clearance between V1 and V2, 
Q2: intercompartmental clearance between V1 and V3 ,CV: coefficient of variation. 
 In the prevention of neonatal GBS disease clindamycin is administered 
intravenously to the mother. The clinical breakpoint of clindamycin for GBS as 
determined by the EUCAST is 0.5 mg/L17. Using the dosing regimen of 900 mg 
every 8 hours and 600 mg every 6 hours, the values of fAUC0-24h/MIC for protein 
binding ranging from 60% to 95% are shown in table 4. The ratio of fAUC0-24h/
Parameter Units Estimates of all patients
Mean CV 95% confidential interval
Structural model parameters
CL L/h 10.0 41.2 1.92 – 18.1
V1 L 12.4 11.5 9.62 – 15.2
V2 L 52.2 6.3 45.8 – 58.6
V3 L 6260 21.2 3650 – 8870
Q1 L/h 137 6.27 120 – 154
Q2 L/h 21.1 10.4 16.8 – 25.4
Variance model parameters
interindividual 
variability in CL 0.293 69.3 -0.105 – 0.691
interindividual 




0.306 50.7 0.22 – 0.61
residual 
variability 0.0425 48.7 0.00193 – 0.0831
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MIC for the total drug concentration is also shown in table 4. Taking into account 
the protein binding, the 900mg dosing regimen results in a ratio of at least 32 for a 
protein binding up to 80%. The limited difference in ratio of fAUC0-24h/MIC for the 
total drug concentration in maternal serum indicates that the dosing regimen of 900 
mg every 8 hours might be more adequate than the dosing regimen of 600 mg every 
6 hours.
Figure 3: plot of the observed versus the predicted concentrations using the final 
3-compartment model.
Discussion
In this study a pharmacokinetic model was developed to describe the 
pharmacokinetics of clindamycin in pregnant women. The pharmacokinetics of 
clindamycin in pregnant patients is best described using a 3-compartment model. 
Clearance and gamma-phase half-life were 10.0 L/h and 2.6 h, respectively. For the 
average pregnant women, the fAUC0-24h/MIC ratio ranges from 64 to 8 for assumed 
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Table 4: ratios of fAUC0-24h/0.5 for different percentages of protein binding and two 
dosing regimens. The MIC value for GBS used (0.5 mg/L) is determined by the EUCAST17. 
Additionally, the minimal value for efficacy as reported in the literature is shown.
protein binding percentages of 60 to 95% using the 900 mg dosing schedule. 
 Data on the pharmacokinetics of clindamycin in pregnant women and non-
pregnant individuals are scarce. Two previous studies determined the ratio of venous 
umbilical cord blood and maternal blood18,19. Weinstein et al found a ratio of 0.4618 
after intravenous administration during caesarean section. In contrast, Philipson et 
al19 found ratios of 0.18 and 0.25 after an oral dose of clindamycin in women with 
a gestational age of 10 – 22 weeks during a therapeutic abortion. Our values are 
comparable to the ratio reported by Weinstein et al18. The low values reported by 
Philipson et al might be explained by the low gestational age and the difference in 
route of administration (orally in the study by Philipson and intravenously in our 
study). The pharmacokinetic parameter estimate in the mother for clearance using 
our 3-compartment model, results in a lower value as compared to values reported 
in the literature (10.3 L/h for our study versus 19.8 – 26.4 L/h in the literature18,20-23).  
 In the final 3-compartment model all structural parameters were estimated 
with an adequate precision (i.e. CV <51%). When the data were analyzed with a 
2-compartment model, the estimates for the volumes of distribution could not be 
determined with adequate precision. As could be explained by the presence of the 
third compartment, the estimated value for the clearance using a 2-compartment 
model was larger than using the 3-compartment model (respectively 28.3 L/h and 
10.0 L/h). This supports the inclusion of a third compartment in the pharmacokinetic 
model.
Percentage of protein binding 600 mg every 6 
hours
900 mg every 8 
hours
Minimal value for 
efficacy16
Total concentration (free and bound 
clindamycin) 129 159 147
60% 51.7 63.6 27
70% 38.7 47.8 27
80% 25.8 31.8 27
85% 19.4 23.9 27
90% 12.9 15.9 27
95% 6.46 7.98 27
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 Clindamycin in mainly bound to alpha1-acid glycoprotein, an acute phase 
protein. The protein binding is dependent on the serum concentration of both 
alpha1-acid glycoprotein and clindamycin8. High concentrations of alpha1-acid 
glycoprotein result in a high protein binding, whereas, due to non-linearity in the 
protein binding an increase in the clindamycin concentration leads to a decrease 
in protein binding8. In our patients the percentage of protein binding is unknown, 
but compared to non-pregnant healthy volunteers it is likely to be reduced due to 
the state of pregnancy, but possibly increased due to being in labor, stress or the 
presence of infection24. Since only the free unbound fraction of drugs is active and 
the plasma protein binding of clindamycin is relatively high, a minor increase in 
protein binding might influence its efficacy.
 Clindamycin has a time-dependent action in vitro, but clinical efficacy is 
more closely related to fAUC0-24h/MIC
16,25. The therapeutic goal to achieve a static 
effect is a ratio of at least 27, taking into account the clindamycin protein binding. 
However efficacy might be increased with higher ratios. Not for all percentages 
of protein binding reported in the literature, the current dosing regimen reaches 
adequate ratios. Furthermore, these concentration time profiles are only applicable 
for the average pregnant women. When one would take into account the inter-
individual variability in pharmacokinetics this regimen is likely to be inadequate 
for some pregnant women.
 Furthermore, to prevent neonatal GBS disease, both concentrations in 
maternal and in fetal serum have to be adequate. The concentration of alpha1-acid 
glycoprotein in the neonate increases with gestational age24. As has been shown 
for alprenolol, the affinity of alpha1-acid glycoprotein for clindamycin might be 
decreased in the first 7 days of life, partly due to displacement by bilirubin24. Peak 
concentrations in the fetus are likely to be lower compared to the maternal peak 
concentrations, as has been shown for amoxicillin previously26. Arterial umbilical 
blood directly originates from the fetus and therefore these concentrations represent 
concentrations in the fetus. The number of measured clindamycin concentrations in 
the arterial umbilical cord samples in our study is relatively low. When the protein 
binding and the inter-individual variability are taken into account, it is doubtful 
whether adequate concentration-time profiles are reached in the fetus.   
 In conclusion, these data indicate that for the average pregnant women the 
current dosing regimen reach adequate concentrations assuming that the protein 
binding will not exceed 80% of the total concentration. To prevent the fetus from 
infection, concentrations in fetal blood have also to be adequate. Unfortunately, these 
data suggest that the concentration-time profiles in the fetus might be inadequate, at 
least for a substantial part of the population. More pharmacokinetic studies including 
data both of the mother and of the neonate are needed to investigate whether the 
currently advised dosing regimen is adequate to use as preventive measure against 
neonatal GBS disease.  
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Pharmacokinetics of penicillin G 
in infants with a gestational age of 
less than 32 weeks.
Anouk E. Muller, Joost DeJongh, Ymka Bult, Wil H.F. Goessens, 
Johan W. Mouton, Meindert Danhof, John N. van den Anker





The pharmacokinetics of penicillin G was studied in 20 preterm neonates with a 
gestational age of less than 32 weeks on day 3 of life using a population approach 
performed with the nonlinear mixed effects modeling program NONMEM. The 
derived population estimates and the correlation matrix of these estimates were 
used to perform Monte Carlo Simulations (MCSs) and obtain the probability of 
target attainment (PTA). Penicillin G pharmacokinetics was best described by a 
two-compartment pharmacokinetic model. The population estimates of the central 
volume of distribution, peripheral volume of distribution, intercompartmental 
clearance and the total body clearance were 0.359+/-0.06 L, 0.152+/-0.03 L, 
0.774+/-0.28 L/h and 0.103+/-0.01 L/h (mean +/-SE), respectively. The terminal t1/2 
was 3.9 h. Clearance increased significantly with increasing birth weight. Assuming 
the percentage of time that the concentration of unbound drug remained above the 
MIC (%fT>MIC) of 50% for preterm neonates, the susceptibility breakpoint based 
on a 100% PTA was ≤4 mg/L simulating the current dosing regimen of 50.000 U/
kg every 12 h. This regimen is therefore adequate for the treatment of common 
neonatal infections on the third day of life. 
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Introduction
Penicillins are important antimicrobial agents in treatment of bacterial infections 
in newborn infants, with a high clinical efficacy in eradicating common pathogens 
in combination with a high degree of safety. Because of lack of evidence from 
randomized clinical trials in favor of any particular antibiotic or antibiotic regimen1, 
penicillin G remains important among the antibiotics most commonly given to 
neonates in the treatment of presumed early neonatal sepsis.
 Infectious complications during the immediate postnatal period are 
not uncommon and require prompt antibiotic treatment2-5. Differences in body 
composition and organ function can significantly affect the pharmacokinetics in 
neonates. In very premature neonates (i.e. gestational age of less than 32 weeks) 
the disposition of antibiotics may differ from full term neonates as a result of 
differences in absorption, distribution, biotransformation and excretion6-8. As 
a result, dose estimation on the basis of body size or allometric scaling may be 
inadequate. Specifically, in very premature neonates maturation processes of the 
organs may influence the relevant pharmacokinetic parameters. 
 The efficacy of the penicillins is primarily correlated to the percentages of 
time that concentrations of unbound drug remained above the MIC (%fT>MIC)9-
11. In general, the therapeutic goal to cure infections caused by Gram-positives 
is a %fT>MIC of at least 40% of the antimicrobial, which corresponds to an in 
vivo static effect in animal studies12. Studies showing a clear relationship between 
exposure and efficacy in premature neonates are not available. Because prematures 
have to be regarded as immunocompromised, to our opinion it is reasonable that 
in this patient group the exposure should correspond to exposures that correlate to 
a 1 to 2 log drop of CFU in various models, and thus be bactericidal rather than 
bacteriostatic. Thus, for penicillins, this percentage should be at least 50%13. Since 
the goal of treatment is to attain this target for every individual in the population, 
the dosing regimen in this age group should be defined taking the inter-individual 
pharmacokinetics variability into account. Monte Carlo Simulations (MCS) is a 
technique that is commonly used to determine the probability of achieving therapeutic 
concentrations on the basis of population pharmacokinetic parameter estimates and 
their measures of dispersion14-19. We investigated the pharmacokinetics of penicillin 
G and the adequacy of the dosing regimen in very premature neonates on the third 
day of life to allow us to construct a population pharmacokinetic model and to use 
the parameter estimates to perform MCS in this specific age group. We then used 





Preterm neonates with suspected or documented septicemia or invasive infection 
were eligible for this study. The neonates were hemodynamically stable (diuresis > 
1 mL/kg/h; systolic and diastolic blood pressure above the third percentile adjusted 
for gestational age), had a normal liver function, had not received inotropic or 
nephrotoxic drugs, did not have an intracranial hemorrhage beyond grade II, and 
had an indwelling arterial catheter for clinical purposes. The partial pressure of 
oxygen in arterial blood was kept at greater than 50 mmHg or oxygen saturation 
between 87% and 92%, and hematocrit values were maintained above 0.32 by 
packed erythrocyte transfusions. Neonates were excluded from the study if they 
had life-threatening illnesses or became hemodynamically unstable (systolic and 
diastolic blood pressure below the third percentile adjusted for gestational age; 
diuresis < 1 mL/kg/h). Also excluded were infants with severe asphyxia, defined as 
having: profound umbilical artery acidemia (pH < 7.00), persistence of an Apgar 
score of 0 to 3 longer than 5 minutes, neonatal neurological sequelae (e.g., seizures, 
coma, hypotonia), and multiorgan system dysfunction (e.g., cardiovascular, 
gastrointestinal, hematologic, pulmonary or renal). Subjects were enrolled after 
parental informed consent. During that period, empirical treatment consisted of 
penicillin G or amoxicillin in combination with tobramycin or cefotaxime. Patients 
treated with penicillin G were eligible for this study. 
 Penicillin G was administered as an intravenous bolus injection of 50.000 
U/kg every 12 hours. From each subject leucocytes-count, platelets-count, blood 
and superficial cultures were performed as part of their routine work-up. 
Pharmacokinetics study
The pharmacokinetics of penicillin G was studied on day three of life. Blood samples 
(200 µL) were taken from an indwelling arterial line just before the administration 
of an intravenous bolus dose and at 0.03, 0.5, 1, 2.5, 4, 8, 12 h after administration. 
A 24 h sample was taken from those patients that did not receive a subsequent 
dose. Samples were immediately centrifuged in a microcentrifuge (Merck-type 
Eppendorf 5414: 3.000 x g) for 1 minute and serum was stored at -70° C.  
Penicillin G HPLC assay
Chromatographic analysis was performed with a glass-prepacked column (100 by 
3 mm) containing ODS-2 Chromospher Spherisorb beads (5-µm-diameter particle 
size; Chrompack, Middelburg, The Netherlands) combined with a guard column. A 
Bio LC pump (model 410, Perkin-Elmer, Norwalk, Conn.) was used to deliver the 
eluent consisting of 16% (vol/vol) acetonitrile and 50 mM sodium phosphate buffer 
(pH 6.9) at a flow rate of 0.8 ml/min. The separations were carried out at room 
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temperature. The eluate was monitored with a Perkin-Elmer LC-95 UV/visible 
spectrophotometer detector at a wavelength of 215 nm. As an internal standard 25 
µg/ml methicillin in 100 % methanol (vol/vol) was used. Briefly, hundred µl of the 
internal standard was added to a 100 µl aliquot of the serum sample. This mixture 
was immediately vortexed for 30 seconds. Subsequently, the sample was kept for 
10 min at -20 °C, again vortexed for 30 seconds and finally centrifuged at 1,500 g 
for 10 min at room temperature. The supernatant was filtered (millipore) and 10 µl 
was injected onto the column. 
 HPLC-grade acetonitrile was purchased from Rathburn (Walkerurb, 
Scotland). The other chemicals were purchased from Aldrich-Chemie (Steinheim, 
Germany). All chemicals applied were of the highest grade commercially 
available.
 The lower limit of detection of penicillin was 0.5 µg/ml. The coefficients 
of inter-assay variation determined at concentrations of 100 and 20 µg/ml were 
2.6% and 2.3%, respectively. The intra-assay values were 0.75% and 1.05%, 
respectively.
Pharmacokinetics analysis
Pharmacokinetic parameters were estimated by means of Non-Linear Mixed Effect 
(population) Modeling (NONMEM). This approach estimates the structural PK 
parameters considering both inter-individual variability within the population and 
the intra-individual (i.e. residual) variability. The model was implemented in the 
NONMEM ADVAN5 subroutine and the analysis was performed using the first-
order conditional estimation (FOCE) method with interaction option. All fitting 
procedures were performed with the use of the Compaq Visual FORTRAN standard 
edition 6.6 (Compaq Computer Cooperation, Euston, Texas, USA) and NONMEM 
version V (NONMEM project group, University of California, San Francisco, 
USA).
 To determine the basic structural pharmacokinetic parameters several 
models were evaluated. One, two, and three-compartment models were tested and 
evaluated for goodness-of-fit. Model selection and identification of variability was 
based on the likelihood ratio test, pharmacokinetic parameter point estimates, and 
their respective confidence intervals, and goodness-of-fit plots. For the likelihood 
ratio test on differences between two models, the objective function value (OFV) with 
a pre-specified level of significance of P<0.001 was used. NONMEM minimizes an 
objective function in performing nonlinear regression analysis. To detect systematic 
deviations in the model fits the goodness-of-fit plots were visually inspected. The 
data of individual observations versus individual or population predictions should 
be randomly distributed around the line of identity. The weighted residuals versus 
time or population predictions should be randomly distributed around zero.
 The stochastic part of the model was selected to describe inter-individual 
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variability in the pharmacokinetic parameters and assumed a log normal distribution 
of all model parameters over the population. Therefore an exponential distribution 
model was used to account for inter-individual variability: 
Pi=θ * exp(ηi),
in which Pi is the individual value of the model parameter P, θ is the population 
estimate for parameter P and ηi is the normally distributed inter-individual random 
variable with mean zero and variance ω2. Selection of an appropriate residual error 
model was based on the likelihood ratio test and inspection of the goodness-of-fit 
plots. The model was modified to objectively account for unexplained inconsistency 
in the data. To reduce the influence of neonates with large unexplained inconsistency 
in the concentration-time profile on the population estimates, these neonates were 
objectively determined by means of the residual error and weighted less in the 
estimates of the population. 
 To refine the stochastic model covariate analysis was also performed. 
The estimated pharmacokinetic parameters were plotted independently against 
the covariates gestational age, birth weight, gender and the presence of a dosing 
history to determine whether this influenced the pharmacokinetics. The effects 
of covariates were tested for statistical significance using the likelihood ratio test 
and the residual intra- and inter-individual variability were visually evaluated. A 
covariate was retained in the model if it produced a decrease in objective function 
of > 10.8 (p<0.001). In addition, we investigated whether there were significant 
differences in the pharmacokinetics between neonates with a birth weight of less 
than 1000 gram and neonates with birth weight of more than 1000 gram. Vss and t1/2 
were calculated following standard procedures20. 
Estimation of fT>MIC and Monte Carlo Simulations
The estimates of the pharmacokinetic parameters and measures of dispersion were 
used to simulate various dosing regimens and obtain %fT>MIC as a function of 
MIC19. Protein binding was estimated at 40% ± 2.5%21. The protein binding of 
penicillin G in premature neonates is unknown. However, protein binding in neonates 
is generally lower compared to adults. It is therefore likely that the estimated protein 
binding of 40% overestimates the not-active protein bound fraction of penicillin 
G in these neonates. The use of 40% is therefore a conservative estimate. MCS 
was performed using the MICLAB version 2.36 program (Medimatics, Maastricht, 
the Netherlands) simulating 10.000 subjects for each regimen. The program 
allows inclusion of the covariance matrix (or correlation matrix) of the parameter 
estimates used in the simulations. The output consisted of a probability distribution, 
a cumulative probability distribution, and specific confidence intervals over user 
defined MIC and %fT>MIC ranges.
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Results
Demographic data.
Twenty neonates with a gestational age under 32 weeks were included in the study. 
Demographic, laboratory and clinical parameters are shown in table 1. The average 
weight was 1195 g (range 650-2030 g). Half of the subjects were born from mothers 
with preeclampsia or HELLP-syndrome. Other reasons for premature birth were: 
suspected intra-amniotic infection, preterm contractions with meconium stained 
amniotic fluid and PPROM.
Table 1: Demographic, laboratory and clinical parameters of 20 patients studied on day 
three after birth.
Parameter Mean SD Range
Gestational age (wk) 29 5/7 1 5/7 26 3/7- 32 0/7
Gender (M/F) 12/8
Weight (g) 1195 387 650-2030
Hematocrit (%) 46 7 33-63
Leucocytes (103/mm3) 15 13 5-54
Platelets (103/mm3) 203 103 74-497
Creatinine 46 17 10-82
APGAR 1 minute 6 3 1-10
APGAR 5 minutes 8 1 6-10
Artificial ventilation (Yes/No) 9/11
No. of positive bloodculture 0






167 samples were included in the pharmacokinetic analysis. In 11 neonates samples 
were obtained only in the first 12 hours after the i.v. bolus and in 9 neonates a 
sample could be obtained after 24 hours. A bi-phasic rate of decline in the penicillin 
G concentration versus time (i.e. a two-compartment model) best described the data 
using a combined error model with an additive and proportional error. Figure one 
shows the observed concentrations in the individual patients as well as the predicted 
concentration time curves as obtained from the final model, while figure 2 shows 
the observed concentrations versus the individual predicted concentrations for the 
whole population. The distribution around the reference line of perfect prediction 
was symmetric with a correlation coefficient of 0.80, but deviates significantly 
from one. The pharmacokinetic parameter estimates are shown in table 2. The 
percent coefficient of variation reflects both the inter-individual or intra-individual 
Figure 1: Individual plots of the 20 very preterm neonates. The black dots correspond 
with the individual datum points. The line represents the individual estimate and the dotted 
line the population estimate. Neonate 1, 3 and 6 were weighted less in the population 
estimation.
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Figure 2: Plot of individual predicted versus observed concentrations of penicillin G for 20 
patients. The correlation coëfficient was 0.801. The individual datum points for the entire 
population and the x=y line is also shown.
Figure 3: Observed relation between body weight and clearance.
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Table 2: Pharmacokinetic parameters of penicillin G in 20 preterm neonates.
Parameter Mean value Standard error
Structural model parameters
CL (L/h) 0.103 0.0104
V1 (L) 0.359 0.0558
V2 (L) 0.152 0.0312
Q (L/h) 0.774 0.277
Variance model parameters
Interindividual variability in CL 0.164 0.0865
Interindividual variability in V1 0.39 0.126
Residual variability (proportional component) 0.104 0.0316
Residual variability  (additive component) 1.12 0.891
Derived pharmacokinetics parameters
Vss (L) 0.540 -
t1/2β (h) 3.9 -
variability of the pharmacokinetic parameters. Estimation of inter-individual 
variability was possible for the parameters CL corrected for body weight, V2 and 
the infusion rate (34.5 % for CL corrected for body weight, 17.1% for V2 and 89.9% 
for the infusion rate). The residuals were generally small, but the additive error of 
neonate 1, 3 and 6 differs 2.5 to 3.5 times from the median of these neonates. 
 We examined the relationship between CL and gestational age, gender, body 
weight and the presence of a dosing history (i.e. whether the neonate had received a 
previous dose of penicillin or not). There were no significant correlations between 
CL and gender or the presence of a dosing history. CL increased significantly with 
an increasing body weight (Figure 3, p<0.01). Incorporation of body weight on 
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clearance in the model improved the model fit significantly. There was a significant 
correlation between gestational age and body weight (p<0.01). Incorporation of 
the gestational age did not further improve the model fit. No significant differences 
in pharmacokinetic parameter estimates could be demonstrated between neonates 
with a birth weight of more and less than 1000 gram. 
 To determine the probability of target attainment (PTA) for the dosing 
regimen used, MCS was performed. Assuming a %fT>MIC of 50% for preterm 
neonates, a PTA of 100% was reached with the currently recommended dosing 
regimen of 50.000 U/kg every 12h for pathogens with MICs of ≤4 mg/L. Figure 4 
shows the %fT>MIC for the dose of 50.000 U/kg and 3 different dosing intervals 
based on mean population parameter estimates and the correlation matrix of these 
estimates. 
 















Figure 4: Percent of time the unbound fraction of penicillin G remained above the MIC 
(%fT>MIC), based on the pharmacokinetic estimates and the correlation matrix of the 




Pharmacokinetics of penicillin G in neonates with a gestational age of less than 
32 weeks was best described by a two-compartment model, yielding estimates of 
the terminal t1/2 of 3.9 h, Vss of 0.54 L and CL of 0.103 L/h. The dosing regimen of 
50,000 U/kg every 12 h is adequate for the treatment of neonatal infections caused 
by common microorganisms on day 3 of life.
 Most studies on the pharmacokinetics of penicillin G in neonates have been 
performed after intramuscular administration22-24. However, the intramuscular route 
should be avoided, because this may result in erratic absorption in the sick, infected 
newborn with restricted blood supply to the extremities25. Mulhall et al.24 performed 
a study on the pharmacokinetics of penicillin G after intravenous administration in 
4 neonates with a gestational age ranging from 27 to 40 weeks and found a CL of 
0.12 +/- 0.07 (mean +/- SD) L/h/kg, V of 0.61 +/- 0.28 L/kg (mean +/- SD) and t1/2 
of 3.8 h. These results are similar to our data. 
 Other penicillins have larger V and longer terminal t1/2 in prematures, 
especially when compared with adults13. V varied from 0.3 L/kg for ampicillin 
to 0.41-0.68 L/kg for amoxicillin in neonates26-28, compared to 0.45 L/kg found 
for penicillin G in our study. The terminal t1/2 of penicillin G in neonates with a 
gestational age of less than 32 weeks was longer compared with the value of 0.5h 
as reported for healthy adults21, but is in the same range as the values of between 2 
to 9.5 h that have been reported for other penicillins in neonates13,26-30.
 Within the limited number of samples available from patients in this age 
group, there is some unexplained inconsistency in the data. This might be caused by 
subcutaneous administration of penicillin G, erratic sampling times, or accidental 
exchange of samples. Three neonates had large unexplained inconsistency in the 
data based objectively on their residual error and were therefore weighted less in 
the population estimates. Using this method none of the neonates were excluded 
from the study and all data were used in the analysis. Consequently, there is a 
deviation between the line of identity and the regression line of the observed versus 
predicted concentrations, indicating that the description of the pharmacokinetics in 
this age group can be improved. To this end more data are needed.
 The presence of a third elimination phase (t1/2,γ) for penicillin G has been 
described previously, both in animal models as well as in adult humans21,31. Our 
data could not be described by a three-compartment model. But the terminal 
elimination phase (t1/2,β) found in our study, was comparable to the t1/2,γ of 3.1 h in 
human adults21. Both the limited number of samples taken in the initial distribution 
phase and the unique body composition of the neonate, comprising approximately 
75% water, complicate the distinction between the initial distribution and second 
elimination phase. Possibly, the initial phase in our study represents both the initial 
and second phase as found in the study of Ebert et al21. Thus, the slow elimination 
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we found may represent the third elimination phase for penicillin G as determined 
in that study.
 Inter-individual variability was partly explained by variation in CL, V2 and 
the infusion rate. The variability in infusion rate represents not only the variation 
in rate of the manually administered intravenous bolus injection, but also variation 
in the sampling times between the first samples. Especially for the first samples the 
exact sampling times are crucial.
 Growth and development are major aspects in infants, therefore both size 
and gestational age may have an impact on the prediction of CL32. Maturation of 
CL begins before birth, suggesting that gestational age would be a physiologically 
appropriate covariate to explain the time course of changes in CL32. In our data 
changes in CL were best explained by differences in body weight. Probably 
because both gestational age and other factors influencing the development of 
renal function are represented by an adequate increase of body weight in time. 
Furthermore, the range in gestational age as included in our study was relatively 
small. While CL slightly increased as a function of birth weight for the entire group, 
differences between subgroups with a birth weight of more and less than 1000 
gram could not be demonstrated. The analysis of correlations between covariates 
and pharmacokinetic parameters estimates is more sensitive when all neonates are 
included in the study.
 The enhanced inter-individual pharmacokinetics variability in prematures 
complicates the calculation of the therapeutic dosing regimen. The dosing regimen 
should be adequate for the entire population. We concluded that the 100% PTA 
obtained with simulation of the recommended regimen was adequate to treat 
neonatal infection on the third day of life. In case of meningeal involvement 
effective concentrations are required in the cerebrospinal fluid (CSF). Little is 
known on the pharmacokinetics of penicillin G in the CSF of premature neonates. 
We do not know what percentage of penicillin G penetrates the CSF in premature 
neonates with meningitis. Given the low MIC of GBS to penicillin (up to 0.12 
mg/L), with use of the currently recommended dosing regimen it is sufficient when 
the penetration of penicillin into the CSF is at least 3%. 
 Shortening the dosing interval to 8 h, will not have additional value in 
treatment of infections in neonates with a gestational age of less than 32 weeks. When 
these infections are caused by microorganisms with low MICs, like Streptococcus 
agalactiae, a regimen with a prolonged dosing interval of 24 h, is also likely to 
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Summary, conclusions and perspectives
Introduction
In the peripartum period infections due to group B streptococci (GBS) play an 
important role in infectious morbidity and mortality. In the 1970s GBS emerged 
as leading cause of neonatal morbidity and mortality1. Neonates suffering from 
GBS disease usually present with pneumonia, sepsis and / or meningitis. Less 
appreciated is the fact that GBS can also cause a variety of maternal clinical 
infections in the peripartum period. Apart from cervicovaginal colonisation, which 
is usually asymptomatic, GBS can cause urinary tract infections, vulvovaginitis, 
intra-amniotic infection, mastitis, bacteremia, sepsis, meningitis, endometritis and 
wound infections. These infections often have an impact on both the mother and 
her child (as reviewed in Chapter 3).
 During the last decades strategies to prevent neonatal GBS disease were 
implemented in several countries2. The cornerstone of these preventive measures is 
the administration of antibiotics shortly before and/or during labor. To recommend 
the use of these antibiotics one has to weigh the benefits and the unintended 
consequences. Overall, most incidence figures of culture-proven GBS disease in 
the first 7 days of life have decreased, suggesting that antibiotics to be effective2. 
However, these incidence figures are influenced by multiple factors3. Furthermore, 
neonatal GBS disease has also been reported in neonates whose mothers did receive 
antibiotic prophylaxis. Therefore, concerns are raised on the antibiotic prophylaxis 
itself. A specific question is whether current guidelines recommend the optimal 
antibiotic dose and dosing interval. Moreover, although unintended consequences 
for the mother, such as an anaphylactic shock, are rare, nowadays there is growing 
concern for potential, unintended consequences for the neonate. Antibiotic use 
during labor might influence the initial bacterial flora in neonates. A changed initial 
flora might have impact on the development of the immune system of the neonate4,5. 
Meanwhile there is moderate evidence on the efficacy of the antibiotics and little 
attention for the unintended consequences of antibiotic use during labor, guidelines 
recommend this prophylaxis to up to 35% of all pregnant women2 (as reviewed in 
Chapter 2). 
 To study the efficacy of antibiotics and to search for the optimal dosing 
regimen used in the prevention of GBS disease, knowledge on the pharmacokinetics 
is needed. Pharmacokinetics is the discipline that applies mathematical models to 
explain and predict the time-course of drug concentrations in the body. Important 
determinants of the time-course of the drug concentrations are the extent and rate 
of absorption, distribution, metabolism and excretion. 
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Pharmacokinetic studies in pregnancy: general approach
Antibiotics in the prophylaxis of GBS disease are administered to the mother, 
while the antibiotics are also meant to protect the fetus. Since fetal antibiotic 
concentrations are reached from the maternal circulation, adequate concentration-
time profiles in the mother are essential and therefore a first issue in pharmacokinetic 
studies during pregnancy. In pregnant women there are changes in the absorption, 
distribution, metabolisation and excretion of drugs. For example, in pregnancy the 
plasma volume increases, while albumin protein binding decreases and the blood 
flow to the liver as well as the glomerular filtration rate rise as well6. Because all 
these adaptations occur simultaneously and change with advancing gestational age, 
extrapolation of pharmacokinetic data from non-pregnant individuals is difficult. 
 When the administered antibiotics reach an adequate concentration-time 
profile in the pregnant woman, the second issue is the transfer of the antibiotic over 
the placental barrier. In this way the antibiotic is able to reach the fetus. The rate 
of transfer over the placental barrier is related to the maternal-fetal concentration 
gradient and is inversely proportional to the permeability of the placental membrane7. 
The thickness of the placenta increases with gestational age and in various disease 
states, like diabetes and hypertensive disorders complicating pregnancy8. Antibiotic 
concentrations determined in venous umbilical cord serum samples can provide 
information on the transfer over the placental barrier. Unfortunately, postpartum 
blood samples from the umbilical cord can be obtained only once per patient and 
also at a time point beyond the control of the investigator. 
 As a third step, the pharmacokinetics in the child need to be studied. This 
can partly be achieved using blood samples of the arterial umbilical cord after birth 
and those of the neonate. It is important to realize that there will be differences 
in pharmacokinetics in the child before and after birth. In the fetus, blood flow 
towards the mother via the arterial umbilical cord to the placenta will be the main 
route of excretion of drug from the neonate. After birth, the only routes of excretion 
of drugs are through the excreting organs of the neonate. Furthermore, the blood 
flow will redistribute after birth, what might influence the pharmacokinetics. 
 In conclusion, to study the efficacy of the GBS prophylaxis pharmacokinetics 
in both mother and neonate has to be determined. In contrast to maternal blood 
samples, which can be obtained relatively frequently umbilical cord samples can 
be obtained once for each patient. This will result in unbalanced study groups. 
Fortunately, pharmacokinetic data can nowadays be analyzed with a so-called 
“population approach” in computer programs such as NONMEM (Non-linear 
Mixed effects Modeling). Using this approach, data of the whole population are 
simultaneously analyzed while taking into account inter-individual and intra-
individual variability. Data of unbalanced groups and sparse data can be analyzed 
in a meaningful manner by using a population analysis9,10.
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 While the availability of pharmacokinetic data is an important prequisite 
to evaluate the prophylaxis, the relationship between pharmacokinetic properties 
and clinical effect is also very important. During pregnancy and delivery several 
antibiotics are used. One of the antibiotics frequently used in Europe in the 
prevention of neonatal GBS disease is amoxicillin. In some hospitals amoxicillin 
combined with clavulanic acid is used in the prevention of neonatal infection, 
including the prevention of GBS disease, because this combination is also 
active against amoxicillin-resistant Escherichia coli. When penicillin allergy 
is encountered, clindamycin is often used as an alternative. The relationship 
between pharmacokinetic properties, microorganism susceptibility (as indicated 
by the minimum inhibitory concentration (MIC)) and clinical effects has been 
increasingly well understood. The efficacy of the penicillins, like amoxicillin, is 
primarily correlated to the percentage of time that the serum concentration of the 
unbound drug remains above the MIC (%fT>MIC)11-13. Similar to amoxicillin, 
clindamycin effect is also dependent on exposure. However, its clinical efficacy is 
more closely related to the area under the concentration curve over the MIC for 24 
hours (fAUC0-24h /MIC) rather than the time that the unbound serum concentration 
exceeds MIC14.
 As a final step, Monte Carlo Simulations (MCS) can be performed to evaluate 
differences in the efficacy of various regimens used to prevent GBS disease. In this 
context MCS is used to evaluate the probability of target attainment (PTA), using the 
derived pharmacokinetic parameters, data on the concentration-effect relationship 
and the inter-individual variability15-17. In this way, the pharmacokinetic data of 
both mother and child, combined with the knowledge on the concentration-effect 
relationship can be used to optimize the antibiotic prophylaxis in clinical practice. 
The aim of the research project presented in this thesis was to describe the 
pharmacokinetics of the antibiotics frequently used during pregnancy and delivery 
to prevent GBS infection. Because amoxicillin is the antibiotic most frequently 
used in the Medical Center Haaglanden, amoxicillin has been used as prototype. 
Furthermore, limited data on the pharmacokinetics of clindamycin and penicillin 
G were described.  
Pharmacokinetics of antibiotics in pregnancy and delivery:
Amoxicillin as a prototype
Pregnant women with preterm premature rupture of the membranes (PPROM) 
are an important group of patients treated with amoxicillin. In these women, the 
mechanical barrier of the membranes is disturbed and it is believed that bacteria 
that are normally present in the lower genital tract might ascend to the uterus and 
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cause intrauterine infection. The immune system of premature neonates is not fully 
developed and therefore they are even more at risk for infection. 
 Estimates of the pharmacokinetic parameters of amoxicillin in women 
with PPROM did not differ significantly from values reported in the literature for 
non-pregnant individuals (Chapter 4). The only difference between the results of 
our study and previously reported values for non-pregnant individuals were the 
peak-concentrations. Peak-concentrations reached in pregnant women were lower 
compared to non-pregnant individuals. This might be explained by an increase of 
extracellular fluid or the presence of the fetus, placenta and amniotic fluid. There are 
previous studies on several drugs that do show differences in the pharmacokinetics 
between pregnant women and non-pregnant individuals18,19. Most of these studies 
included both patients before the onset of and during labor. Patients with PPROM 
were all included before the onset of labor. One study on the pharmacokinetics of 
ampicillin found that the terminal half-life was increased in women during labor 
when compared to pregnant women before the onset of labor20. Since the patients in 
our study were not in labor this could explain why our study did not show differences 
in pharmacokinetics between non-pregnant individuals and pregnant women. In 
other words, not the state of pregnancy, but being in labor might influence the 
pharmacokinetics. And indeed, for amoxicillin we found a minor influence of labor 
on the pharmacokinetics (Chapter 5). The volume of distribution of the peripheral 
compartment was decreased, but this did not result in a changed terminal half-life. 
Thus, although we did observe some slight differences, we do not consider them 
clinically relevant.
 Another factor that might influence the pharmacokinetics of amoxicillin is 
the simultaneous administration of clavulanic acid. Potential interactions between 
simultaneously administered drugs might be caused by inhibition of metabolic 
enzymes, competition for protein binding in plasma or changes in renal transporter-
system. When amoxicillin and clavulanic acid are administered simultaneously, 
the activity spectrum of amoxicillin against both gram-positive and gram-negative 
bacteria is enhanced. Amoxicillin is inactivated by β-lactamases produced by 
several microorganisms. When clavulanic acid is administered simultaneously it 
protects the amoxicillin from enzymatic inactivation21 by irreversibly binding and 
inhibiting a wide range of these β-lactamases. The intrinsic antibacterial activity of 
clavulanic acid alone is negligible21. In practice different dose ratios of amoxicillin/
clavulanic acid have been used. As there are no reports that the efficacy of the these 
dose ratios are different, the amount of clavulanic acid may not be that critical22. 
Time-concentration profiles of amoxicillin are therefore even more important. 
Clavulanic acid and amoxicillin have, in part, similar routes of metabolization and 
excretion. But, the pharmacokinetics of amoxicillin in maternal serum was found 
not to be influenced by simultaneous administration of clavulanic acid (Chapter 
6). 
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 In patients with a intra-amniotic infection (IAI) antibiotic treatment will be 
continued following delivery. In the immediate postpartum period, physiological 
changes in the mother start to take place. Such changes may have major influences 
on the pharmacokinetics as has previously been shown for the antiepileptic drug 
lamotrigine23. After delivery the concentration of lamotrigine rises to toxic levels. 
Therefore knowledge on the pharmacokinetics after delivery is needed. The 
peripheral volume of distribution of amoxicillin appeared to be decreased during 
labor, but decreases further immediately after delivery. A decrease in volume of 
distribution might result in higher concentrations in maternal serum, as has been 
shown for lamotrigine. However, for amoxicillin toxic concentrations are not 
reached and the current dosing regimens do not need to be adapted (Chapter 5).
 For ampicillin/ amoxicillin, two different dosing regimens are described in 
the literature to prevent neonatal GBS disease. The Centers for Disease Control and 
Prevention (CDC) recommend an initial dose of 2 gram, and subsequent doses of 1 
gram every 4 hours2. In the Cochrane Library a dosing regimen of 1 gram every 6 
hours is described as the usual regimen24. Although the rate of infusion influences 
the PTA, infusion rates are not described in the current guidelines. Doses of 2 gram 
amoxicillin are administered by infusion over 30 minutes, whereas doses of 1 gram 
amoxicillin may be administered by infusion (i.e. over 15 minutes) or as bolus 
injection. However, our simulation studies suggest that the 2 gram starting dose does 
not have additional value over a 1 gram dose. In general, a slower infusion rate will 
increase the PTA and for that reason infusions are preferred over bolus injections. 
However, bolus injections are in clinical practice more convenient. In our simulation 
study, the %fT>MIC after a bolus injection was only 4% lower compared to an 
infusion over 15 minutes. Values for the %fT>MIC found for both regimens with 
the antibiotics administered by bolus injections reached adequate concentrations 
taking into consideration the mean population and the 99% confidential intervals. 
Therefore, we conclude that bolus injections can be used in these regimens without 
a reduction in the efficacy (Chapter 8).
 To recommend a particular dosing regimen, several aspects should be 
taken into account. Since the initial dose of 2 gram does not have additional value 
over a 1 gram dose, the only difference between the two regimens is the dosing 
interval of 4 hours versus 6 hours. Although larger intervals reduce the %fT>MIC, 
both regimens reach adequate maternal concentration-time profiles. However, to 
guarantee that the efficacy to prevent neonatal GBS disease is not reduced using 
a 6-hour dosing interval, time-concentration profiles in the fetus should also be 
taken into account. To remain on the safe side, we recommend a dosing interval 
of 4 hours. Another argument to recommend a 4-hour dosing regimen instead of 
a 6-hour dosing interval is the clinical situation in which the prophylaxis has to 
be administered. The often urgency of care in delivery rooms can easily result in 
inaccuracies in the administration. Using a 4-hour dosing interval results in a higher 
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PTA, also when doses are accidentally skipped (Chapter 8).
 So far, we conclude that the recommended dosing regimens reach adequate 
concentration-time profiles in maternal serum. Being in labor as well as the co-
administration of clavulanic acid does not result in clinically relevant changes in the 
amoxicillin pharmacokinetics. Since the most important question is whether these 
regimens are also adequate to prevent neonatal GBS disease, we have also studied 
the transfer of amoxicillin over the placental barrier and the pharmacokinetics in 
the fetus. 
 Antibiotics administered to the mother reach the fetus via the umbilical 
cord. Venous cord blood reaches the fetus after placental exchange, whereas arterial 
umbilical cord blood originates from the fetal circulation. Drug concentrations in 
the arterial umbilical cord serum are therefore representative of the concentrations 
in the fetus. In the investigation described in chapter 7 these concentrations have 
been analyzed together with samples from the neonates taken approximately 20 
minutes after birth with a heel puncture. Specifically in this investigation data on the 
maternal pharmacokinetics, transfer over the placental barrier and pharmacokinetics 
in the fetus were all analyzed simultaneously in a 5-compartment model. This gave 
us the unique opportunity to study the different concentration-time profiles in the 
mother and the fetus in relation to the time. The peak-concentration in fetal serum 
was lower and delayed compared to the maternal peak-concentration. The peak-
concentration in venous umbilical cord serum was lower compared to the maternal 
peak-concentration, but higher in comparison to the fetal peak-concentration. After 
similar values for venous umbilical cord and fetal serum were reached, the fetal 
concentrations exceeded the concentrations in umbilical cord. Considering the 
population estimates for the pharmacokinetics in the venous umbilical cord and the 
fetus, the initial infusion of 2 gram amoxicillin is adequate to prevent GBS infection 
in the fetus (Chapter 7). However, data on the inter-individual variability were not 
included and these results are therefore only valid for the average pregnant women 
with an average fetus. Therefore no final conclusion on the efficacy of amoxicillin 
in the prevention of neonatal GBS disease can be drawn from these data.   
 In clinical practice, the period between the start of the first antibiotic dose 
and birth is often used as measure of the adequacy of the prophylaxis. A period of less 
than 4 hours is considered as inadequate and antibiotic therapy is often continued in 
these neonates. In contrast, when neonates are born more than 4 hours after the start 
of the first dose, prophylaxis is considered adequate and they are usually not treated 
with antibiotics. This clinical measure of adequacy is based on two premises: first 
on the relation between the number of positive blood cultures and the time after a 
single antibiotic dose and secondly on the number of vertical transmissions from 
the maternal vagina to the neonatal mucocutaneous surfaces. Both the number of 
positive blood cultures and the number of vertical transmissions will decrease with 
time, because a minimum amount of time is needed to eradicate microorganisms. 
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After the peak-concentration in the fetus has been reached (31 minutes after the 
maternal peak-concentration) the concentration will decrease. Antibiotic present in 
the fetus will eradicate microorganisms and this eradication will occur independent 
from birth. Therefore, the current clinical measure of efficacy is not correlated to 
the true efficacy of the antibiotic prophylaxis (Chapter 2 and 7).
 Patients treated with amoxicillin in our study groups were all relatively 
healthy. One patient was diagnosed with PPROM and suffered from severe vomiting 
during the first part of the study (Chapter 9). Her concentration-time profile during 
the first amoxicillin administration deviated substantially from the normal profile, 
but after she stopped vomiting the profile became comparable to the profiles 
described in chapter 4. As after both antibiotic administrations, the entire doses were 
absorbed in the body, improper infusion could not explain the difference between 
the two profiles. We hypothesized that several (patho)physiological changes had 
occurred, that all influenced the peripheral blood flow and thereby changed the 
distribution of the amoxicillin. As a possible explanation it was suggested that the 
arm in which the amoxicillin was infused might act as depot for the amoxicillin. 
After the blood flow slowly normalizes the amoxicillin is steadily released from the 
depot. The registration of this profile is unique because blood samples were taken 
frequently in an acute, emotional and very stressful situation. This indicates that 
although the pharmacokinetics is quite well described in healthy volunteers and 
several groups of patients, unexpected differences in the pharmacokinetic profile 
can occur in (critically) ill patients.
To conclude, for amoxicillin the concentration-time profiles in pregnant patients 
before the onset of labor, during labor and in the immediate postpartum period were 
such that the currently advised dosing regimens in the prevention of GBS disease 
may be considered adequate. The results of the MCS showed that even when a 
dose is accidentally skipped, the percentage of time the concentration exceeded 
the MIC for GBS still reached the threshold value. The pharmacokinetic profile 
for the average pregnant women and the predicted concentration-time profile in 
the average fetus indicated that the dosing regimen is also adequate in preventing 
neonatal GBS disease, albeit that in this prediction the inter-individual variability 
could not be taken into account.
Clindamycin
Clindamycin is often used as an alternative to amoxicillin in the prevention of GBS 
infections2. The efficacy of the clindamycin dosing regimens in this indication 
should be studied in a similar manner as performed for amoxicillin. However, to 
date only a limited number of patients treated with clindamycin could be included 
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in the study. Therefore no final conclusions can be drawn from this study (Chapter 
10). 
 With regard to the pharmacokinetics of clindamycin plasma protein binding 
is a critical factor as it is an important determinant of efficacy. As clindamycin binds 
largely to alpha-1-acid glycoprotein wide variations in the degree of protein binding 
may be expected. Most values on the plasma protein binding of clindamycine 
reported in the literature range between 80-90%25-27. The percentage might be 
decreased in pregnant women, but in patients with an infection or stress it is shown 
to be increased. Therefore, the protein binding in our patients at risk is not likely 
to be less than 80%. For the average pregnant women the currently used dosing 
regimen leads to adequate concentrations assuming that the protein binding will not 
exceed 80% of the total concentration. However, to recommend a dosing regimen 
for the entire population of pregnant women, an adequate concentration-time profile 
for the average women is not sufficient and the inter-individual variability has to 
be taken into account. When taking into account the 99% confidence intervals, this 
regimen was shown not to be adequate when protein binding exceeds the value of 
80% (Chapter 10).
 There were insufficient data of the transfer of clindamycin over the placental 
barrier to incorporate these data in the pharmacokinetic model. Therefore the 
individual concentrations in umbilical cord serum are presented which ranged from 
0.1 mg/L to 4 mg/L. Considering the protein binding, dosing interval of 8 hours 
and the MIC value for GBS (0.5 mg/L)28, these data indicate that with the current 
dosing regimen the exposure of the fetus to clindamycine may be inadequate for the 
prevention of neonatal GBS disease. 
 It has been demonstrated that not all women with a penicillin-allergy in 
their history are actually allergic to penicillins29,30. It may therefore be useful to 
re-evaluate the hypersensitivity to penicillin. It has previously been shown that 
allergy testing is safe during pregnancy and that penicillins can be used in women 
with a negative allergy skin test31. Until further studies performed demonstrating 
adequate pharmacokinetics of clindamycin in pregnancy and especially in the 
arterial umbilical cord or fetus for the prevention of GBS disease in the mother and 
the infant, allergy skin testing can be performed to avoid the use of clindamycin.
Treatment with penicillin G in premature neonates
In neonates with suspected GBS infection, the administration of antibiotics to 
the neonate will be started immediately after birth. For several drugs it has been 
demonstrated that the pharmacokinetics in neonates differs substantially from 
that in adults32-34. Especially in premature neonates the terminal half-life is often 
prolonged. Similar to this, we found a prolonged terminal half-life of penicillin G 
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of 3.9 h in neonates with a gestational age of less than 32 weeks on the third day of 
life. Taking into account the inter-individual variability, the currently used dosing 
regimen of 50.000 U/kg every 12 h was shown to be adequate for the treatment of 
neonatal infections caused by common microorganisms on day 3 of life (Chapter 
11). 
 The prolonged half-life in (premature) neonates is particularly beneficial 
for antibiotics with a time-dependent mechanism of action, since the time the 
concentration remains above the MIC will be increased. The prolonged half-life is 
most likely caused by immature renal function. This supports our opinion that the 
clinically used measure of efficacy (i.e. a period of 4 hour between the start of the 
antibiotic administration and birth) may need to be reconsidered. After the peak 
concentration in fetal serum has been reached the concentration will decrease. Since 
the terminal half-life in the fetus is likely to be lower compared to the neonatal half-
life, the highest values for the T>MIC will be reached when birth takes place soon 
after the peak concentration has been reached.  
Future perspectives
The frequency of the use of antibiotics in the peripartum period to prevent GBS 
disease has increased the last decades. This is the result of the change in prevention 
strategy to a screening-based strategy and an increase in the prevalence of GBS in 
pregnant women. In the near future more sensitive detection methods are likely 
to become available. As a result also women with a low number of GBS in their 
rectovaginal tract will be identified as GBS carrier. It is doubtful whether these 
women indeed have an increased risk on giving birth to a neonate with GBS disease. 
Nevertheless since increasing percentages of pregnant women will be candidates 
for antibiotic prophylaxis, it is important that the dosing regimen is adequate for 
the entire population. Suboptimal concentrations pose patients at risk for failure of 
prophylaxis and might cause selection of resistant bacterial strains. 
 From the data described in this thesis, it is likely that for amoxicillin 
current dosing regimens are adequate for healthy women, also when minor dosing 
inaccuracies occur. However, to guarantee that the concentrations reached in the 
fetus are also adequate, Monte Carlo Simulations should be performed using the 
5-compartment model for the simultaneous analysis of the concentration-time 
profiles in the mother and the fetus, taking into the account the inter-individual 
variability. In this way, an optimal dosing regimen can be chosen for the entire 
population. Unfortunately, there are no computer programs available to perform 
MCS with a 5-compartment model. 
 Patients treated with amoxicillin included in our study were all healthy, 
with one exception. This patient was included while she suffered from unexplained 
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severe vomiting. The pharmacokinetic profile in this patient was dramatically 
different from profiles in relatively healthy patients. This indicates that physiological 
changes might have major influences on the pharmacokinetics. In our study group 
it was found that several physiological factors had an influence on the amoxicillin 
pharmacokinetics. For example, the amount of edema influenced the volume of 
distribution. Pregnancy and delivery are sometimes complicated by particular 
disorders. One of these pregnancy related disorders, preeclampsia, is reknowned 
for an increased amount of edema. This can add up to 10 liter of extracellular fluid. 
One can therefore not assume that the concentration-time profiles in women with 
preeclampsia are also adequate. Therefore, pharmacokinetic studies in patients with 
pregnancy-related disorders should be performed.  
 For clindamycin limited pharmacokinetic data are available. Considering 
high plasma protein binding for clindamycin, it appears that the concentration-
time profiles may be inadequate for the prophylaxis of GBS infections in both the 
mother and the fetus. Only the unbound fraction of the drug is active and crosses 
the placental barrier and therefore changes in protein binding might influence the 
efficacy of the clindamycin. It is known that protein binding of clindamycin is 
dependent both on the serum concentration of alpha1-acid glycoprotein, which 
changes in pregnant women, and on the serum clindamycin concentration. 
Unfortunately, relatively large blood samples are needed to determine the protein 
binding in serum. The volume of the blood samples obtained in our study was 
too small to determine the protein binding. Patients with chronic hart conditions 
were included in the study. The pharmacokinetics were found to be unaltered in 
this patient group. Future studies are needed to prove the efficacy of the current 
dosing regimen and they should include patients with pregnancy-related disorders 
and information on the protein binding. Finally, a pharmacokinetic model should 
be developed based on pharmacokinetic parameter estimates of both the mother 
and fetus, the inter-individual variability as well as data on the clindamycin protein 
binding to investigate the predicted efficacy of the different dosing regimens using 
Monte Carlo Simulation. 
 In the US, Eschericia coli is becoming more common as a cause of neonatal 
infection, especially in premature neonates35,36. Many strains of E. coli are resistant to 
amoxicillin and therefore the use of amoxicillin/clavulanic acid might become more 
commonly used in the future. We showed that the pharmacokinetics of amoxicillin in 
pregnant women is not influenced by the simultaneous administration of clavulanic 
acid. However, for inactivation of β-lactamases by clavulanic acid, there has to 
be a minimal amount of clavulanic acid present. Therefore, future studies should 
be performed on the pharmacokinetics of clavulanic acid. This harbors a practical 
problem. Clavulanic acid is a very unstable compound. Therefore, concentrations 
of clavulanic acid should preferably be determined immediately after the samples 
are obtained from the patients and a special HPLC method should be developed to 
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make sure that the clavulanic acid is not degradated during the procedure. Finally, 
the development of methods for the stabilization in clavulanic acid in plasma should 
be explored.
 In conclusion, the present study indicates that the currently advised dosing 
regimen for amoxicillin is effective to prevent neonatal GBS disease. But research 
on the pharmacokinetics of various antibiotics should be continued for optimization 
of the GBS disease prophylaxis. Especially, the development of pharmacokinetic 
models describing the maternal and fetal pharmacokinetics simultaneously as 
well as their relation in time, taking into account the inter-individual variability 
and degree of protein binding is of importance. Patients with pregnancy-related 
disorders should be included in these studies. Also for the currently recommended 
dosing regimen for clindamycin, the results of current study raise some doubt on 
the efficacy to prevent neonatal GBS disease. The antibiotics of first choice remain 
the penicillins. When penicillin allergy is encountered, skin testing is advised to 
ensure that the use of amoxicillin is contraindicated.   
 
References
1. Fry RM. Fatal infections caused by haemolytic Streptococcus group B. Lancet 1938;1:199-
201.
2. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal 
disease. Revised guidelines from CDC. MMWR Recomm Rep 2002;51:1-22.
3. Gilbert R. Prenatal screening for group B streptococcal infection: gaps in the evidence. Int J 
Epidemiol 2004;33:2-8.
4. Bedford Russell AR, Murch SH. Could peripartum antibiotics have delayed health consequences 
for the infant? BJOG 2006;113:758-65.
5. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001;357:1057-9.
6. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. 
Clin Pharmacokinet 2005;44:989-1008.
7. Mirkin BL. Perinatal pharmacology: placental transfer, fetal localization, and neonatal 
disposition of drugs. Anesthesiology 1975;43:156-70.
8. Hays DP. Teratogenesis: a review of the basic principles with a discussion of selected agents: 
Part II. Drug Intell Clin Pharm 1981;15:542-66.
9. Liefaard LC, Ploeger BA, Molthoff CF, Boellaard R, Lammertsma AA, Danhof M, Voskuyl 
RA. Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) 
in vivo by positron emission tomography. Mol Imaging Biol 2005;7:411-21.




11. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining 
dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-
96.
12. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. 
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis 
and thigh-infection models. J Infect Dis 1989;159:281-92.
13. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of 
antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J 
Infect Dis 1988;158:831-47.
14. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. 
Clin Infect Dis 2007;44:79-86.
15. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic 
variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. 
Diagn Microbiol Infect Dis 2000;38:151-7.
16. Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince 
W, Bye A, Bilello JA. Use of drug effect interaction modeling with Monte Carlo simulation to 
examine the impact of dosing interval on the projected antiviral activity of the combination of 
abacavir and amprenavir. Antimicrob Agents Chemother 2000;44:1655-9.
17. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to 
evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic 
fibrosis, and patients in the intensive care unit. Clin Ther 2005;27:762-72.
18. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977;136:370-6.
19. Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and 
sulbactam in pregnancy. Am J Obstet Gynecol 1993;168:667-73.
20. Voigt R, Schroder S, Meinhold P, Zenner I, Noschel H. Klinische Untersuchungen zum Einfluss 
von Schwangerschaft und Geburt auf die Pharmacokinetik von Ampizillin.[Clinical studies 
on the influence of pregnancy and delivery on the pharmacokinetics of ampicillin.] Zentralbl 
Gynakol 1978;100:701-5.
21. Neu HC, Fu KP. Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents 
Chemother 1978;14:650-5.
22. Vree TB, Dammers E, Exler PS. Identical pattern of highly variable absorption of clavulanic 
acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob 
Chemother 2003;51:373-8.
23. de Haan GJ, Edelbroek P, Segers J, Engelsman M, Lindhout D, Devile-Notschaele M, Augustijn 
P. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 
2004;63:571-3.
24. Smaill F. Intrapartum antibiotics for group B streptococcal colonisation. Cochrane Database 
Syst Rev 1996:CD000115.
25. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health 
and disease. Pharmacol Rev 1988;40:1-47.
26. Kays MB, White RL, Gatti G, Gambertoglio JG. Ex vivo protein binding of clindamycin in 
205
Summary, conclusions and perspectives
sera with normal and elevated alpha 1-acid glycoprotein concentrations. Pharmacotherapy 
1992;12:50-5.
27. Flaherty JF, Jr., Gatti G, White J, Bubp J, Borin M, Gambertoglio JG. Protein binding of 
clindamycin in sera of patients with AIDS. Antimicrob Agents Chemother 1996;40:1134-8.
28. Eucast. (European Committee on Antimicrobial Susceptibility Testing) see website 
http://217.70.33.99/Eucast2/.
29. Luskin AT, Luskin SS. Anaphylaxis and Anaphylactoid Reactions: Diagnosis and Management. 
Am J Ther 1996;3:515-520.
30. Haupt M, Fuiji T, Carlson R. Anaphylactic reactions. In: Grenvik A AS, Holbrook PR, 
Schoemaker WC, ed. Textbook of criticalcare. Philadelphia, Pennsylvania: WB Saunders 
Company, 2000.
31. Macy E. Penicillin skin testing in pregnant women with a history of penicillin allergy and group 
B streptococcus colonization. Ann Allergy Asthma Immunol 2006;97:164-8.
32. Adrianzen Vargas MR, Danton MH, Javaid SM, Gray J, Tobin C, Brawn WJ, Barron DJ. 
Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant 
cardiopulmonary bypass surgery. Eur J Cardiothorac Surg 2004;25:256-60.
33. Huisman-de Boer JJ, van den Anker JN, Vogel M, Goessens WH, Schoemaker RC, de Groot R. 
Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. 
Antimicrob Agents Chemother 1995;39:431-4.
34. Yoshioka H, Takimoto M, Riley HD, Jr. Pharmacokinetics of ampicillin in the newborn infant. 
J Infect Dis 1974;129:461-4.
35. Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, Schuchat A. Trends in incidence and 
antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco 
and Atlanta. Pediatrics 2002;110:690-5.
36. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and 
drug-resistant infant sepsis. Am J Obstet Gynecol 1999;181:816-21.

Samenvatting in het Nederlands
Populatie farmacokinetiek van 
antibiotica ter preventie van groep B 
streptokokken-ziekte: 




AUC  Area under the curve - oppervlak onder de grafiek
CDC  Centers for Disease Control and Prevention
GBS  Groep B streptokokken
MCS  Monte Carlo Simulaties
MRC  Minimaal remmende concentratie
PPROM Preterm Premature Rupture of the Membranes - prematuur 
  preterm gebroken vliezen
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Introductie
Groep B streptokokken (GBS) zijn belangrijke veroorzakers van infectie 
gerelateerde morbiditeit en mortaliteit rondom de bevalling. Vanaf 1970 zijn GBS-
gerelateerde infecties in opmars en ze werden zo de meest frequente oorzaak van 
neonatale morbiditeit en mortaliteit. GBS-ziekte komt bij neonaten meestal tot 
uiting als pneumonie, sepsis of een meningitis. Het is minder bekend dat GBS 
rondom de bevalling ook verschillende infecties bij de moeder kan veroorzaken. 
Cervicovaginale kolonisatie is meestal asymptomatisch, maar GBS kan ook 
urineweginfecties, vulvovaginitis, intra-uteriene infectie, mastitis, bacteriemie, 
sepsis, meningitis, endometritis en wondinfecties veroorzaken. Deze infecties 
hebben vaak niet alleen consequenties voor de moeder, maar ook voor het kind 
(beschreven in Hoofdstuk 3).
 Sinds de jaren negentig zijn in verschillende landen maatregelen getroffen 
om neonatale GBS-ziekte te voorkomen. Het preventief toedienen van antibiotica 
aan de moeder kort voor of tijdens de bevalling is hierbij het belangrijkste onderdeel. 
Om het gebruik van deze antibiotica te kunnen aanbevelen is het noodzakelijk de 
positieve effecten en de bijwerkingen tegen elkaar af te wegen. Globaal genomen 
is het voorkomen van bewezen vroege neonatale GBS-ziekte (GBS-ziekte in 
de eerste 7 dagen na de geboorte bewezen met een kweek) met introductie van 
deze maatregel gedaald. Dit wekt de indruk dat de antibiotica effectief zijn. Deze 
incidentie cijfers worden echter beïnvloed door meerdere factoren. Daarnaast zijn 
er gevallen van neonatale GBS-ziekte beschreven bij kinderen van wie de moeder 
tijdens de bevalling was behandeld met antibiotica. Hierdoor ontstaat twijfel over 
de effectiviteit van de profylaxe. Een specifieke vraag hierbij is of in de huidige 
richtlijnen de optimale dosering en het optimale doseringsinterval wordt gehanteerd. 
Bijwerkingen van antibiotica bij de moeder, zoals een anafylactische reactie, 
komen zelden voor, maar zullen bij sterk toenemend gebruik vaker gezien worden. 
Tevens is er toenemende bezorgdheid over mogelijke negatieve effecten voor het 
kind. Het gebruik van antibiotica tijdens de bevalling heeft mogelijk effect op de 
samenstelling van de initiële bacteriële flora van het kind. Een veranderde bacteriële 
flora zou een effect kunnen hebben op de ontwikkeling van het immuunsysteem 
van de neonaat. Terwijl er matig bewijs is voor de effectiviteit van de antibiotica en 
weinig aandacht voor de bijwerkingen, wordt in de richtlijnen van de Nederlandse 
Vereniging van Obstetrie en Gynaecologie en de Centers for Disease Control and 
Prevention het gebruik van antibiotica rondom de bevalling geadviseerd aan hoge 
percentages zwangere vrouwen (tot 35% van alle zwangere vrouwen) (beschreven 
in Hoofdstuk 2). 
 Om onderzoek te doen naar de effectiviteit van antibiotica en om het 
optimale doseringschema ter preventie van GBS-ziekte te bepalen, is kennis over 
de farmacokinetiek noodzakelijk. Farmacokinetiek is het vakgebied dat wiskundige 
210
modellen toepast om het verloop van de concentraties van geneesmiddelen in het 
lichaam te beschrijven en te voorspellen. Het verloop van de concentratie van het 
geneesmiddel in de tijd wordt bepaald door de mate en snelheid van absorptie, 
distributie, metabolisatie en excretie. 
Farmacokinetische studies in de zwangerschap: 
algemene benadering
Antibiotica die gebruikt worden ter preventie van GBS-ziekte worden toegediend aan 
de moeder, terwijl deze tevens bedoeld zijn om de foetus te beschermen. Antibiotica 
in de foetale circulatie zijn afkomstig van de maternale circulatie na passage van 
de placenta. Het is hierom essentieel voor de foetus dat het concentratieverloop in 
de moeder adequaat is. Bij het bestuderen van de farmacokinetiek ten behoeve van 
de profylaxe tegen GBS-ziekte dient het concentratie-tijd verloop in de moeder dus 
als eerste bestudeerd te worden. Tijdens de zwangerschap zijn er veranderingen in 
de absorptie, distributie, metabolisatie en excretie van geneesmiddelen. Zo neemt 
bijvoorbeeld het plasma in volume toe, terwijl de binding aan albumine afneemt. 
Ook de bloedstroom naar de lever, evenals de glomerulaire filtratiesnelheid in de 
nier neemt toe. Omdat al deze veranderingen tegelijkertijd optreden en tevens 
afhankelijk zijn van de zwangerschapsduur, is het niet op voorhand duidelijk hoe de 
farmacokinetiek geëxtrapoleerd moeten worden uitgaande van gegevens verkregen 
in niet-zwangere personen. 
 Wanneer vastgesteld is dat het toegediende antibioticum bij de moeder 
een adequaat concentratie-tijd verloop heeft, dan is als tweede de passage van 
het antibioticum door de placenta van belang. Zo bereikt het antibioticum 
immers de foetus. De snelheid waarmee het antibioticum over de placenta wordt 
getransporteerd is afhankelijk van de maternale-foetale concentratie gradiënt en 
omgekeerd evenredig met de doorlaatbaarheid van het membraan van de placenta. 
De dikte van de placenta neemt toe met de zwangerschapsduur maar ook bij een 
aantal aandoeningen die de zwangerschap kunnen compliceren, zoals diabetes 
mellitus en zwangerschapsvergiftiging. Concentraties die gemeten worden in 
bloedmonsters van het veneuze navelstrengbloed kunnen informatie geven over 
het transport van het antibioticum over de placenta. Helaas kunnen bloedmonsters 
van de navelstreng na de bevalling slechts één keer per patiënt afgenomen worden 
en het moment van afname kan niet door de onderzoeker gepland worden. 
 Ten slotte dient de farmacokinetiek van de antibiotica in het kind 
bestudeerd te worden. Dit kan gedeeltelijk worden gebaseerd op concentraties in 
arteriële bloedmonsters afkomstig uit de navelstreng direct na de geboorte, maar 
ook met bloedmonsters van de neonaat. Hierbij is het belangrijk te onderkennen 
dat er farmacokinetische verschillen zijn tussen de foetus en de neonaat. Voor de 
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geboorte is de bloedstroom terug naar de moeder de voornaamste route van excretie. 
Echter na de geboorte is de navelstreng afgeklemd en vindt de excretie plaats via 
de organen van de neonaat. Daarnaast zal ook het bloed zich na de geboorte anders 
over het lichaam  verdelen dan voor de geboorte. Ook dit zou de farmacokinetiek 
kunnen beïnvloeden. 
 Samenvattend kan gesteld worden dat het nodig is om allereerst de 
farmacokinetiek in zowel de moeder als het kind te bestuderen bij onderzoek naar 
de effectiviteit van antibiotica die gebruikt worden als profylaxe tegen GBS-ziekte. 
In tegenstelling tot maternale bloedmonsters, die relatief vaak afgenomen kunnen 
worden, kunnen na de geboorte bloedmonsters van de navelstreng slechts één keer 
per patiënt afgenomen worden. Dit zal resulteren in groepen van ongelijke grootte. 
Gelukkig, kunnen data tegenwoordig geanalyseerd worden met de zogenaamde 
"populatie benadering" met computerprogramma's zoals NONMEM (Non-linear 
Mixed Effects Modeling). Bij deze benadering worden de data van alle individuen 
in de populatie tegelijkertijd geanalyseerd, waarbij rekening gehouden wordt 
met de inter-individuele en intra-individuele variabiliteit. Ook kunnen gegevens 
van groepen met verschillende grootte evenals gegevens van patiënten waarvan 
onvolledige gegevens beschikbaar zijn, met deze methode worden geanalyseerd. 
 Om de profylaxe te kunnen evalueren is naast kennis van de farmacokinetiek 
ook inzicht in de relatie tussen de farmacokinetische eigenschappen en het 
klinisch effect van groot belang. Tijdens de zwangerschap en bevalling worden 
verschillende antibiotica gebruikt. In Europa wordt amoxicilline vaak gebruikt 
ter preventie van GBS ziekte. In sommige ziekenhuizen wordt amoxicilline 
gecombineerd met clavulaanzuur, omdat deze combinatie ook werkzaam is tegen 
amoxicilline-resistente Escherichia coli. In geval van allergie voor penicillines wordt 
clindamycine voorgeschreven als alternatief. De relatie tussen de farmacokinetische 
eigenschappen, de gevoeligheid van het micro-organisme (als weerspiegeld door de 
minimaal remmende concentratie, MRC) en de klinische effecten wordt steeds beter 
begrepen. De effectiviteit van de penicillines, zoals amoxicilline, is gecorreleerd 
met het percentage van de tijd dat de serum concentratie van het ongebonden 
geneesmiddel hoger is dan de MRC (%fT>MRC). Het effect van clindamycine is, 
net zoals dat van amoxicilline, afhankelijk van de blootstelling, maar de klinische 
effectiviteit wordt voor dit antibioticum het best beschreven door het oppervlak 
onder de grafiek (area under the curve, AUC) boven de MRC gedurende 24 uur 
(fAUC0-24h/MRC). 
 Met behulp van Monte Carlo Simulaties (MCS) kunnen verschillen in 
effectiviteit tussen verschillende doseringschema's voor de preventie van GBS 
ziekte worden geëvalueerd. Bij deze simulaties wordt gebruik gemaakt van de 
waarden van de farmacokinetische parameters, de relatie tussen de concentratie van 
het antibioticum en het effect alsmede de inter-individuele variabiliteit. Zo kan een 
aantal scenario’s worden geëvalueerd. Op deze manier kan de farmacokinetische 
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data van zowel moeder als kind worden gecombineerd met de kennis over de 
concentratie-effect relatie om de antibioticum profylaxe in de klinische praktijk te 
optimaliseren. 
    
Het doel van het onderzoeksproject gepresenteerd in dit proefschrift was om 
de farmacokinetiek van antibiotica die veelvuldig gebruikt worden tijdens de 
zwangerschap en bevalling ter preventie van GBS ziekte te beschrijven. In het 
Medisch Centrum Haaglanden wordt meestal amoxicilline gebruikt. Om deze reden 
is amoxicilline in dit proefschrift als prototype gebruikt. Daarnaast werden ook in 
beperktere mate onderzoek verricht naar clindamycine en penicilline G. 
De farmacokinetiek van antibiotica tijdens de zwangerschap 
en bevalling: Amoxicilline als prototype.
Zwangere vrouwen met prematuur preterm gebroken vliezen (PPROM) vormen 
een belangrijke groep van patiënten die met amoxicilline wordt behandeld. Bij 
deze vrouwen is de mechanische barrière tegen infectie die gevormd wordt door 
de vliezen verstoord en men neemt aan dat de normale genitale flora de uterus 
kan binnendringen, waarna een intra-uteriene infectie kan ontstaan. Het immuun 
systeem van premature neonaten is bovendien nog niet volledig ontwikkeld en dat 
maakt juist deze groep extra gevoelig voor infectie.  
 De schattingen voor de farmacokinetische parameters van amoxicilline bij 
vrouwen met PPROM waren niet anders dan de waarden die eerder in de literatuur 
zijn beschreven voor niet-zwangere individuen (hoofdstuk 4). Alleen de piek-
concentraties in onze groep patiënten waren lager dan bij niet-zwangeren. Mogelijk 
is dit te verklaren door de toegenomen hoeveelheid extracellulaire vloeistof of de 
aanwezigheid van de foetus, placenta en vruchtwater. In de literatuur zijn voor 
een aantal andere geneesmiddelen wel verschillen gevonden in de farmacokinetiek 
tussen zwangeren en niet-zwangeren. In de meeste van deze studies werden zowel 
vrouwen voor de bevalling als tijdens de bevalling geïncludeerd. Bij patiënten 
met PPROM is de bevalling nog niet op gang gekomen. Een studie naar de 
farmacokinetiek van ampicilline toonde aan dat er verschillen in de farmacokinetiek 
waren tussen zwangere vrouwen voor de bevalling en tijdens de bevalling, terwijl 
er geen verschillen tussen zwangere vrouwen en niet-zwangere vrouwen werden 
gevonden. Het zou dus zo kunnen zijn dat de veranderingen die optreden tijdens 
de bevalling zorgen voor verschillen in farmacokinetiek tussen de groepen en 
niet de zwangerschap op zich. Net zoals bij deze studie met ampicilline vonden 
wij inderdaad een kleine invloed van de bevalling op de farmacokinetiek van 
amoxicilline (hoofdstuk 5). De grootte van het verdelingsvolume was afgenomen 
tijdens de bevalling. Deze verandering was echter zo klein dat het geen invloed heeft 
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op de halfwaarde tijd. De verandering in farmacokinetiek is daardoor waarschijnlijk 
niet klinisch relevant. 
 Een andere factor die invloed zou kunnen hebben op de farmacokinetiek van 
amoxicilline is de gelijktijdige toediening van clavulaanzuur. Eventuele interacties 
tussen twee geneesmiddelen kunnen veroorzaakt worden door remming van 
metabole enzymen, competitie voor eiwit binding in het plasma of veranderingen 
in het transporter-systeem van de nier. De gelijktijdige toediening van amoxicilline 
en clavulaanzuur vergroot het antibacteriële spectrum tegen gram-positieve en 
gram-negatieve bacteriën. Amoxicilline kan namelijk worden geïnactiveerd door 
β-lactamases, enzymen die door verschillende micro-organismen geproduceerd 
worden. Wanneer clavulaanzuur toegevoegd wordt aan de amoxicilline beschermt 
het clavulaanzuur amoxicilline tegen enzymatische inactivatie door irreversibel te 
binden aan deze β-lactamases. Clavulaanzuur zelf heeft nauwelijks een antibacterieel 
effect. In de loop der jaren is de verhouding in de hoeveelheid amoxicilline en 
clavulaanzuur gewijzigd, maar dit lijkt geen invloed te hebben op de effectiviteit. 
Waarschijnlijk is de hoeveelheid clavulaanzuur dus minder van belang dan de 
hoeveelheid amoxicilline. Ondanks dat clavulaanzuur gedeeltelijk via dezelfde 
routes van metabolisatie en excretie wordt geëlimineerd als amoxicilline, wordt de 
farmacokinetiek tijdens de zwangerschap niet beïnvloed door de toevoeging van 
clavulaanzuur (hoofdstuk 6). 
 Voortzetten van de antibiotische behandeling onmiddellijk na de bevalling 
wordt geadviseerd bij vrouwen bij wie een intra-uteriene infectie wordt vermoed. 
Direct na de bevalling beginnen er fysiologische veranderingen op te treden. Deze 
veranderingen in de fysiologie kunnen leiden tot relevante veranderingen in de 
farmacokinetiek. Een goed voorbeeld hiervan is dat bij vrouwen met epilepsie de 
concentratie lamotrigine kort na de bevalling kan stijgen tot toxische waarden. 
Dit voorbeeld laat zien hoe belangrijk het kan zijn om veranderingen in de 
farmacokinetiek te bestuderen. Voor amoxicilline is het verdelingsvolume direct 
na de bevalling kleiner geworden. Net zoals voor lamotrigine zou dit kunnen 
leiden tot hogere concentraties. Met het huidige doseringschema worden toxische 
concentraties echter niet bereikt en daardoor zijn aanpassingen in de dosering direct 
na de geboorte niet nodig (Hoofdstuk 5). 
 In de literatuur zijn voor ampicilline en amoxicilline twee verschillende 
doseringschema’s beschreven ter preventie van GBS ziekte. Het ‘Centers for 
Disease Control and Prevention’ (CDC) adviseert een initiële dosis van 2 gram en 
vervolgens elke 4 uur een dosis van 1 gram. De ‘Cochrane Library’ beschrijft echter 
het doseringschema van 1 gram elke 6 uur als het meest gebruikte. Een belangrijke 
vraag is of er verschillen zijn in de effectiviteit van deze behandelschema’s. Zoals 
hierboven vermeld kan deze vraag worden beantwoord op basis van de uitkomsten 
van Monte Carlo Simulaties. Ondanks het feit dat de toedienings-snelheid van de 
antibiotica invloed kan hebben op de effectiviteit, wordt dit nergens beschreven in 
214
de richtlijnen. Een dosis van 2 gram amoxicilline wordt toegediend in een infuus 
van 30 minuten, terwijl de dosis van 1 gram gegeven kan worden als infuus van 
15 minuten of als bolus injectie. De resultaten van Monte Carlo Simulaties van 
deze verschillende doseringen laten zien dat het geven van een initiële dosis van 
2 gram waarschijnlijk geen toegevoegde waarde heeft boven de dosis van 1 gram. 
In principe kan een langzamere infusie de waarschijnlijkheid op het behalen van 
het therapeutische doel vergroten. Hierdoor worden deze verkozen boven de 
bolus injecties, die in het dagelijkse gebruik eenvoudiger zijn. Onze studie laat 
zien dat het percentage van de tijd dat de ongebonden concentratie boven de MRC 
(%fT>MRC) is, inderdaad hoger is bij een infusie dan bij de bolus injectie. Het 
verschil in %fT>MRC tussen de infusie van 15 minuten en de bolus injectie is echter 
slechts 4%. Bij simulatie van de in de literatuur beschreven doseringsschema’s met 
bolus injecties van 1 gram, bleek dat de verkregen concentratie-tijd profielen voor 
de populatie rekening houdend met het 99% betrouwbaarheidsinterval adequaat 
waren. Hieruit concluderen we dat bij de dosering van ampicilline en amoxicilline 
bolus injecties gebruikt kunnen worden zonder dat de effectiviteit van de profylaxe 
minder wordt (Hoofdstuk 8).
 Om een bepaald doseringsschema aan te bevelen, moeten een aantal 
aspecten in acht worden genomen. We hebben eerder al laten zien dat de initiële 
dosis van 2 gram geen toegevoegde waarde heeft boven de dosis van 1 gram. Het 
enige verschil tussen de beschreven doseringsschema’s is dan het doseringsinterval 
van 4 uur versus 6 uur. Ondanks dat het verlengen van het doseringsinterval de 
%fT>MRC verlaagt, worden bij de moeder adequate concentraties bereikt bij beide 
doseringsschema’s. Echter, om zeker te zijn dat de effectiviteit van de profylaxe 
in het voorkomen van neonatale GBS-ziekte niet is afgenomen wanneer gebruik 
wordt gemaakt van een doseringsschema met een interval van 6 uur, moet ook 
rekening gehouden worden met het concentratie-tijd profiel in de foetus. Daarom 
raden we voor de zekerheid een doseringsinterval van 4 uur aan. Dit interval 
wordt ook aangeraden gezien de klinische situatie waarin de profylaxe wordt 
toegediend. De vaak hectische situatie in de verloskamer kan gemakkelijk leiden 
tot onnauwkeurigheden in de toediening. Wanneer gebruik wordt gemaakt van het 
doseringsinterval van 4 uur leiden onnauwkeurigheden in de toediening minder 
snel tot inadequate concentraties, zelfs wanneer per ongeluk een dosis wordt 
overgeslagen (hoofstuk 8). 
 Tot nu toe kunnen we concluderen dat de aanbevolen doseringsschema’s 
bij de moeder adequaat zijn. Zowel de bevalling als het tegelijkertijd toedienen van 
clavulaanzuur leiden niet tot klinisch relevante veranderingen in de farmacokinetiek 
van amoxicilline. Maar omdat de belangrijkste vraag is of ook GBS-ziekte bij het 
kind voorkomen wordt, is ook onderzoek gedaan naar het transport van antibiotica 
over de placenta en naar de farmacokinetiek bij de foetus.  
 Antibiotica die toegediend worden aan de moeder bereiken de foetus via 
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de navelstreng. Het veneuze bloed in de navelstreng stroomt naar de foetus nadat 
het de placenta gepasseerd heeft, terwijl het arteriële bloed in de navelstreng direct 
afkomstig is uit de foetale circulatie. De antibioticum concentratie in het arteriële 
bloed in de navelstreng is daarom representatief voor concentraties in de foetale 
circulatie. In de studie beschreven in hoofdstuk 7 worden deze concentraties 
geanalyseerd samen met concentraties in bloed dat werd afgenomen door middel 
van een hielprik bij de neonaten ongeveer 20 minuten na de geboorte. Bij deze 
studie werden gegevens over de farmacokinetiek bij de moeder, het transport over 
de placenta en de farmacokinetiek bij de foetus allemaal tegelijkertijd geanalyseerd 
door gebruik te maken van een 5-compartimenten model. Hierdoor was het 
mogelijk om de concentratie-tijd profielen van de moeder en de foetus met elkaar 
te vergelijken. Deze analyse laat zien dat de piek concentratie die in het foetale 
bloed wordt bereikt, lager en vertraagd is ten opzichte van de piek concentratie in 
het maternale bloed. De piek concentratie in het veneuze bloed van de navelstreng 
was lager dan die van de moeder, maar hoger dan die van de foetus. Op een bepaald 
moment worden de concentraties in het veneuze bloed van de navelstreng en 
in het foetale bloed gelijk, en daarna worden in het bloed van de foetus hogere 
concentraties bereikt dan in het veneuze bloed van de navelstreng. Wanneer 
gebruik wordt gemaakt van de verkregen populatie farmacokinetische schattingen 
voor de farmacokinetiek van amoxicilline in het veneuze bloed van de navelstreng 
en het bloed van de foetus, lijkt de initiële dosis van 2 gram adequaat voor het 
voorkomen van neonatale GBS-ziekte (Hoofdstuk 7). Echter, hierbij zijn gegevens 
over de inter-individuele variabiliteit nog niet meegenomen. Daarom gelden deze 
gegevens alleen voor de gemiddelde zwangere vrouw met een gemiddeld kind. Een 
definitieve conclusie die geldt voor de gehele populatie kan hieruit daarom niet 
worden getrokken.  
 In de praktijk wordt voor het bepalen van de effectiviteit van de profylaxe 
vaak gebruik gemaakt van de duur tussen de start van de toediening van de 
amoxicilline aan de moeder en de geboorte. Wanneer deze periode minder dan 4 
uur is, wordt de profylaxe vaak als inadequaat beschouwd en wordt begonnen met 
antibiotische therapie bij de neonaat. Wanneer echter deze periode langer dan 4 uur 
is, wordt de profylaxe als adequaat beschouwd en ontvangt het kind doorgaans verder 
geen antibiotica. Deze klinische maatstaf voor effectiviteit is gebaseerd op twee 
waarnemingen. Ten eerste neemt het aantal positieve bloedkweken af bij het groter 
worden van het tijdsinterval tussen het toedienen van een enkele dosis antibioticum 
en het afname tijdstip van de bloedkweek.Ten tweede neemt het aantal transmissies 
van de maternale vagina naar de mucocutane oppervlakte van de neonaat af in de 
tijd. Een aannemelijke verklaring is dat er altijd een minimale tijdsduur nodig is om 
bacteriën te doden. Nadat de hoogste concentratie in het foetale bloed bereikt is (31 
minuten na de hoogste concentratie bij de moeder), zal de concentratie dalen. De 
antibiotica in de foetale circulatie zullen micro-organismen doden onafhankelijk van 
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de geboorte. Hierdoor is de klinische maatstaf niet gecorreleerd met de werkelijke 
effectiviteit van de profylaxe (hoofdstuk 2 en 7).
 Patiënten in onze studie zijn allemaal relatief gezond. Eén patiënt die 
opgenomen werd met PPROM braakte zeer hevig gedurende het eerste gedeelte 
van de studie (Hoofdstuk 9). Het concentratie-tijd profiel dat bij haar werd 
gemeten tijdens de eerste antibioticum toediening was afwijkend van het profiel 
bij gezonde patiënten. Nadat het braken was gestopt, was het concentratie-tijd 
profiel bij haar vergelijkbaar met dat van andere patiënten met PPROM (zoals 
beschreven in Hoofdstuk 4). Aangezien na beide toedieningen de totale doses 
geabsorbeerd waren door het lichaam, kon het verschil tussen de twee profielen 
niet verklaard worden door fouten in de toediening. Onze hypothese is dat een 
aantal (patho)fysiologische veranderingen die optraden, invloed hebben gehad op 
de perifere bloedstroom. Hierdoor veranderde de distributie van de amoxicilline in 
het lichaam. Onze hypothese is dat de arm waarin de amoxicilline toegediend was 
als een depot gefunctioneerd heeft. Nadat de bloedstroom langzaam normaliseerde, 
werd de amoxicilline alsnog langzaam over het lichaam verdeeld. Het vastleggen 
van een dergelijk concentratie-tijd profiel is uniek, aangezien bloedafname frequent 
plaatsvond in een acute, emotionele en zeer stressvolle situatie. Het concentratie-
tijd profiel bij deze patiënte geeft aan dat ondanks dat de farmacokinetiek redelijk 
goed beschreven is bij gezonde vrijwilligers, er onverwachte veranderingen in de 
farmacokinetiek kunnen optreden bij (ernstig) zieke patiënten. 
Samenvattend kan gezegd worden dat de concentratie-tijd profielen van amoxicilline 
bij zwangere vrouwen voor het begin van de bevalling, tijdens de bevalling en 
direct na de bevalling met de momenteel geadviseerde doseringsschema’s adequaat 
zijn. MCS laten zien dat ook wanneer een dosis overgeslagen wordt, de tijd dat de 
ongebonden fractie amoxicilline hoger is dan de MRC nog steeds voldoende is. 
Voor de gemiddelde zwangere vrouw en haar gemiddelde kind is deze dosering 
eveneens adequaat om GBS-ziekte bij het kind te voorkomen. Gegevens van de 
inter-individuele variabiliteit konden in deze analyse helaas niet meegenomen 
worden. 
Clindamycine
Ook clindamycine is een veelvuldig gebruikt antibioticum bij de preventie van 
GBS infecties. De effectiviteit hiervan voor deze indicatie dient op dezelfde wijze 
bestudeerd te worden als beschreven voor amoxicilline. Helaas kon slechts een 
beperkt aantal patiënten dat behandeld moest worden met clindamycine in de 
studie worden geïncludeerd. Hierdoor kunnen uit deze studie nog geen definitieve 
conclusies getrokken worden (Hoofdstuk 10). 
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 Bij het bepalen van de effectiviteit van clindamycine is de eiwitbinding in 
het plasma van groot belang. Clindamycine bindt voornamelijk aan het acute fase 
eiwit alfa1-zure glycoproteine en het percentage eiwitbinding in het plasma varieert 
daardoor aanzienlijk. Het meest frequent worden echter waarden gerapporteerd 
tussen de 80% en 90%. Dit percentage neemt waarschijnlijk af tijdens de 
zwangerschap, maar neemt toe bij patiënten met een acute infectie of stress. Daarom 
is het aannemelijk dat het percentage eiwitbinding in onze patiënten ten minste 
80% is. Voor de gemiddelde zwangere vrouw leidt het huidige doseringsschema 
tot adequate concentraties mits het percentage eiwitbinding niet hoger is dan 80%. 
Maar om een doseringsschema te adviseren dat adequaat is voor de gehele populatie 
is dit onvoldoende en dient tevens de inter-individuele variabiliteit in de resultaten 
verwerkt te worden. Uit de huidige resultaten kan niet geconcludeerd worden dat 
het toegepaste doseringsschema adequaat is voor de gehele populatie, vooral niet 
wanneer de eiwitbinding hoger is dan 80% (Hoofdstuk 10).
 Om gegevens van de passage van clindamycine door de placenta in het 
model op te nemen, zijn meer gegevens nodig. Individuele concentraties in het 
bloed afkomstig uit de navelstreng variëren van 0.1 mg/L tot 4 mg/L. Wanneer 
rekening wordt gehouden met de eiwitbinding, een doseringsinterval van 8 uur 
en de MRC voor GBS (0.5 mg/L), geven deze data aan dat de concentraties in de 
foetus mogelijk inadequaat zijn voor de preventie van neonatale GBS-ziekte.
 Het is bekend dat niet alle vrouwen die aangeven allergisch te zijn voor 
penicilline dit ook daadwerkelijk zijn. Het kan nuttig zijn om de allergie te 
herevalueren. Allergietesten kunnen uitgevoerd worden tijdens de zwangerschap 
en vrouwen waarbij de test negatief is kunnen met penicilline behandeld worden. 
Totdat meer onderzoek verricht is naar de effectiviteit van clindamycine ter preventie 
van neonatale GBS-ziekte, wordt een allergietest aanbevolen om het gebruik van 
clindamycine zo veel mogelijk te vermijden. 
Behandeling met penicilline G van premature neonaten.
Bij neonaten bij wie een GBS infectie wordt vermoed zal direct na de geboorte 
met antibiotische behandeling begonnen worden. Van een aantal geneesmiddelen is 
bekend dat de farmacokinetiek in neonaten significant anders is dan in volwassenen. 
Vooral bij premature neonaten is de halfwaardetijd vaak verlengd. Ook wij vonden 
op de derde dag na de geboorte een langere halfwaardetijd van penicilline G (3.9 
uur) bij neonaten geboren na een zwangerschapsduur van minder dan 32 weken. 
Wanneer rekening gehouden wordt met de inter-individuele variabiliteit, bleek dat 
het momenteel gebruikte doseringsschema van 50.000 eenheden/kg elke 12 uur 
adequaat is voor de behandeling van neonatale infecties die veroorzaakt worden 
door gebruikelijke micro-organismen op de derde dag na de geboorte. 
 De langere halfwaardetijd in (premature) neonaten is gunstig voor de 
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behandeling met antibiotica met een tijdsafhankelijk werkingsmechanisme, omdat 
hierdoor de tijd dat de concentratie boven de MRC blijft zal toenemen. De langere 
halfwaardetijd wordt vermoedelijk veroorzaakt doordat bij neonaten de nieren nog 
niet volledig ontwikkeld zijn. Deze bevinding ondersteunt onze mening dat de 
eerder beschreven klinische maatstaf voor effect (d.w.z. een tijdsduur van 4 uur 
tussen de antibioticum toediening en de geboorte) heroverwogen dient te worden. 
Nadat de hoogste concentratie in het foetale bloed bereikt is, zal de concentratie 
afnemen. Omdat de halfwaardetijd in de foetus waarschijnlijk korter is dan in de 
neonaat, zal de hoogste waarde voor T>MRC bereikt worden wanneer het kind 
geboren wordt kort nadat de hoogste antibioticum concentratie bereikt is.
Toekomstperspectieven
De laatste tijd is het gebruik van antibiotica rondom de bevalling ter preventie van 
GBS-ziekte toegenomen. Deze toename is deels toe te schrijven aan de verandering 
van de richtlijnen in de Verenigde Staten van Amerika naar een preventiestrategie 
die op screening gebaseerd is en aan een toename van de prevalentie van GBS-
dragerschap onder zwangere vrouwen. Met het ter beschikking komen van detectie 
methoden met een hogere sensitiviteit, zullen ook vrouwen met een gering aantal 
groep B streptokokken geïdentificeerd worden als GBS-draagster. Het is de vraag 
of ook deze vrouwen een verhoogd risico hebben op een kind met GBS-ziekte. Met 
het toenemende aantal dat in aanmerking komt voor antibiotische profylaxe tijdens 
de bevalling, wordt het des te belangrijker dat het geadviseerde doseringsschema 
adequaat is voor de gehele populatie. Met een suboptimale behandeling kan 
profylaxe falen en dit zou selectie van resistente bacteriële stammen in de hand 
kunnen werken. 
 Uitgaande van het onderzoek dat beschreven wordt in dit proefschrift, 
is het waarschijnlijk dat de huidige doseringschema’s die gebruikt worden voor 
amoxicilline adequaat zijn bij gezonde zwangere vrouwen, ook wanneer geringe 
fouten in de toediening worden gemaakt. Maar om zeker te zijn dat deze dosering 
ook adequaat is voor de foetus dienen simulatie studies uitgevoerd te worden die 
gebruik maken van het 5-compartimenten model met de farmacokinetische gegevens 
van de moeder, het kind evenals de gegevens van de inter-individuele variabiliteit. 
Op deze manier kan een optimaal doseringsschema gekozen worden voor de 
gehele populatie. Helaas zijn er op dit moment nog geen computerprogramma’s 
beschikbaar die deze simulaties kunnen uitvoeren.
 De patiënten die in onze studie geïncludeerd werden, waren op één na 
allemaal relatief gezond. Bij deze gezonde patiënten konden we aantonen dat een 
aantal fysiologische factoren invloed heeft op de farmacokinetiek van amoxicilline. 
Zo heeft de hoeveelheid oedeem invloed op het verdelingsvolume. Zwangerschap 
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en de bevalling worden soms gecompliceerd door specifieke aandoeningen. Een 
van deze zwangerschapsgerelateerde aandoeningen in pre-eclampsie, waarbij 
bekend is dat de hoeveelheid oedeem toeneemt. Hierbij kan de hoeveelheid 
extracellulair vocht toenemen met 10 liter. Of de huidige doseringsschema’s ook 
adequaat zijn bij patiënten met pre-eclampsie is dus niet zeker. Dit geeft aan dat 
het belangrijk is om ook farmacokinetisch onderzoek te doen bij patiënten met 
zwangerschapsgerelateerde aandoeningen. 
 Voor clindamycine waren slechts weinig data beschikbaar. Wanneer rekening 
gehouden wordt met de eiwitbinding zou het kunnen zijn dat de concentraties die 
in de moeder en de foetus bereikt worden niet adequaat zijn om GBS-ziekte te 
voorkomen. Omdat alleen de fractie van de antibioticumconcentratie die niet aan 
eiwit gebonden is de placenta kan passeren, kunnen veranderingen in het percentage 
eiwitbinding invloed hebben op de effectiviteit van de clindamycine. Het is bekend 
dat de eiwitbinding van clindamycine afhangt van zowel de concentratie alfa1-
zure glycoproteine, die verandert tijdens de zwangerschap, als van de clindamycine 
concentratie zelf. Helaas is er voor het bepalen van de eiwitbinding een relatief 
grote hoeveelheid bloed nodig. De bloedmonsters afgenomen in het kader van onze 
studie bleken hiervoor te klein te zijn. Om de effectiviteit van clindamycine voor 
de preventie van GBS-ziekte aan te tonen, is verder onderzoek nodig. In deze studie 
dient dan voldoende bloed afgenomen te worden voor het verrichten van bepalingen 
van de eiwitbinding en tevens dienen patiënten met zwangerschapsgerelateerde 
aandoeningen geïncludeerd te worden. Met deze gegevens kan dan een 
farmacokinetisch model ontwikkeld worden dat gebaseerd is op de farmacokinetiek 
in de moeder en in de foetus, de inter-individuele variabiliteit en de eiwitbinding 
van clindamycine. Met behulp van dit model en simulatie studies kan dan ook het 
optimale doseringsschema voor clindamycine bepaald worden. 
 In de Verenigde Staten van Amerika is Escherichia coli een steeds frequenter 
voorkomende oorzaak geworden van neonatale infectie, vooral in premature 
neonaten. Omdat bij deze stammen resistentie tegen amoxicilline vaak voorkomt, 
zal in de toekomst wellicht de combinatie van amoxicilline met clavulaanzuur meer 
voorgeschreven gaan worden. We hebben laten zien dat de farmacokinetiek van 
amoxicilline niet beïnvloed wordt door het tegelijkertijd toedienen van clavulaanzuur, 
maar voor een goede werking is ook een minimale hoeveelheid clavulaanzuur 
nodig. Farmacokinetische studies naar de farmacokinetiek van clavulaanzuur 
zijn daarom ook nodig. Bij het bepalen van de concentraties clavulaanzuur dient 
rekening gehouden te worden met een aantal problemen. Clavulaanzuur is een 
instabiele verbinding. Idealiter dienen de concentraties dus bepaald te worden 
direct na afname van het bloedmonster en een speciale methode dient ontwikkeld 
te worden om te voorkomen dat het clavulaanzuur tijdens de bepaling afgebroken 
wordt. 
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 Concluderend kan gezegd worden dat het huidige onderzoek laat zien dat 
het doseringsschema dat momenteel gebruikt wordt ter preventie van neonatale 
GBS-ziekte hoogst waarschijnlijk effectief is. Maar om de gebruikte profylaxe te 
optimaliseren dient meer onderzoek verricht te worden naar de farmacokinetiek 
van de verschillende antibiotica. Bij dit onderzoek is het belangrijk dat zowel de 
farmacokinetiek in de moeder als die in het kind, hun onderlinge relatie, de inter-
individuele variabiliteit en de eiwitbinding tegelijkertijd in kaart gebracht worden. 
Daarnaast dienen ook patiënten met zwangerschapsgerelateerde aandoeningen 
geïncludeerd te worden. Omdat onze studie geen zekerheid kon bieden over de 
effectiviteit van clindamycine, blijft preventie met een penicilline de voorkeur 
houden. Wanneer een patiënt aangeeft dat zij allergisch is voor penicilline, kan een 
allergietest uitgevoerd worden om zeker te zijn dat penicillines gecontraïndiceerd 
zijn. 
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Chapter 2, Figure 1: Hypothesized pathogenesis of GBS-EOD.
1 Colonization in the rectovaginal compartment; 2 Rupture of the membranes; 3 GBS enters 
the amniotic fluid; 3a GBS colonization of skin and mucocutaneous areas; 4 Aspiration of 
infected amniotic fluid; 5 Infected amniotic fluid causes pneumonia (if the bacterial load 
is high enough); 6 Entry of GBS in the bloodstream (sepsis or bacteremia); 7 Entry in 
cerebrospinal fluid after hematogenous spread (meningitis). 












































































































































































































































Chapter 4, Figure 1: Observed concentration-time profiles in patients with PPROM.
The superimposed bold line shows the predicted profile obtained with the final model. The 
blocks indicate the time at which the infusions of the amoxicillin was started and stopped. 
Because there was variation in the start-time of the second infusion due to the clinical 
situation, in this graph the data were adapted assuming that the second infusions started at 
t=5.05h for all patients. 
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Chapter 5, Figure 3: Figure 3a shows the observed amoxicillin concentrations after a 2 
gram dose and figure 3b after a 1 gram dose. Time of infusion is indicated by black bars. 
The blue squares represent all data points of the patients before the onset of labor; the 
red dots data points of patients during labor and data points of patients in the postpartum 
period are indicated by the green triangles. Because there was variation in the start-time of 
the second infusion, in figure 3b the data were adapted assuming that the 1 gram infusions 
started at t=0 for all patients. 
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Chapter 7, Figure 4: Simulated concentration-time profiles for the mother, umbilical 
cord and neonate.
Concentration-time profile of amoxicillin in maternal, umbilical cord and neonatal 
serum simulated after a single dose of 2 gram amoxicillin infused over 30 minutes. 
The simulations were performed with PK parameter estimates based on the final 
5-compartment model and carried out for 12 hours after a single antibiotic dose.
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Chapter 8, Figure 2: Percent of time the unbound fraction of amoxicillin remained above 
the MIC (%fT>MIC) as a function of the MIC for two dosing intervals, 4 hours (figure 2a) 
and 6 hours (figure 2b), in pregnant women with PPROM after the inital dose (black lines) 
and in steady state situation (red lines). 
Chapter 8, Figure 3: Percent of time the unbound fraction of amoxicillin remained above 
the MIC (%fT>MIC) as a function of the MIC for three different initial doses for a 4 hours 
dosing interval in pregnant women with PPROM. In figure 3A the %fT>MIC for a dose of 1 
gram administered as bolus (black lines) and the 1 gram dose administered over 15 minutes 
(red lines) are shown. In figure 3B the %fT>MIC for the 1 gram dose administered over 
15 minutes (red lines) and the 2 gram dose administered over 30 minutes (blue lines) are 
shown. The solid lines are the values for the average pregnant women; the interrupted lines 
represent the 95% confidence intervals and the dotted lines the 99% confidence intervals. 
